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AllSTRACT 
The research programme was initiated by a study of possible 
non-"...rug "aids" to insomnia •. Using a group of self-reported, sleep 
onset insomniacs, the efficacies of cycloid vibration, Horlicks and 
cocoa (placebo condition) were assessed byall-night EEG recordings. 
None of these "aids" were found to have significant effects upon 
.. 
either the quality or quantity of sleep. However, two interesting 
observations of this study were: 
1. the unreliability of subjective reports of insomnia; the insomniacs, 
in general, tended to overestimate their sleep onset times, 
2 •. the frequent use of Aspirin by the self-reported insomniacs to 
relieve their sleeping difficulties. 
These observations served as the bases for further investigation. 
With respect to the first observation, selecting a group of insomniacs 
who satisfy EEG criteria can be a very time cons~ procedure. To 
partly overcome this difficulty, an EEG model of sleep. onset insomnia 
was created, using daytime nap sleep onset times of geod sleepers. The 
, 
morning sleep onset times were found to simulate sleep onset insomnia. 
This model was then used to assess the sedative potential of a known 
tranquiliser (Temazepam); F.P., a drug supplied by Fisons Pharmaceuticals 
Limited, which was believed to have mild sedative properties; and a placebo. 
The results showed that Temazepam exerted a stronger sedative effect upon 
the model than either F.P. or placebo. 
Concerning the second observation, from the literature·it appeared 
that Aspirin (acetylsalicylic acid) would affect sleep. Initially, a 
pilot study was conducted with geod sleepers who received a normal, 
therapeutic dose of Aspirin. A significant decline in stage 4 sleep 
· Hi 
was found, .which appeared to be more marked in the females. A larger, 
controlled study was then conducted with 16 females; eight received 
Aspirin and eight placebo, under double blind conditions. A significant 
increase in stage 2 sleep was found on the drug nights. Upon drug 
withdrawal, there was a significant decline in REM latency. 
Two supplementary pilot studies were carried out; one to investigate 
the·effects of Paracetamol upon sleep, the other to investigate the effects 
of Aspirin upon the urinary output of 5-HIAA. Neither study produced 
. marked significant results. 
., 
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SCHEMA 
2 
SCiIEl-!A. 
The research programme began with an EEG evaluation of two, 
cOm::lerc!.::.:!., non-d..~ "eleep;ng aids" using a gro'.l? of =df-repcrted~ 
sleep onset insomniacs. The findings and observations of this initial 
study gave rise to two lines of further investigation. One was to 
create an EEG model of sleep onset insomnia. and the other was to 
investigate the effects of Aspirin (acetylsalicylic acid) upon sleep. 
The stimulus for the former aspect of further research stemmed from 
the difficulties encountered in selecting from a group of self-reported, 
sleep onset insomniacs some who actually satisfied the EEG criteria. 
These difficulties arose primarily because the insomniacs tended to 
overestimate their sleep onset times. The aim of the EEG model of sleep 
onset insomnia was to provide a long sleep latency, which would form the 
basis of the initial evaluation procedure for various "sleeping aids". 
The approach adopted was to measure, by EEG criteria, the sleep onset 
times of good sleepers during daytime naps. This approach was successf'ul. 
The model was then 'modified slightly and used to assess the sedative 
properties of two drugs. 
The interest in the Aspirin aspect of insomnia arose from the 
comments made by many of the self-reported insomniacs that they frequently 
took Aspirin to relieve their sleeping difficulties. A literature search 
indicated that Aspirin (acetylsalicylic acid) might be expected to 
affect sleep, but the possible mechanisms involved were unclear and gave 
rise to much speculation. Nevertheless,'sufficient interest had been 
aroused to warrant a pilot study. On the basis of the results of the 
pilot study, this aspect of insomnia was pursued further by means of a 
large, controlled study on the effects of acetylsalicylic acid upon sleep. 
Two supplementary pilot studies were then conducted in an attempt 
to determine the mechanisms by which Aspirin may be exerting its effects 
upon sleep. One of these studies was concerned with the effect of 
Aspirin upon the daily urinary output of 5-hydroxyindoleacetic acid (5-HIAA) , 
which is a breakdown product of 5-hydroxytryptamine. The other study 
examined the effects of Paracetamol (Acetaminophen) upon sleep. 
Although all the studies in this research programme have a common 
starting point, they deal with quite different aspects of insomnia. 
Thus, rather than presenting an extensive introduction, covering a wide 
variety of topics, each chapter will have its own introductory sections 
explaining the background behind the aspect of insomnia under consideration. 
An overall view of the research programme is presented in the flow diagram 
below: 
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Not poppy nor mandragora, 
Nor all the drowsy syrups of the world, 
Shall ever medicine thee to that sweet sleep 
Which thou owed'st yesterday~ 
SHAKESPEARE, Othello 
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Chapter One 
NON-DRUG "SLEEPING AIDS" 
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1.0 INTRODUCTION 
Sleep disorders can be olassified into three, broad, general 
categories (TIauri, ~915): 
1. Insomnia - An inability to obtain adequate sleep. 
2. Hypersomnia - A need for excessive amounts of sleep, in some cases 
accompanied by short, irresistible sleep attacks during the day, 
known as narcolepsy. 
3. Dysomnias - The exclusive occurrence of'pathologies during sleep, 
such as somnambulism. 
Insomnia is the sleep disorder with the highest incidence in the 
population. Johns (1912) stated that approximately 14 per cent of the 
people ·of the British Isles suffered from insomnia. It is also the 
sleep disorder which presents the largest problem with respect to 
treatment and management. 
The literal translation of insomnia is, "no sleep". However, 
insomnia seldom results in total sleeplessness and the term usually 
refers to a sleeping difficulty. It is inadequate to define a sleeping 
difficulty simply in terms of hours of sleep, because of the wide 
range in individual sleep requirements. In the rare, extreme oases 
, 
some individuals can sleep for as little as approximately three hours 
per night without complaining of insomnia (Jones & Oswald, 1968); 
\mereas, others who feel they need ten hours sleep per night may 
complain of insomnia if they only have eight hours sleep. An individual 
is classified as an insomniac if he considers his sleep to be 
inadequate and if this sleeping difficulty is actually troubling him. 
Although most people at some time have experienced such difficulties, 
generally on a temporary basis, for many it· is a chronic problem. 
Aooording to Worster-Drought (1921) there are three primary" 
sleep disturbanoes making up the insomnia syndrome: 
1. long sleep latenoies -known as sleep onset insomnia, 
2. frequent nooturnal awakenings, 
3. early morning awaken1ngs. 
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However, in praotioe these categories are seldom distinot and it is 
often very diffioult to determine ~lhich is the major sleep disturbance 
for a particular insomniao. These sleep disturbanoes may ooour singly 
or in oombination, with varying degrees of severity. Kleitman (1963) 
reported that sleep onset insomnia was the oommonest reoorded and 
that this ~JPe of insomnia was the one usually refe=ed to by a patient 
when he oomplains to the dootor that "he cannot sleep". 
The most widely presoribed treatments for insomnia are hypnotio 
and sedative drugs. Johns (1972) reported that approximately three 
million sleeping tablets were oonsumed eaoh night in the British Isles. 
Apart from the large number of sleeping tablets presoribed, many 
insomniaos, who do not seek medical attention, try various non-clrug 
"sleeping aids" in an attempt to improve their sleep. These "sleeping, 
aids" oan range from various folk remedies suoh as oounting sheep or a 
warm bath at night, to other oommeroial "aids". These latter "aids" 
inolude malted milk beverages, taped relaxation instruotions and 
herbal pillows. Many olaims are made by the manufaoturers with regard 
to the effioaoy of these various "aids"; however, as will be disoussed 
in later seotions, there is little experimental evidenoe to support 
these olaims. In some of the studies whioh will be considered, various 
possible non-clrug treatments of insomnia were found to be no more 
effeotive than a plaoebo condition., This might be expected, since it 
would appear from the literature survey that a major oomponent of the 
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complaint of insomnia is psychological in origin. 
Nia.gara. Therapy (U.K.) Limited are a company who manU£acture 
expensive "sleeping aids". Their products include cycloid vibrating 
cushions, chairs and bed 'units which they claim relieve sleeping 
difficulties, because these devices have been found to enhance muscle 
,relaxation. At the request of this Company, and with their funding, an 
EEG, evaluation of their products was ca.:rried out using a group of self-
reported, sleep onset insomniacs. This type of sleep disorder was 
investigated since it would appear that sleep onset insomnia is one 
of the most commonly recorded sleep disorders and it was also considered 
that this group of insomniacs may try such devices. The Nia.gara Therapy 
cushions were evaluated against another commercial "sleeping aid", 
namely Horlicks, a milk beverage without the cereal component and the 
pre-treatment baseline condition. 
2.0 INSOMNIA 
2.1 Causes of Insomnia 
There is no simple, straight forward answer to the question, 
nVlhat causes insomnia?" An insomniac group is very heterogeneous. 
Although the majority of sU£ferers view their sleep disorder as the 
primary complaint, in most cases it is symptomatic of a wide variety of 
underlying causes, of which the following are some examples: 
1. Somatic Disorders - for example, arthritic pain and various respiratory 
complaints. 
2. Psychiatric Disorders and Mood Changes- In an extensive questionnaire 
study of referrals to a psychiatric clinic ca.:rried out by Stonehill, 
Crisp and Koval (1976), it was found that various moods and psychiatric 
states were associated with different sleep characteristics; anger 
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was associated with the greatest sleep disturbance throughout the 
night, and neurotic depression was characterised by reduced sleep 
length, wi 'w.'l both sleep onset insoIlIl1la. and early morning awakening. 
Kales, Caldwell, Preston, Healey and Kales (1976) reported similar 
findings although they used a different approach. The personality 
profiles of 128 self-reported insomniacs were examined; 85 per cent 
had personality profiles in the pathological range. The scale 
with the highest mean value was depression and .the authors 
concluded that, "Overall this profile indicates neurotic depression 
and unhappiness and reflects internal reactions of stress that are 
handled by depression or inhibition of anger". 
Although an association between psychiatric disturbance, mood 
changes and insomnia has been established, this does not indicate 
a direct cause-effect relationship. 
3. Situational Phenomena - for example, worry and anxiety about a 
pressing problem or factors such as a hot, underventilated room or 
traffic noise. 
4. Rhythm Disorders - for example, in the case of shift work. 
·5. Sleep Anomalies - for example, night te=ors. 
6. Drug Related Insomnia - this may be due to stimulants taken during 
the day or to drug withdrawal insomnia. 
7. Pseudoinsomnia - the patient believes that he has insomnia, but 
in fact he is a good sleeper, according to the EEG. 
8. Exnectancy Effects - the patients often expect to sleep for eight 
hours and believe it to be detrimental if they do not. 
9. Autonomic Arousal - Monroe's (1967) study formed much of the basis 
of the assumption that the insomniac is an "aroused" individual. 
This characteristic of insomnia will be discussed further in section 
2.2, ohapter one. Many of the non-drug treatments of insomnia, 
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such as relaxation therapy, are based on the assumption that the 
insomniac is an aroused individual whose sleeping difficulties may be 
alleviated if his anxiety is reduced ~,d he is relaxed, but it will ca· 
argued that the claim that physiological arousal is a major cause of 
insomnia is inconclusive. 
2.2 Characteristics of Insomniacs 
Monroe's (1967) study of good and poor sleepers indicated that 
poor sleepers have higher levels of autonomic arousal than good sleepers, 
using the following measures: number of body movements per hour, number 
of peripheral vasoconstrictions and the group mean rectal temperature 
measured during the one recording night. The poor sleepers were also 
found to have significantly higher heart rates during a 30 minute 
pre-sleep period. 
However, caution· must be applied when generalising these findings 
to the sleep onset insomniac population. Although the poor sleepers 
had a self-reported group mean sleep onset time of 60 minutes, the group 
mean sleep onset time according to the EEG measure was only 15 minutes. 
Nevertheless, the poor sleepers did have a significantly shorter total 
sleep time and spent a longer time awake on the one recording night 
than good sleepers. Even the good sleep group's total sleep time 
(388 minutes) was lower than would be expected for these subjects,. with 
a mean age of 26 years. According to the graph compiled by Roffwarg, 
MUzio and Dement (1966) the average range of total sleep time for 
the age range 19 - 30 years is 420 - 465 minutes. The fact that the 
subjects were not studied over consecutive nights may have contributed 
to this relatively low group mean total sleep time. After the subjects 
had been adapted to the laboratory, one or two nights elapsed before 
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they returned for the recording night. This may have resulted in some 
subjects not being fully adapted to the laboratory. The results of this 
study were based on only cnc night's EEG a.,d physiological reoordings. 
Monroe's (1967) findings were supported in part by Johns, Masterton 
and Bruce (1971) who differentiated between good and poor sleepers on 
the basis of a sleep habits questionnaire, similar to that of Monroe's. 
Evidence of greater psychological distress in poor sleepers Was seen 
both in their higher scores on psychiatric tests and in biochemical 
measures of stress, namely adrenocortical activity, in comparison with 
the good sleepers. Monroe (1967) has suggested that a high level of 
autonomic arousal may be a concomitant, if not causal factor in abnormal 
sleep patterns. Sleep is associated with low levels of autonomic arousal; 
individuals who are highly aroused may therefore experience difficulty 
. in falling asleep. However, the studies discussed below would fail to 
support this suggestion. 
Hauri and Good (1975) found a slight negative relationship 
between frontalis musole tension and sleep onset time. They studied 15 
subjects ranging from self-defined excellent to very poor sleepers;· 
poor sleepers did not show higher El1G levels than good sleepers five 
minutes prior to "lights out", and throughout the first "sleep cycle". 
The authors found that there was no threshold below which frontalis 
muscle tension had to drop before sleep could occur. Freedman and 
Papsdorf (1976) and Browman and Tepas (1976), using·a group of. insomniacs 
and good sleepers respectively, were also unable to find any significant 
relationships between initial autonomic level and sleep onset times. 
The former measured heart rate and the El1G from the frontalis, masseter 
and forearm extensor muscles, and the latter heart rate and forearm 
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muscle tension. Furthermore, Borkovec and Fowles (1973) reported that 
reduction of physiological arousal as measured by skin conductance, 
forearm muscle tension and heart rate was Ultrelated to the insomniacs' 
self-reported reduction in sleep onset time. It has been suggested 
by Jacobson (1938) that insomnia might be caused by fluctuations 
of the ~~ level rather than by the absolute EMG level. 
In the studies discussed above, the ~ has 'been used as an 
indicator of body tension. However, it is debatable whether the ~ 
measured at a particular muscle site can be extrapolated to the muscle 
groups of the whole body. There is some disagreement as to which muscles, 
if any, are predictive of the overall state of muscle tension in the 
body. Nidever (1959) and Balshan (1962) concluded that a general 
muscle tension factor did exist. They found that the factor of general 
muscle tension was centred about the limb muscUlature in both males 
and females. Balshan (1962) found that in response to an auditory 
stimulus, the muscle tension pattern remained the same; 'but this was 
not true for all conditions, for when Nidever's subjects performed a 
serial learning task the muscle tension factor shifted to the neck and 
head muscles. This shift may be attributable; to the head movements 
the'subjects made in order to view the display. Voas (1952) reported 
that the arm muscles were the best indicators of muscle tension during 
mental work. However, during stress and frustration, tension was found 
to be most prominent in the trapezius and masseter muscles. These 
findings suggested that there may not be just one muscle tension factor 
for all individuals under all conditions. As stated by Goldstein (1972), 
"since there is no i=ediate answer to the problem of selection of 
muscle groups, it would be best for the investigator to sample several 
------~------------------........ 
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muscles in different parts of the body". There is also the problem of 
comparing the EMGs from different muscle groups, as they may be at 
different depths which can cause distortion and attentuation of the signal. 
Of the studies previously considered, only the Freedman and Pa.psdorf (1976) 
study attempted to measure the EMG from more than one muscle group. 
Although the EMG can provide information'about the state of tension 
at a particular muscle site, caution must be applied when extrapolating 
,these findings to the whole body. 
With regard to the psychological characteristics of self-reported 
insOmniacs, Ka.les et al. (1976), Johns et al. (1971), Monroe (1967) 
and Stonehill et al. (1976) have all found a relationship between 
self-reported insomnia and psychological disorders associated with 
personality and mood. Overall, the self-reported insomniacs appeard 
to be anxious, depressed, tense and unhappy. 
The literature does not indicate any strong causal relationship 
between physiological arousal and insomnia; it could be the psychological 
component which is all important with the "aroused mind" rather than the 
aroused sympathetic nervous system being the cause of many reports of 
,insomnia. Thus, "psychological relaxation" might be the major component 
of ncn-drug treatments of insomnia and not "physiological relaxation"., 
Physiological relaxation is defined as an absence of muscle tension, that 
is the muscle fibres lengthen. However, when referring to physiological 
relaxation in this context, it does not necessarily imply a total absence 
of muscle tension, but rather a reduction in its level accompanied by 
a reduction in the level of some other indicators of autonomic arousal, 
such as heart rate or respiratory rate. Paul (1969) found that training 
in relaxation techniques brought about a reduction in several parameters 
! 
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associated with physiological arousal. Psychological relaxation is 
a more ambiguous term and refers to a "quietening of the mind". The aim 
of psychological relaxation is to prevent the individual from worrying 
and pondering about various issues and to encourage him to place his 
worries and amcieties on one side. Both forms of relaxation are seen 
here as contributing to the general "winding down" of the subject. 
However, it is quite possible that a relationship between 
"psychological tension" and "bodily tension" does exist, but this is 
a debatable point, due to·the varying results which have been obtained. 
These differences in results may be due to some of the following reasons: 
1. the difficulties involved in defining amciety itself, 
2. some investigators have recorded from one muscle group only, 
3. there are problems in determining whether the experimental conditions 
are free of stress dUring the resting condition. 
In one investigation conducted by Malmstrom (1968), the Zuckerman 
Affect Adjective Check List (AACL), (Zuckerman & Lubin, 1965) and the 
Nowlis Mood Adjective List (MCL), (Nowlis & Nowlis, 1956) were utilised 
... 
together. During a motion picture and during radio static noise, 
frontalis muscle tension was found to correlate positively with the· 
AACL, but·negatively with the MCL: apparently, these two scales have 
tapped different aspects of the psychophysiological state of anxiety. 
Balshan: (1962) eri.mined the EMG from 16 muscle groups of subjects 
selected because of their extreme scores on the Freeman (1953) and 
Taylor (1953) Anxiety Scales. There was no difference between the 
groups according to the EMG measure during the resting state; during 
an audio stimulus, however, the more amcious group responded with 
significantly greater activity in nine of the muscle groups. Sainsbury 
and Gibson (1954) found elevated muscle action potentials in the 
~------------------------------....... 
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frontalis and forearm extensors of anxious patients during a resting 
state. However, these subjects were selected on the basis of signs of 
tension and symptoms of anxiety. 
There appeared to be no obvious relationship between Er1G measures 
and anxiety, but the result-s were clearly dependent upon the definition 
. . 
of anxiety, the procedure for selecting subjects, the experimental setting, 
whether the subjects were studied at rest or whilst performing a task, 
and which muscle groups were measured. Nevertheless, the possibility 
still exists that if the inscmniacs do suffer from high levels of 
anxiety which might be reflected in both psychological and physiological 
measures, then lowering anxiety, for example, by relaxation training 
might reduce their sleeping difficulty. Studies which have evaluated 
various methods of relaxation as a treatment for insomnia will be reviewed 
in later sections. 
3.0 POSSIBLE NON-DRUG f1ETHODS FOR THE TREATMENT OF INSmlNIA 
3.1 Practical Difficulties in Comparing Studies 
It is very difficult to make direct comparisons between studies 
using insomniacs for the following reasons: 
1. Some studies are entirely based upon self-report questionnaire 
responses, for example, Borkovec and Fowles (1973), whilst others 
use the objective measure, the EEG, either alone or in combination 
with the questionnaires (Borkovec & Weerts, 1976). The subjective 
reports are prone to intervening variables such as response set, 
whereby the subjects might respond in accordance with the experimenteri 
expectations and to the problem of overestimation of sleep cnset 
times by insomniacs (Monroe, 1967). Hdwever, as suggested by Hinkle 
and Lutker (1972), the subjective experience may be the critical 
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factor in the complaint of insomnia. Therefore, one cannot dismiss 
self-repor't studies. 
2. There is a difference of opinion in some cases between those 
experimenters who use the EEG measure of sleep onset time; some 
use the stage 2 criterion for defining sleep onset time, some 
stage 1 and others fail to state their sleep onset criteria. 
3. It is often not clear whether or not the insomniacs were receiving 
any treatment either prior to, or during the study. If they were, 
it is necessary to know the length and type of treatment. 
4. The type of insomnia under investigation is seldom clearly defined, 
for example, it is often not stated whether the insomniac suffers 
primarily from a sleep onset disturbance, early morning awakening, 
or a combination of both. It is also useful to know whether the 
insomnia is chronic or acute. 
5. Some studies are carried out on hospitalised patients suffering 
from either physical or mental disorders. Such patients are likely 
to be receiving various treatments which may confound any results 
obtained. Also, many of these patients may be spending the majority 
of their time in bed and therefore, it is to be expected that they 
would experience difficulties in falling asleep at night. 
Taking these points into consideration, subsequent sections will 
survey and evaluate some of the insomnia studies relevant to the 
present research. 
3.2 Relaxation Therapy 
One possible method of reducing anxiety is by means of relaxation 
training. Jacobson (1938), using his progressive relaxation technique, 
was the first to report the use of relaxation therapy in the treatment 
of insomnia. However, it vIas not until the self-report study of Kahn, 
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Baker and Weiss (1968) that this method of treatment was further 
assessed. They employed a relaxation technique known as autogenic 
training, devised by Schultz.and Luthe (1959). As wita the progressive 
relaxation technique, the subjects were taught to relax voluntarily the 
main muscle groups; autogenio training simply places greater emphasis· 
on the awareness of sensations than the progressive relaxation technique. 
Eleven of the t~irteen subjects who completed the training programme 
reported a decline in their sleep onset times. This study was later 
criticised by Eisenman (1970) on the following grounds: 
1. for confounding relaxation therapy with Rogerian interviewing, as 
all the subjects wera interviewed prior to the study, 
2. for their lack of an independent control group, 
3. for failing to obtain behavioural or physiolOgical measures to 
correct for possible biases of verbal report~ 
A variety of similar studies have since been conducted with slight 
modifications. Eorkovec and Fowles (1973) attempted to control for 
possible placebo and demand effects. Their placebo group participated 
in self-relaxation which involved concentration on neutral and relaxing 
images. The other conditions consisted of a no treatment control group, 
a progressive relaxation group and an hypnotic relaxation group. In 
order to reduce demand effects, the experimenters told the subjects that 
the actual purpose of the study was to assess the effect of the techniques 
in reducing physiological arousal. The reason for this was that in some 
cases an individual may simply respond in accordance with the expectations 
and attitudes conveyed by the experimenter with respect to a particular 
treatment and not to the treatment alone. These expectations are 
normally conveyed by the instructions given to the subjects: for example,-
if an insomniac is told that. drug X has strong hypnotic properties and 
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is expected to send him to sleep in minutes, then the experimenter is 
almost "deinandirig" the subject to respond favourably to the drug. 
Self-report studies ~~ more susceptible to de~d effects tr~ studies 
employing objective measures. Demand effects can sometimes be reduced 
by appropriately adjusting the instructions given to the subjects. One 
may even give some counterdemand instructions·; for example, the subjects 
could be instructed that the treatment would not be effective until after 
the fourth day. Eorkovec and Fowles (1973) found that all three treatment 
conditions were almost equally effective in improving the reported time to 
fall asleep, number of awakenings and how rested the subjects felt in the 
morning in comparison with the no treatment control group. If these 
non-drug treatments exert their effects via physiological relaxation, then 
one would expect the progressive relaxation group to show significantly 
greater improvement than the other two groups. Paul (1969) has shown 
that an abbreviated form of relaxation training was significantly more 
effective than hypnotic suggestion and self-relaxation in producing 
decreased physiological arousal as determined by heart rate, muscle 
tenSion, respiratory rate and skin conductance. 
In a similar study carried out by Haynes, Woodward, Moran and 
Alexander (1974), the placebo group, who discussed neutral topics with a 
therapist reported a reduced sleep onset time. This finding partly 
supported the results of the Eorkovec and Fowles (1973) study. However, 
in the Haynes et al. (1974) study the relaxation therapy was significantly 
more effective than the placebo treatment. These authors suggested that 
the effectiveness of the group relaxation could be a function of cognitive 
control rather than de.creased physiological arousal. Once again the 
issue was raised that "psychological relaxation" rather than "physiological 
relaxation" may be the important factor in reducing sleep onset times. It 
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is also interesting to note that the placebo conditions in these two 
studies were not matched. In the Borkovec and Fowles (1973) study, the 
placebo group focused .:.pon neut:r::.l' !:na.ges, whereas, in the Haynas et al. 
(1974) study, the placebo group actually discussed sleep topiCS, as well 
as neutral topics with the therapists. Such a discussion may have 
caused the'insomniacs to focus more upon their sleeping difficulties. 
If the psychological component is of major importance in the treatment 
of insomnia, as was suggested earlier, then the Borkovec and Fowles' 
(1973) placebo group would be expected to have had more therapeutic 
value than that of Haynes et al. 's (1974) study. Fuxthermore, since 
the placebo treatments in both the Borkovec and Fowles (1973) and the 
Haynes et al. (1974) studies were able to reduce sleep onset times, it 
suggested that placebo, expectation and demand effects all play an 
important role in the alleviation of self-reported insomnia. Another 
factor which may have contributed to the difference in results from 
these two studies is the scheduling of the relaxation training sessions. 
In the Haynes et al. (1974) study, the subjects were given 30 minute 
training periods, twice per week for three weeks. In the Borkovec and 
Fowles (1973) study the subjects were given three, one hour training 
sessions. 
Nicassio and Bootzin (1974) foUnd that both autogenic training 
and progressive relaxation were markedly superior to the placebo 
self-relaxation and the no treatment group. This result appears to, 
be contrary to the findings of the Borkovec and Fowles' (1973) study, 
which showed that relaxation therapy did not result in significantly 
greater improvements than a form of self-relaxation. One explanation 
for this difference is that Borkovec and Fowles' (1973) subjects could 
be classified as moderate insomniacs, with a group mean sleep onset 
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time of 45 minutes, in oontrast to Nioassio and Bootzin's (1974) severe, 
ohronio insomniaos, with a mean reported sleep onset time of 120 minutes. 
The insomniao3 of the Nioassic and Bootzi.~ (1974) s~udywere- mere-
comparable with those of the Haynes et al. (1974) study who had a mean 
reported sleep onset time of 94 minutes. A study oonduoted by Nioolis 
and Silvestri (1967) indicated that chronic, severe insomniaos may be 
more resistant to placebo therapy than moderate insomniaos. However, 
this study examined only hospitalised, psychiatrio patients over two 
nign:ts, with the sleep onset defined by observation. Also 17 of _ -
Nioassio and Bootzin's (1974) subjeots had stopped taking their 
medioations only one week prior to the oommencement of the study. 
Therefore, some of these subjects may have been experienoing drug 
withdrawal effects. Another differenoebetween this study and the 
majority of others is that the subjeots were drawn from the general 
population, whereas, for the other studies they were ohosen from the 
student population. Again the plaoebo oonditions were not matohed, 
for in the Nioassio and Bootzin (1974) study the placebo group was 
simply scheduled time to relax, but in the Borkoveo and Fowles (1973) 
study the plaoebo group aotually had oontaot with a therapist and 
oonoentrated upon neutral images whioh appeared to be of greater 
therapeutio value. 
One important failure, common to the studies so far considered, 
has been the absence of suitable control groups to allow for the effeots 
of demand oharaoteristios, speoifio therapist effeots and other treatment 
variables; for example, Borkoveo and Fowles (1973), Haynes et al. (1974), 
~ahn et~. (1968) and Nioassio and Bootzi.~ (1974) alL failed to 
oontrol for at least one of these variables. Of the self-report 
studies, the one oonduoted b~Steinmark and BorkQveo (1974) was well 
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. controlled. The results of this study indica~ed that under conditions 
of counterdemand instructions, relaxation training was more effective 
than a placebo condition at reducing reported sleep onse~ times. But, 
this was not the case when positive demand instructions were given. 
One objeotive study by Borkovec and Weerts (1976) indicated that 
relaxation training was only marginally more eff:ective than the placebo 
condition at reducing the sleep onset time of insomniacs, as measured 
by the first appearance of stage 1 sleep, under positive demand conditions. 
This finding did not hold for the sleep onset times when measured to the 
time of the first appearance of stage 2 sleep. The findings of this 
study were weakened by the fact that both the placebo and the no treatment 
control groups showed a marked reduction in their sleep onset times under 
counterdemand instructions. The authors suggested that the laboratory 
setting itself may have contributed a ~jor placebo component, thus 
accounting for the improvement of these groups. However, this explanation 
is not completely satisfactory as these groups showed an increased 
sleep onset time under positive demand conditions, in comparison with 
their sleep onset times under counterdemand instructions. If it was 
the laboratory setting which was bringing about their improvement, one 
would still expect its effects to be present, maybe even to a greater 
extent, under positive demand instruction conditions. Alternatively, 
these results might be due to the large amount of night-to-night 
variability reported by Karacan, Williams, Littell and Salis (1973) 
for insomniacs on various sleep parameters. ~ney stated that a night 
of poor sleep tends to be followed by a better night's sleep, which 
would account for the non-systematic variation in sleep onset times. 
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From the literature reviewed, it is debatable whether relaxation 
training can be classified as a "sleeping aid". In many of the studies 
it appeared to have little advantage over the placebo conditioIl, 
especially when the placebo was 'administered under positive demand 
conditions, ~Iith moderate insomniacs. 
3.3 Systematic Desensitisation Therapy 
, 
In brief, systematic desensitisation therapy consists of neutralising 
the anxiety provoking stimuli by counter conditioning a relaxation 
response to the stimuli. This technique was devised by I'Tolpe (1958) 
and has been used in the field of psychotherapy. Gershman and Clouser 
(1974) applied this therapy to a group of insomniacs. They compared the 
techniques of muscle relaxation training and systematic desensitisation, 
using recorded instructions in a group setting. It was found' that 
both treatments were equally effective and significantly superior to 
the no treatment control group in improving reported sleep quality. 
llut no data were presented on the changes in the various sleep parameters. 
This study failed to control for possible placebo and demand effects on 
self-report questionnaire responses: it therefore provided only slight 
evidence for the efficacy of progressive relaxation and systematic 
desensitisation as possible treatments of insomnia. Both techniques 
appeared to have similar effects' 
Ribordy (1976) carried out a controlled, self-report study with 
insomniacs in order to compare the following treatments: 
a) relaxation training, 
b) systematic desensitisation, 
c) distraction procedure, subjects in this group were trained with 
an imagery prooedure involving "neutral scenes". 
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d) no treatment, control condition. 
CO'llllterdemand instructions were employed. It was fO'Ulld that all three 
treatment procedures produced a signit'icant decline in reported sleep 
onset time, in comparison with the no treatment control condition. 
Thus, neither of, the studies discussed above has shown systematic 
desensitisation therapy to be superior to relaxation therapy in the 
treatment of insomnia. Moreover, neither of these treatments appeared 
to be significantly superior to the placebo condition, 'Illlder cO'llllter-
demand instructions. 
3.4 Biofeedback 
The role of biofeedback training as a possible treatment for 
insomnia has not been investigated to the same extent as the other 
techniques. The two main EEG studies were conducted by Hauri and 
Good (1975) and Freedman and Papsdorf (1976). The former fO'lllld that 
biofeedback was ineffective as a treatment for insomnia, according to 
EEG criteria, but effective when the change was measured by questionnaire 
responses. The latter found it be effective, according to both EEG 
and subjective measures. Both studies employed frontalis muscle EMG 
biofeedback. The difference in results may be attributable to some of 
the reasons listed in section 3.1, chapter one. For example, Freedman 
and Papsdorf (1976) defined sleep onset as the time from "lights out" 
'Illltil the first two minutes of stage 1 sleep, whilst Hauri and Good (1975) 
did not even define their sleep onset criteria. The former used six, 
30 minute biofeedback training sessions and the latter employed cne 
hour'biofeedback sessions until both patient and therapist felt that 
maximum benefits had been achieved (mean 22 sessions, range 13-67). 
The Freedman and Papsdorf (1976) study also included a control group 
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and a group who underwent progressive relaxation training. The Hauri 
and Good (1975) study did not employ a control group. It did appear 
from the results of the Freed.ma.n and Papsdori' (1976) si;-.;.dy that 
biofeedback was no more effective than progressive relaxation in the 
treatment of insomnia, but both were markedly superior to the control 
condition in this study. 
Other investigators, for example, Budzynski (1973) recommended 
a more elaborate biofeedback training sequence for the treatment of 
insomnia. This sequence includes: 
1. frontalis muscle EMG training, 
2. alpha EEG training, (for those individuals who still exhibit 
predominantly beta rhythms after EMG training), 
3. theta EEG training. 
However, the evaluation o~ the above procedure has been limited to 
self-report studies which in many cases lack a control group. Budzynski 
(1973) has evaluated the above sequence with six chronic insomnia clients 
and has reported that four moderately improved and one markedly improved. 
3.5 Summary of Non-Drug Treatments 
A major component in the treatment of insomnia appears to be 
anxiety reduction which can be achieved by a variety of methods, some of 
which were discussed in the previous sections. OVerall, the literature 
reviewed suggested that there is some doubt as to the effectiveness of 
these possible non-drug treatments.~ly progressive relaxation 
training, systematic desensitisation therapy and biofeedback as alleviators 
of insomnia. In some studies, for example, Borkovec and Fowles (1973) 
and Ribordy (1976), the non-drug "aids" appeared to be no more effective 
than the placebo condition, especially when administered under positive 
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demand conditions with moderate insomniacs. This may have been because 
the placebo conditions themselves, in some studies, appeared to have 
therapeutic value. :.~ tieusral, there was no significant difference 
between the three possible treatments, with respect to their "sleeping 
aid"'potential (Freedman &Papsdorf, 1976; Ribordy, 1976). 
An element common to all, three possible treatments and some of 
the placebo conditions was that they involved the active participation 
of the insomniac. This may be an important component of these possible 
treatments, since the Davison and Valins' (1969) study indicated that 
when patients believed that they had contributed to their own treatment, 
their improvement, was maintained. Sinceinsolllllia. can be associated 
with "taking one's, worries to bed", then the concentration involved in 
the above procedures would be beneficial. storms and Nisbett (1970) 
have illustrated,this point; by describing the insomniac as being 
trapped in a vicious circle, consisting of' three stages: 
1. the occurrence of symptoms, 
2. worry about symptoms, 
3. consequent exacerbation of symptoms. 
Thus, to alleviate the insomnia this cycle must be broken at some point. 
Any teChnique which distracts the insomniac"s attention away from his; 
sleeping difficulty may have beneficial effects; this was indicated, 
by the favourable results produced by some of the placebo conditions, 
previously discussed. As already mentioned "psychological relaxation" 
may be necessary prior to the onset of sleep. Although no causal 
relationship between physiological arousal and insomnia has been 
established, the sensation of muscle relaxation, as suggested by the 
instructions of these behavioural techniques may bring about 
"psychological relaxation". 
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3.6 Drug versus Non-Drug Treatments 
Although the previous sections have focused upon non-drug 
treatments for insomnia, if; is the hypnotic and sedative drugs which 
are normally prescribed for the treatment of insomnia. Clearly, as 
new hypnotics and sedatives become available the prescribing trends 
will change. This can be seen from table 1, in Appendix I. These 
data refer to the United states, but Cohen and Blutt (1978) claimed 
that there have been similar trends of increasing benzodiazepine 
prescriptions in England. It is also noteworthy, that during the period 
investigated (1974 - 1976) there was a decline in the total number 
of hypnotics prescribed. This may indicate that doctors are now more 
aware of the underlying causes of the symptom insomnia. 
Several recent review articles, for example Mathis (1978), 
discussed.drug treatments of insomnia, but also emphasised that another 
important aspect in the treatment of some cases of insomnia was the 
establishment of a psychotherapeutic relationzhip with the patient in 
... . . 
order to determine th~ underlying causes. There is an indication that 
not only are prescribing trends changing, but that non-drug methods are 
also being employed in conjunction with drug treatments. "What are 
the advantages and disadvantages of drug and non-drug treatments?" 
Some of the major points are listed below. 
Drug Treatments 
Advantages 
1. HYPnotics and sedatives generally produce the desired effect, at 
least initially and can be very useful if used for a short time, 
for example, during times of emotional stress. 
2. They are quick and easy to take. 
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Disadvantages 
1. Tolerance to the intial hypnotic/sedative dosage can build up. 
This develops at different rates according to the hypnotic used, 
but a few weeks is sufficient for most drugs (Kales, Kales, Bixler & 
Slye, 1971). It is then necessary to increase progressively the 
drug dosage in order to maintain the improvement. In the case of 
the barbiturates the risk of self-poisoning and the likelihood 
of drug dependence are also increased. However, those insomniacs 
who fail to increase the dosage of the hypnotic/sedative may 
eventually have a longer sleep onset time, after· having taken the 
drug for several weeks, than they did prior to the commencement of 
the treatment. It is· more frustrating for an insomniac to be 
unable to fall asleep quickly when taking an hypnotic/sedative 
than when receiving no treatment. This is referred to as the 
reverse placebo effect or attribution process (storms & Nisbett, 
1970). 
2. Hypnotics/sedatives interfere with the quality of the night's 
sleep. The barbiturates, in general, reduce the amount of rapid 
eye movement (REM) sleep. However, repeated drug administration 
can cause REM sleep to return to baseline values. These effects 
appear to be drug and dose related. For example, a low therapeutic 
dose of the benzodiazepine Flurazepam (15 ~.) has little effect 
on either REM or stage 4 sleep. At higher doses there may be 
reduced stage 4 sleep with inhibition of RD! sleep (Kales et al., 
1971). It is not clear at present what effects REM sleep 
suppression will have upon the individual, but it is apparent 
that the effects are not as dramatic as the early researchers 
had envisaged. Although this property of hypnotics/sedatives 
has been listed as a disadvantage, one cannot be certain 
28 
whether these changes in sleep patterns are detrimental. 
3. There is also the problem of drug withdrawal insomnia. This is 
characterised by ~ rebound of REM sleep, often with disturbing 
dreams or nightmares accompanied by frequent awakenings (Oswald & 
Priest, 1965). The individual may then feel compelled to take a 
"sleeping pill" in an attempt to return to sleep. In other words 
a vicious circle can be set up. 
4. They often leave one with a hangover the next dsy (OSwald, 1973). 
The commonest symptoms being fatigue, sluggishness, apathy, decreased 
motivation and clouded thought. The degree of this effect depends 
upon the individual, the tests used to assess this effect and 
the hypnotic/sedative type and dosage. These effects can lead to 
the insomniac taking counteracting stimulants during the day. 
5. Hypnotics, upon interaction with other drugs, can produce dangerous 
side-effects. 
Conclusions 
The drug treatments of insomnia have many disadvantages, but they 
do appear to be beneficial if used for a short period under close 
supervision. 
Non-Drug Treatments 
Advantages 
1. They are non-toxic. 
2. It is unlikely that they will interfere with the stages of sleep. 
However, little work has been done in this area as many of the 
studies are based on self-report measures. 
3. Some forms of non-drug treatments, such as relaxation therapy, may 
make the patient feel that he is "helping himself", which may be 
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a critical component in the treatment of insomnia. Also, these 
treatments involve a large amount of therapist-patient contact, 
so enhancing a placebo effect. 
4. Tolerance to these treatments seems unlikely.' Borkovec and Weerts 
(1976), in a one year follow up questionnaire study, found progressive 
relaxation therapy to be more effective than placebo in maintaining 
reported sleep improvement. 
Disadvantages 
1. The initial effects produced by these treatments are likely to be 
less marked than those produced by hypnotics. For example, 
relaxation training requires practice and is time consuming; so, 
although 20 minutes relaxation.training may result in a 30 minute 
reduction of sleep onset time, the procedure may not be cost 
effective of time. 
2. Since these procedures are often time consuming, the insomniacs 
may not continue with the treatment for any great length of time. 
Conclusions 
The non-drug treatments have several advantages over the drug 
treatments, but in the majority of cases they would not be cost effective 
of time. Furthermore, the majority of insomniacs may prefer their 
doctors to prescribe a drug'rather than, for example, a relaxation 
training programme. 
Al though various claims are made by the manufacturers of "sleeping 
aids" concerning the hypnotic potential of their products, there has 
been little objective evaluation conducted in this field. Cycloid 
vibration is the "aid" which will be objectively evaluated in this 
research programme. This "aid" was chosen primarily because the 
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manufacturers were willing to provide the fUnding for the evaluation 
and also because it is a ·relatively new, expensive "aid" on the market. 
The rationale for the claims· that cycloid vibration, provided by the 
Niagara Therapy cushicns,"aids" sleep is presented in the next section. 
4.0 THE RATIONALE BEHIND THE CYCLOID VIBRATION STUDIES 
Bierman (1960) found cycloid vibration applied to the subjects' 
"back and posterior aspect of their lower extremities" to be effective 
in increasing trunk flexibility as measured by the finger to floor test. 
It would appear that this effect is brought. about by muscle relaxation. 
Atha and \fueatley (1976) reported that cycloid vibration at a frequency 
of 44 Hz., provided by two Niagara Therapy vibrating cushions, under 
the thighs and lower back of the seated subject, was as effective as 
classical mobilising exercises in improving joint mobility. Joint 
mobility was measured by a modified sit-and-reach test whiCh focused 
primarily upon hip flexion mobility. The authors tentatively suggested 
that "the primary mechanism involved in increasing short term mobility 
in joints limited by mtlsculo-tendinous ties, is a re-setting, under 
conditicns of excessive proprioceptor activity, of some centrally 
controlled level of mtlscle relaxation". Matheson, Edelson, Hiatrides, 
Newkirk, Twinem and Thurston (1976) were also able to demonstrate the 
"relaxing powers of vibration". Frontalis muscle activity, as measured 
by the EMG, was shown to decrease after vibration in comparison with 
a control group. The authors ·concluded that these results indicated 
that vibrotactile stimulation, especially in the lower back, is able 
to enhance muscle relaxation. In view of some of the comments made in 
section 2.2, chapter one, although the Er-1G was lowered in the frontalis 
muscle group, this does not necessarily imply that mtlscle tension 
throughout the body was reduced. The same·holds for the mtlscle 
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relaxation measures used in other studies • 
. Nevertheless, since c~cloid vibration has some muscle relaxing 
properties, it may be a useful "aid" for some psychotherapeutic 
treatments of, for example, tension and insomnia. However, the evidence 
cited in the previous sections for phYSiological arousal being one 
of the main causal factors of insomnia was very weak and seemed to . 
indicate no necessary, causal relationship between the two. But, some 
of the relaxation techniques such as biofeedback, systematic desensitis-
ation and progressive relaxation have produced some favourable, positive 
results in the treatment of insomnia, although in many cases the 
improvement was seldom greater than that produced by the placebo 
condition. It is therefore debatable whether the improved sleep is 
brought about by psychological rather than physiological means. 
Furthermore, of the 11 studies considered in t..'1.e non-drug treatments 
of insomnia,(sections 3.2 - 3.4, chapter one),.only three h3n used 
EEG criteria for measuring sleep onset times. Thus, there is a need 
for more objective studies in this particular field. 
The "sleeping aid" to be investigated, cycloid vibration, is 
quite different from the techniques already examined in that it 
requires no training of the subject: . he simply has to sit on the cushions •• 
The relaxation is brought about by mechanical means, whereas, with 
the other techniques the subject had to learn to relax. It could be 
implied therefore, that vibration may have different properties with 
regard to the possible treatment of insomnia in compa=ison with the 
other techniques. 
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5.0 PILOT STUDIES - INTRODUCTION 
Since the sensations provided by the vibrating cushions were 
rather novel .:md. unusual, and because' there' appeare,d,' to the subjects, 
to be no obvious connection between vibration and sleep, the experimenter 
was rather hesitant about initially using these devices with sleep onset 
insomniac subjects. It was therefore decided that, before using the 
vibrating cushions with insomniac subjects, these devices should be 
first evaluated with a group of good sleepers, if the vibration 
disrupted their sleep patterns, it would be unwise to test these "aids" 
on a group already suffering from sleeping difficulties. A further 
reason for this pilot study was to familiarise the experimenter with 
the laboratory techniques, the EEG and the experience of being al'1ake 
all-night. Should the insomniac group be more am:ious than the good 
sleepers, as the literature suggested, then it is essential that the 
experimenter should appear confident. 
Initially nine subjects were brought into the laboratory in order 
to determine: 
1. a suitable position for the two cushions, 
2. a suitable frequency of vibration., 
The cushions were tested in three different positions, as recommended 
by the manufacturer: 
a) applied to the lower back and thighs of seated subjects (Atha & 
Wheatley, 1976), 
b) applied to the calves and thighs of the recumbant subject, 
Matheson et al. (1976) found that vibration in the lower half 
of the body was more effective in producing muscle 'relaxation, 
c) applied to the upper and lOl'1er back of the seated subject. 
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The frequencies of the cushions were set at 74Hz., 44Hz. and 14 Hz. 
The 44 Hz. setting was chosen on the basis of Atha and Wheatley's (1976) 
study, where this setting was found to enhance musole relaxation. The 
other two frequenoies were employed in order to provide a range above", 
and below 44 Hz. A duration of 15 minutes was used, as in the A tha 
and Wheatley (1976) study, for it was oonsidered that beyond this time 
limit the subjects may begin to feel bored. Subjects were asked to 
rate both the frequenoyand the"positicn of the oushions on a five 
point rating soale. After only the first three subjeots it beoame 
obvious that 74Hz. was very unpleasant as was position (0), the reason 
being that vibration at the upper level caused the neok and head to 
vibrate. This set of conditions were therefore not applied to 
subsequent subjeots. 
One interesting observation was that the majority of the subjeots 
found that the most pleasant f:requenoy was 14 Hz. This raised the; 
issue of whether this frequenoy of vibration was sufficient to produoe 
physiologioal relaxation. This low frequenoy may simply have been 
produoing a "relaxing sensation". Sinoe the introduotory seotions 
indioated that "psyohologioal arousal" may be one of the oauses of inomnia, 
it would be very interesting to investigate the effeots of this frequncy 
upon the sleep of insomniaos. 
However, sinoe the initial interest was in the muscle relaxing 
properties of oyoloid vibration, it was deoided to employ a frequenoy 
of 44 Hz., for it was this frequenoy and similar ones whioh brought 
about musole relaxation in the Atha and Wheatley (1976) and Matheson 
et al. (1976) studies. Postion (a) was chosen as the subjeots did not 
find this unpleasant in any way and this position has also been 
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previously used in the Atha and Wheatley (1976) study. It also has 
the advantage that some of the major muscle groups are situated in this 
area. 
For the pilot study, it was therefore decided to use two cushions, 
applied to the lower back and thighs of the seated subject, at a 
frequency of 44 E'z., for a duration of 15 minutes. 
6.0 METHOD 
6.1 Subject Selection 
The aim was to select six good sleepers, that is, individuals 
who have a sleep onset time of less than 30 minutes and who are not 
troubled by frequent nocturnal or early morning awakenings. They also 
had to satisfy the following criteria: 
i) they had to be unaccustomed to daytime napping, 
ii) they had to have no obvious signs of physical or psychiatric 
illness, 
iii). they had to be drug free, 
iv) they had to be non-smokers. 
Advertisements were displayed on the University campus calling for paid 
volunteers. All those who wished to participate were reqUired to 
complete a sleep questionnaire, a copy of which is in Appendix II. 
The responses to this questionnaire gave the experimenter an indication 
of their sleeping habits. The experimenter delivered the questionnaires 
personally, as this enabled the experimenter to chat with the 
prospective subjects and to explain in detail the full procedure. 
Before admitting subjects to .the study they were asked to view the 
laboratory bedrooms and they were shown the equipment, so that they 
were familiar with the laboratory setting. The laboratory consists of 
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two, private, comfortably furnished bedrooms. 
This subject sel~cticn procedure was applied to the majurity of 
subsequent studies. 
6.2 General Instructions to Subjects 
The subjects were urged to comply with the following conditions 
during the course of the sleep study: 
i) to refrain from alcohol, 
ii) to refrain from taking daytime naps, 
iii) to refrain· from any strenuous, physical exercise to which they 
were unaccustomed, 
iV) to refrain from taking medications, such as,·analgesics and 
cough medicines, 
v) to keep a fairly constant daily routine, as far as possible, 
vi) to keep their daily dietary intake fairly constant. 
These general instructions are applicable to all other subsequent 
studies. 
6.3 General Laboratory Procedure 
Subjects were studied in pairs. They arrived at the laboratory 
approximately one hour before retiring. As far as possible, subjects 
with similar retiring times came to the laboratory on .the same nights 
to avoid unnecessary disturbance to the subjects. 
A monoPolar recording technique was employed. Electrode placements 
were made according to the 10 - 20 system, they were as follows; A1, A2, 
C3, C4 and lateral to each eye •. The electrode placements are shown 
diagrammatically in Appendix VI. A ground electrode Cc ) was used. 
z 
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Eleotrodes were silver/silver ohloride disos attaohed to the scalp'by 
" 
"oollodton" glue and to the faoe by means of adhesive eleotrode disos 
I. ' 
and mioropore tape. Eleotrode gel was used to establish eleotrioal 
oontaot with the skin. Eleotrode'resistanoes were kept below 5kA and 
the eleotrodes were sealed. For each subjeot the following eleotrode 
montage was used: left eye (E1) - A1; right eye (E2) - A 1; C4 - A 1. 
A2 and C3 were not employed, but were held in reserve in oase of loss 
of either A1 or C4 during the night. Onoe the eleotrodes were affixed, 
the subjeots went about their normal preparations for bed. When the 
subjeots were settled, the eleotrodes were plugged into the individual 
headboards. The eleotrode leads were long enough to allow the subjeots 
freedom of movement. 
Reoordings were made at a paper speed of 10 mm. per seo. on a 
Grass model 78 - 12 ohannel EEG maohine. The EEG gain was set at 
101" V per mm.; the low frequenoy filter, on all ohannels was set at 
a t amplitude frequenoy of 0.3 H2., with a fall time oonstant equal to 
250 ms •. The pen filter on all ohannels was set at 30 H2. The 50 H2. 
filters were not switohed in. 
Although the same prooedure was oarried out with eaoh subjeot on 
every night, the first two nights in the laboratory were for adaptation 
purposes and EEG reoordings were not made, (Agnew, liebb and Williams, 1966). 
The subjeots were allowed to retire and rise at their usual times and 
these were kept to within ! 15 minutes on each night and morning. 
This general laboratory procedure also applies to the subsequent 
studies. 
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6.4 Analysis of Sleep Records 
Each sleep record was scored, using one minute epochs, according 
to the standardised criteria of Rechtschaffen and Kales (1968). The 
EEG measurement of sleep is explained in Appendix VII. The records 
were scored blind and independently by two, experienced scorers. If 
the disagreement between the scorers exceeded five percent of the 
epochs, it'was resolved by discussion.' Sleep onset time was defined 
as the time from "lights out" to the first sign, of stage 2, generally 
indicated by a spindle (12 - 14 HZ. activity) which was of at least 
0.5 sec. duration. The duration of the stage 2 period had to exceed 
five minutes. 
In qualifying the amounts of each sleep stage, the problem arose 
as to whether to use total sleep time, that is the period between sleep 
onset and the final awakening, including intervening wakefulness, or to 
use a fixed length of sleep time common to all subjects and nights. 
Taking total sleep time and calculating the percentage or absolute time 
in minutes of each sleep stage, has the disadvantage that REM sleep and 
the lighter stages are favoured. These stages of sleep predominate in 
the latter part of sleep, unlike stages 3 and 4. Thus, for example, 
stages 3 and 4 tend to be diluted by an increasing sleep length. It 
was therefore decided to express the stages of sleep in absolute minutes 
of a fixed length of sleep time, common to all subjects and nights. 
6.5 Experimental Design 
Six subjects, three males and females, mean age 19.6 years, were 
selected as described in section 6.1, chapter one. The general 
laboratory procedure of section 6.3, chapter one was carried out and 
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the "general instructions to subjects", as listed in secticn 6.2, 
chapter one, were given to the subjects. Each subject spent seven 
corsecutive nights in the laboratory. The expericental protocol .as: 
Nights 1 234 567 
Condition Ad Ad ]1 ]2 V1 V2 R 
Key: 
Ad - Adaptation 
] - :Baseline 
v - Vibration 
R - Recovery 
The c7cloid vibration was applied to the lower back and thighs of the 
seated subject, at a frequency of 44 Nz. and for a duration of 
15 minutes. The treatment was given 40 minutes before the subjects 
retired to bed. 
6.6 Data Analysis 
The first 450 minutes of the sleep records from sleep onset were 
analysed, this was the lowest measure of total~sleep time for all 
subjects on all nights. Stages W+1, 2, 3, 4, (3+4) and REM were all 
expressed in minutes; sleep onset time and total sleep time were also 
calculated. 
The average baseline value was, calculated for each sleep parameter, 
for each subject, and expressed to the nearest whole number. The results 
are presented in Tables (2 - 9), section 14.0, chapter one. A two-way 
ANOVA for repeated measures was performed for each sleep parameter in 
, 
order to determine if there were .~ significant differences between 
the nights (McNemar, 1969, page 338). F values yielding P levels 
equal to or less than .05 were considered to be statistically 
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significant. The summa.ry ANOVA tables are presented in Appendix VIII. 
7.0 P.EStLTS 
No significant differences were found between the baseline, 
vibration and recovery nights, for any of the sleep parameters considered. 
8.0 CONCLUSIONS 
If the vibration was disruptive to sleep one might,expect 
stage W+1 to show an increase on vibration nights, or sleep onset time 
to increase, or total sleep time to decrease. It would appear that 
cycloid vibration was having no statistically significant effect upon 
the sleep patterns of normal, healthy, young adults. Thus, the next 
step was to test the manufacturer's claims that cycloid vibration 
, would be an effective "sleeping aid". 
9.0 SLEEP ONSET INSOMNIA STUDY - INTRODUCTION 
The aim of this study was, to evaluate objectively cycloid 
vibration, provided by two Niagara Therapy cushions in the manner 
determined in the pilot study, as a possible "sleeping aid" for sleep 
onset insomniacs. The rationale for believing that cycloid vibration 
may be a possible "sleeping aid" was described in section '4~O, chapter 
one. It was decided to evaluate the cycloid vibration against: 
i) a commercial "sleeping aid", such as Horlicks, 
ii) a warm, milk. beverage without the cereal component, control 
condition, 
iii) a no treatment pre-condition, that is, two baseline nights. 
The only EEG evaluation of the effects of Horlicks upon sleep 
was conducted by Br~zinova and Oswald (1972). The subjects employed 
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in this study were not self-reported insomniacs. The results of this 
study indicated that restlessness during sleep, at the end of the night, 
was diminisheu in a group of young adults, mean age 22 years, after 
Horlicks. Restlessness was reported as being measured by "scoring all 
transitory increases of submental EMG when they rose to a level three 
times as high as the previous level and lasted more than two seconds, 
whether or not accompanied by movement artifact". In an older group 
of adults, mean age 55 years, sleep after Horlicks was of longer 
duration and less broken by periods of wakefulness. It would therefore 
be interesting to investigate if Horlicks does aid sleep in a group 
of self-reported sleep onset insomniacs. ' 
Since Horlicks has a distinctive malt flavour, the lesser known 
and more unusual tasting chocolate flavoured Horlicks was used in this 
study, with the aim of reducing the placebo effect associated with 
Horlicks. As it is claimed by the manufacturers of Horlicks that it 
is primarily the malt component of the beverage which contributes to 
its beneficial effects, it was decided to administer a control 
condition of a milk and cocoa beverage. This control condition was more 
for means of comparison with the efficacy of Horlicks rather than 
with cycloid vibration. Thus, although this study was primarily 
concerned with the evaluation of cycloid vibration, it,was thought that 
a concurrent evaluation of Horlicks would be interesting. However, the 
aim was' not to determine whether it may be the milk, malt or cereal 
component of the beverages which mayor may not improve sleep. This 
would need to be investigated in a series of separate, subsequent 
studies if an effect were to be found. The control condition in the 
Er~zinova and Oswald (1972) study consisted of a yellow'capsule which 
did not resemble Horlicks, the treatment under investigation. It might 
41 
be expected that a "pill" would elicit a.n entirely di££erent placebo 
response in comparison with a milk beverage. 
10.0 METHOD 
10.1 Subject Selection 
The aim was to select twelve subjects who were moderate sleep onset 
insomniacs. That is, indivi~uals who took between approximately 
30 minutes a.nd one hour to £all asleep, according to EEG criteria, but 
who, when once asleep were not troubled by £requent nocturnal or early 
morning awakenings. Ideally, the individuals should have been 
experiencing this sleeping di£ficulty £or approximately six months a.nd 
have been completely drug £ree. A similar subject. selection procedure 
to that in section 6.1, chapter one was adopted. As well as advertising 
on the campus for subjects a.n advertisement was also placed in the local 
paper. The heading of the advertisement being: "Does It Take You 
45 Minutes or Longer to Fall Asleep?" At no time, either during the 
initial advertiSing a.nd interviewing, or during the study, were the 
subjects given the impression that they were being treated for their 
insomnia: this was made quite clear to the subjects before they agreed 
to take part. 
Special care was taken in the insomniac subject selection procedure 
to avoid selecting those who were obviously physically or mentally ill, 
receiving treatment, or who relied upon their own sleep remedies, such 
as a sherry before bed. Out of the 45 subjects who applied, 14 were 
selected who appeared to satisfy the above criteria, according to their 
resporises to the sleep questionnaire. The aim was to obtain 12 subjects; 
the two extra were to allow for drop outs due to illness or subjects 
failing to meet the EEG criteria £or sleep onset insomnia. Freedman 
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and Papsdorf (1976) and 11o=oe (1967) had previously reported that 
insomniacs, in general, tended to overestimate their sleep onset times 
and it was anticipated that this problem would also be experienced in 
the present study. 
Thirteen subjects, selected on the basis of their questionnaire 
responses (one had been .taken ill), had their sleep onset times 
measured according to EEG criteria on their third adaptation night in 
.the laboratory. In view of the fact that all 13 subjects were self-
reported insomniacs, five had exceptionally short sleep onset times, 
(Table 10, section 14.0, chapter one) I two had a sleep onset time of 
eight minutes, two fell asleep in eleven minutes and one in thirteen 
minutes. Although several other sleep onset times measured on the 
third adaptation night failed to reach the thirty minute sleep onset 
criteria, they were not as low a~ those previously. mentioned. Subject C 
had a sleep onset time of 17 minutes which was low, but this subject 
actually commented that he considered this short sleep onset time a 
rare occ=ence. l'ihereas, the other five subjects with short sleep 
onset times, during the morning conversation with the experimenter, 
all commented that they had a fairly typical night's sleep. This 
finding posed a difficult problem. "Should all 13 subjects be employed 
in the study or should the five suspect subjects be eliminated at the 
start, leaving only eight subjects for the evaluation?" 
Although some subjects failed to satisfy the EEG definition of 
insomnia, that is a sleep onset time* of at least 30 minutes, they were 
* According to EEG criteria, sleep onset time is defined as the time 
from lights out until the first appearance of a stage 2 sleep period 
of at least five minutes duration. 
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insomniacs according to subjective criteria. All the subjects 
volunteered to take part in the study claiming that it took them at 
least 30 minutes to fall asle~p. However, the aim of the present 
study was to evaluate objectively two, commercial "sleeping aids" and 
with initial sleep onset times as low as eight minutes, one could hardly 
expect the "aid" to be able to bring about a reduction in the sleep 
onset time. One could argue that these insomniacs, since they had 
not sought medical attention for their sleeping difficulty may try such 
devices. Consideration must also be given to the fact that sleep' 
onset times of both good and poor sleepers have been shown to vary 
from night-to-night (Agnew & Vebb, 1971; Karacan et al., 1973). It 
could be therefore, that by chance the sleep onset time recording night 
coincided with a short sleep onset time for these five subjects; however, 
this idea was not bo=e out by the majority of their mo=ing comments, 
but it did hold for subject C. Maybe if these five subjects were studied 
for a greater number of nights, a long sleep latency may be observed on 
some nights. This would be a rather costly procedure in o:tder to 
obtain a few long sleep onset times. Furthermore, there would be no 
obvious method of determining which subject would experience a long 
sleep latency on a particular night. 
After careful consideration, it was decided that these five subjects 
were not representative of the sleep onset insomniac popUlation, according 
~o EEG criteria on the third laboratory night. These subjects were told 
that they would not be suitable for the present study. Two of the subjects 
were so convinced that they had taken at least 45 minutes to fall asleep 
that the supervisor had to explain to the subjects the reasons for their 
being rejected from the study. 
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At the end of the selection procedure there were only eight 
subjects, three females and five males, average age 25.6 years, with 
a group mean baseline sleep onset time of 34 minutes. Although the 
experimenter was not entirely satisfied with this group of sleep onset 
insomniacs, with respect to the length of their sleep onset times 
~ 
according to the EEG criteria, the evaluation was conducted with the~. 
It would appear that the selection of a group of sleep onset insomniacs 
which satisfies EEG criteria is a major problem in the objective 
evaluation of "sleeping aids". 
The subjects were given the "general instructions to subjects", 
as listed in section 6.2, chapter one. 
10.2 Experimental Design 
The subjects attended the laboratory in pairs and the general 
laboratory procedure as described in section 6.3, chapter one was 
carried out. After much discussion with insomniacs not used in this 
stud~, and consideration. of the fact that,' in general, inSomniacs tend 
to be rather anxious, it was decided not to use a post-sleep questionnaire. 
It was thagght that the subjects' concern about having to complete 
the questionnaire may interfere with their recorded. sleep onset times. 
However, the experimenter did informally and discretely question the 
subjects about their n.ight's sleep and any important comments were noted 
later. No feedback was given to the subjects in the mOrning; if they 
asked how long it took them to fall asleep, they were told that the 
data had not been analysed. This study was to be as objective as possible. 
Each subject underwent all three treatment conditions, vis: 
i) Horlicks made up according to the manufacturer's recommendations 
with 25 gms. chocolate flavoured Horlicks dissolved in 
250 mls. of warm milk. 
ii) 5 gms. cocoa powder dissolved in 250 mls. of warm milk. 
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This mixture was chosen in order to produce a chocolate flavour 
almost equivalent to that of chocolate flavoured Horlicks. 
The subjects were allowed to add sugar to taste to both 
beverages. The maximum amount added was 7 gms. 
iii) 15 minutes of 44 HZ. cycloid vibration, supplied by means of 
two Niagara. Therapy cushions alld applied as determined by the 
pilot study. 
All experimental conditions were administered so as to terminate 
at least 15 minutes before the subjects retired. Each "aid" was given 
.to all subjects twice over a period of six nights. No two subjects 
received the same treatment on the same night. The experimental 
conditions were administered in a detached, clinical m=ner, without 
the subjects receiving any obvious indication as to whether they may 
or may not aid sleep. The subjects were informed that it was simply 
all exploratory study alld that litUewas known about the effects of 
the three conditions upon sleep. The beverages were labelled A alld B 
alld at no time were they given their br=d names. 
It was decided to allow the insomniacs three adaptation nights; 
it is reasonable to assume that if they tend to be rather anxious alld 
tense, then it may take them longer to adapt to the laboratory setting 
thall. good sleepers. Two, baseline, no-treatment nights followed. Each 
subject spent eleven consecutive nights in the laboratory. 
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The experimental protocol was: 
Night 1 2 3 4 5 , 7 8 9 10 11 0 
Subjects 
Condition Ad Ad Ads B1 B2 H V C C V H 1, 4, 7 
" 
. III 
" " 
", V C H H C V 2, 5, 8 
• n. 
" " " 
11 C H: V V H C 3, 6 
Key: 
Ad - Adaptation 
Ads- Sleep onset time recorded 
B - Baseline 
V - Vibration 
H - Horlicks 
C - Cocoa 
10.3 Data Analysis 
The first 380 minutes of the sleep records from sleep onset were 
analysed, in one minute epochs, according to the standardised criteria 
of Rechtschaffen and Kales (1968). A total sleep time of 380 minutes 
was chosen as this was the lowest common measure of total sleep time 
for all subjects, on all nights. The records were scored blind and 
independently by two, experienced scorers. If the difference between 
·the scorers exceeded five per cent of the epochs, it was resolved by 
discussion. 
1. The sleep paraceters stage W+1, 2, 3, 4, (3+4), REM, sleep onset 
time, REM latency and total sleep time were all expressed in 
absolute minutes of the total sleep time. Sleep onset time was 
measured as the time from "lights out" until the first appea..""aIlce 
of a stage 2 period, of at least five minutes duration. The number 
of stage changes were also counted, as they are thought to be a 
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measure of restlessness during sleep. The average score for the 
two baseline nights and for each pair of treatment nights, for 
each subject, on each sleep parameter ;was used for the data- analysis. 
The results are presented in Tables (11-22),(section 14.0, chapter 
one). 
2. In order to determine if there were any significant differencee 
between the treatments a two-way ANOVA for repeated measures 
was performed for each sleep parameter (McNemar, -1969,. page 3.38) 
stage (W+1) was analysed for both the first and second halves 
- of the night. The SUIlllllaXY A1!OVA table are :presented' in Appendix IX. 
3. The sleep onset times of the insomniacs, over the recording 
nights, were analysed for trend effects to determine whether sleep 
onset times changed simply as a function of the number of nights the 
individual spent in the laboTatory, regardless of the treatment 
(Table 23, section 14.0, chapter one). 
4. It was decided to compare this group of eight insomniacs with a 
group of eight good sleepers, who are aC,tually the placebo control 
group from chapter three. Al though the two groups Were not exactly 
matched for age and sex, a general comparison between the two 
groups was seen to be worthwhile. The good sleep group's total 
sleep time was reduced to 380 "minutes and only the first eight 
\ recorded nights were used for the purpose of comparison with the 
insomniac group. 
a) To compare the night-to-night variability of the two grOUPSf 
_the standard deviations across all recording nights were 
calculated for each parameter and each subject. In order to 
be consistent with Ka.ra.can et al. (1973),:the logarithrirl6 
standard deviation scores were used when comparing the group 
mean standard deviations by the method of unrelated t-tests. 
" I 
b) To determine whether or not insomniacs differed from each other 
more than the good sleep group differed amongst themselves, 
the between subject variance estimate was calculated for each 
group of subjects, for each of the ten parameters, listed 
in 1. The results are presented in Table 25,( section 14.0, 
chapter one):. 
50' The correlation coefficient (Pearsonts r) ~~s computed between 
the actual sleep onset time, as measured by the EEG criteria on 
the third night in the laboratory, and the sleep onset time as 
estimated by the 13 subjects prior to the commencement of the 
study. The third laboratory night was considered for this 
comparison, as it was the only night on which the sleep onset 
times of all of the 13 self-reported insomniacs had been measured. 
For caloulating purposes, the lower range of estimated values was 
used. For example, if the subject estimated 30-60 minutes, then 
30 minutes was the time used. Logarithmically transformed sleep 
onset time scores were used, because the raw scores were not 
found to be normally distributed, but severely skewed to the right. 
This can be clearly seen from Graph A, (section 14.0, chapter one} 
which is a frequency plot of 35 independent sleep onset times, 
from the baseline data of good sleepers of the various studies 
in the research programme. There is a strong tendency for the 
majority of individuals to fall asleep in a relatively short 
time. In this case 24 subjects fell asleep in less than 24 minutes, 
which is the group mean sleep onset time. Graph B, (section 14.0, 
chapter one) illustrates that the logarithmic transformation 
performed on the data normalises the distribution. Skewness in 
a sleep onset time distribution was also reported by Johns (1977) 
and Agnew and Webb (1971). Johns' (1977) data showed a much 
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greater range of sleep onset times, of 2 to 186 minutes, compared 
with the scores of the present study which ranged from 5 to 82 
minutes. As commented upon by Jor.ns (1977), in order to be 
statistically correct the mean sleep onset time should be quoted 
as the geometric rather than the arithmetic mean. Throughout 
this text both are quoted in order to make comparisons with other 
studies easier. 
'Since the t and F tests have been shown tc be robust (Boneau, 1960; 
Havlicek & :i?eterson, 1974), it was considered =ecessary 'to use 
the transformed sleep onset times for these statistical tests. 
Johns (1977) also performed the t test on the untransformed scores. 
However, the Pearson's r test does not appear to have been as 
rigorously tested to determine the effects of violating the 
assumptions of the test. Therefore, the Pearson's r was computed 
using both the transformed scores, in order to be consistent with 
Johns (1977), ,and 'the untransformed scores for means of comparison. 
The computational procedure was carried out according to the 
method of I'Ieddis (1975, chapter eight). .' 
6. Table 27 (section 14.0, cljapter one) of the accumulation of the 
various sleep stages in 15 minute epochs over a period of one ' 
hour was drawn up for both the irisomniac and good sleep grouP,. 
The aim of this was to determine whether there were any 
distinguishing features between the two groups during the first 
hour of sleep. kny differences may account for the insomniacs 
feeling that they were still awake when, according to the EErr, 
they were in fact asleep. It was suggested by l'lonroe (1967) that 
poor sleepers require a longer time to reach the stages of deep 
sleep. 
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The sleep parameters of major interest when studying insomnia.cs 
are sleep onset time, tota.l sleep time, stage (W+1) a.nd the number of 
stage cha.nges, a.s they are the most dire()t .indica.tors of how ~lell a.n 
individual is sleeping. 
In a.ll sta.tistica.l tests a. P level of less than or equal to .05 
was considered to be statistica.lly significa.nt. 
11.0 RESULTS 
None of the trea.tment conditions, namely cycloid vibration, Horlicks 
or cocoa.-produced any significa.nt changes with respect to the ba.seline 
for any sleep parameter~ There were no significa.nt differences between 
the trea.tments. 
The insoIllliia.c group was found to exhibit significa.ntly grea.ter 
inter-subject varia.bility than the good sleepers for sleep onset time, 
(i1' = 4.7, df 2, 7, P .;;; .05). There was only one varia.ble, the number 
of stage changes, for which the insomnia.cs exhibited grea.ter night-to-
night varia.bility than the good sleepers, (t = 2.4, df 14, P .:; .05. two 
tailed test). No trend effects were found for sleep onset times. 
There was no significa.nt correla.tion between the prior estimated 
sleep onset times and the sleep onset times a.s mea.sured objectively on 
the third night in the la.boratory, using both the transformed (r = 0.39) 
, 
a.nd the raw scores (r = 0.45). The a.ctual sleep onset time, a.s mea.sured 
objectively for the initia.l 13 subjects, had an arithmetic mea.n of 
25 minutes a.nd a. geometric mean of 21 minutes. The lower range of 
estimated sleep onset times had a.n arithmetic mea.n of 41 minutes a.nd a. 
geometric mea.n of 32 minutes. 
----------------~--------.......... ... 
51 
12.0 DISCUSSION OF RESULTS 
These non-drug "sleeping aids" were found to be ineffective in 
reducing the objectively measured sleop onset times in this group of 
sleep onset insomniacs. However, one could argue from the mean baseline 
sleep onset times given in Table 22 (section 14.0, chapter one), that 
there was little room for improvement in some cases, where the mean 
baseline sleep onset time was less than 30 minutes. Maybe these "aids" 
, 
ought to have been evaluated upon a group of sleep onset insomniacs 
suffering from longer sleep onset-times than the present group. It 
is generally believed that the majority of more severe insomniacs 
are likely to be receiving medical treatment for their sleeping 
difficulty, which would therefore eliminate them from the present study. 
Nevertheless, with reference to Table 22 (section 14.0, chapter one) 
subjects 2 and 4, with mean baseline sleep onset times of 59 and-50 minutes 
respectively, appeared to be suffering from relatively long sleep onset 
times. The only treatment which brought about a slight reduction in 
_their sleep onset times was cycloid Vibration, which reduced the sleep 
onset time of subject 4 by 10 minutes. Upon administration of Horlicks 
the sleep onset time of subject 4 increased by 11 minutes. Subjects 
3 and 8 were also worthy of the title insomniacs; according to EEG criteria, 
with mean baseline sleep onset times of 37 and 46 minutes respectively. 
These two subjects showed a decline in sleep onset times upon administration 
of all the experimental conditions, but this was most marked for the 
cocoa control condition. Therefore, even by examining the responses 
of these four insomniacs no clear pattern emerges in response to the 
"aids". 
Another interesting observation was that, as expected, the insomniacs 
of the present study, in general, were poor estimators of their sleep onset-
I 
52 
time, even when the lower of the range of estimates was taken. 
Consideration must be given to the fact that the data used for computing 
the correlation coefficient w~re to some extent limited, as they were 
based on only one night's EEG recorded sleep onset time and upon the 
subjective estimate of sleep onset time prior to the commencement of 
the study. However, it did indicate this problem of overestimation of 
sleep onset times by insomniacs. Only three of the 13 subjects originally 
selected can be classified as insomniacs according to EEG criteria 
(Table 10, section 14.0, chapter one), that is, a sleep onset time of 
at least 30 minutes. Nevertheless, not all of the researchers who have 
studied insomnia objectively have reported that they experienced this 
problem of overestimation to the same extent. For example, in the 
Borkovec and Weerts (1976) study there was good agreement" between the 
group mean reported sleep onset times of three groups of insomniacs 
and the group mean EEG recorded sleep onset times, as measured to the 
first occurrence of stage 2 sleep. There was no individual subject 
data provided, but the authors did comment that there was considerable 
variability between "the lengths of the individual sleep onset times. 
The present group of subjeots, mean age 25.6 years, with an average 
sleep onset time of 34 minutes to some extent matched the young group 
of subjects in the Brl1zino~ and Oswald (1972) study, mean age 22 years 
and average sleep onset time equal to 27 minutes. However, the 
" subjects used in the :Br~zino~ and Oswald (1972) study were not self-
reported insomniacs. In neither the present study nor the Br~zinova 
and Oswald (1972) study was Horlicks found to reduce the" sleep" onset times 
by a significant amount. Br~zinova. and OS1mld. (1972) did find that Horlicks 
reduced the amount of restlessness in the latter hours of sleep, when 
measured by an increase in submental ~m, but not according .to the 
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number of stage changes. In view of section 2.2, chapter one, it 
would appear that muscle tension measured at only one muscle site is 
not necessarily a good indicator of general muscle tension ~~oughout 
the body. stage (\1+1) and the number of stage changes alone were used 
as indicators of restlessness in the present study, because it seems 
reasonable to assume that the subjects may only be aware of the "tossing 
and ~I associated with wakefulness or a stage change, regardless 
of the submental ~1G level. Although the ANOVA revealed no significant 
differences between the nights for these measures of restlessness, 
which supported the findings of BrE!z.inova. and Oswald (1912), the insomniacs 
were found to exhibit greater night-to-night variability for the number 
of stage changes than·othe. good sleepers. This was-the onlj parameter 
which yielded a significant difference in the night-to-night variability 
comparison between good sleepers and the self-reported insomniacs .. 
The group of self-reported, sleep onset insomniacs used in this 
study showed much less night-to-night variability when compared with 
the control group than Karacan et al.'s (1913) group of insomniacs. 
Furthermore, they only showed significantly higher inter-subject 
variability than the control group for sleep onset time. The reasons 
for this could be: 
1. Karacan' s group consisted of mixed types of insomniacs: some bad 
long sleep latencies and others early morning awakenings. The 
present group reported difficulty in falling asleep, but some 
subjects on some nights failed to satisfy the EEG criteria for a 
sleep onset insomniac. Furthermore, the present group's claim 
that they did not suffer from nocturnal awakenings was supported 
by the EEG measures, with a group mean total sleep time of 428 
minutes and the amount of stage (W+1) equal to 19 minutes on 
54 
the two baseline nights. 
2. Only one adaptation night was used by Karacan et al. (1973), whilst 
the present study allowed three adaptation nights. 
3. Karacan et al. (1973) expressed the various sleep parameters as 
percentages, which will vary as the total sleep time varies. In 
the present study the sleep parameters were expressed in absolute 
minutes of a fixed length of total sleep time which was common 
to all subjects on all nights. 
4. Unlike the present study, Karacan et al. fS (1973) experimental 
and control groups were matched. 
5. In comparison with the present study, Karacan et al. (1973) examined 
a.wider range of sleep parameters, such as the ratio of minutes 
of REM sleep to non REM sleep. 
There are two major shortcomings of this present insomnia study: 
1. Due to the difference between the subjectively· reported sleep 
onset times and the EEG measured sleep onset times, at the end 
of the subject selection procedure, there were insufficient subjects 
to study the number of experimental conditions in a balanced, 
well-designed manner. 
2. According to the EEG criteria, apart from subjects 2, 3, 4 and 8 
(Table 22, section 14.0, chapter one) it is _debatable whether·the 
other subjects should be classified as insomniacs. This group 
of eight insomniacs, as a whole, just satisfied the EEG criteria 
for a group of sleep onset insomniacs, with a group mean sleep 
onset time of 34 minutes. However, there was no significant 
difference between the group mean baseline sleep onset times 
of 'theinsomniacs and good sleepers (Table 24, section 14.0, chapter 
oneY~ when compared by an unrelated ·t test, (t = 0.2, df 14, two 
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tailed test). 
One would have expected the self-reported, sl",ep ons'!lt insomniac 
group to have had a significantly greater group mean sleep onset 
time than the good sleep group. Also worthy of ~omment is the 
fact that five subjects from the good sleep group had a sleep 
onset time greater than ,0 minutes, whereas, only four subjeots 
from the self-reported, sleep onset insomniac group had a sleep 
onset time greater than ,0 minutes. Two subjects in the good 
sleep group, subjects 1 and 6 (Table 24. section 14.0, chapter 
one), actually had longer sleep onset times than the insomniacs, 
yet they considered themselves to be good sleepers. The difference 
between the two groups appeared to be due to the subjects' 
expectations and attitudes concerning sleep and not solely to a 
time difference. Nevertheless, the experimenter was to some 
extent justified in using such a group of insomniacs because: 
i) all the subjects did claim to be suffering from sleep onset 
times of at least ,0 minutes, 
ii) none of these subjects had sought medical attention for 
their sleeping difficulty and it is therefore highly 
probable that such a group would try various non-drug 
"sleeping aids". 
Ideally, more advertisements should have "been made caliing'for 
more "insomniacs". However, since 69 per cent of the subjects ()riginally 
chosen 'had failed to' satisfy the EEG criteria for sleep onset inSomnia' 
it was predicted that, with this failure rate, selecting more subjects 
by EEG methods would be a time consuming process. Due to time restraints, 
this proposal was not feasible. Furthermore, the majority of individuals 
~-------- -- -- ----
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who claimed to have relatively long sleep onset times were receiving 
medical treatment for their sleeping difficulty, which therefore 
. elimi:la.ted them from the present study. 
''Why did al~ the subjects considered for this study initially 
present themselves as insomniacs?" ''What makes the majority of them 
'believe that they are awake, when according to the EEG criteria they are 
aSleep?" The following points are put forward as possible explanations: 
1. The sleep of the sell-reported, sleep onset insomniacs may be 
more disturbed and broken than that of a good sleep ·group, during 
the first hour of sleep. This may be reflected by such measures 
as an increased amount of stage (W+ 1) or an increased numbell-' of 
stage changes. Table 27, (section 14.0, chapter one) which was 
compiled by calculating for each subject the accumulation of the 
various sleep parameters in 15 minute epochs during the first hour 
of sleep and then expressing them as group means, clearly shows 
a marked similarity between the two groups. However, the insomniacs 
did show more stage changes than the good s~eepers during the 
first 15 minute epoch, (t = 2.36, df 14, p~ .05~ two tailed test). 
This may have created the feeling that they had been awake for 
the first 15 minute epoch. 
2. The insomniacs might fall asleep, then awake after about 40 minutes 
and then quickly fall asleep again. lifaybe the sleep onset insomniac 
meas=es his sleep onset time from the time of "lights out" until 
he falls asleep the second time. The lengths of such intervals 
were calculated for the two baseline nights and expressed as the 
average, (Table 26, section 14.0, chapter one). The group 
arithmetic mean sleep onset time increased·to 243 minutes and the 
,----------- - - --------
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geometrio mean to 196 minutes. There was no signifioant oorrelation 
between the subjeotive and the reoaloulated objeotive sleep onset 
times. Subjeot 4 ~ras the or.ly individual whose subjeotive 
estimate was in better agreement with the reoalculated EEG sleep 
onset time. In general, the time to the ocourrenoe of the seoond 
sleep onset does not offer a ~ati~fa~tor.r explanation for the 
problem of overestimation of sleep onset time by the insomniaos. 
3. There is the possiblity that the change of sleeping environment 
may have alleviated the sleeping diffioulty to some extent, 
without the subjeots oommenting upon it. In some oases the insomnia 
may have been oonditioned to the subjeott's bedroom. Therefore, 
simply a ohange in the environment; would tend to aid sleep. 
However, during the morning conversations with the subjeots the 
general response was that they felt as though they had slept the 
same as they usually did at home, thus failing to support this 
idea. It oould be that the insomniacs themselves were unaware 
of the improvement. 
4. Another reason could be that the entire laboratory setting may 
have been acting as a placebo. A lot of attention was being paid 
to the insomniacs in the laboratory setting. Someone was actually 
interested in their oomplaints of a sleeping difficulty and the 
subjects were a~e that the experimenter remained awake in 
the laboratory all-night, a faotor which they may have found 
reassuring. Thus, it is possible that the insomniacs oould 
.. 
sleep better in the laboratory than at home. However, as~entioned 
in (3), the subjeotsl olaims did not support this idea. 
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5. The insomniacs, sometime previously, may have elqlerienced a period 
of relatively long sleep onset times due, may'l:;le,. to some temporary 
anxieties or worries. Aaa result of this ~pisode they may have 
come to label themselves as "insomniacs", even though they 
elqlerience insomnia orily on a very irregular basis. This point 
can be further illustrated by reference to the findings of the 
present study, (Table 23, section 14.0, chapter one). For 
example, subject &on the fourth treatment night elqlerienced a 
long sleep onset time of 126 minutes, whereas, on every other 
laboratory night his sleep onset time had not exceeded 30 minutes, 
according to EEG criteria. If this self-reported insomniac had 
been the subject of an EEG assessment of sleep onset times on 
any night but the fourth treatment night, he would not have been 
*. 
classified as an insolllIliac, according to the EEG definition. 
However, on the fourth treatment night he would have been class-
i£ied as suffering from severe, sleep onset insomnia. It would 
therefore appear that an important feature of insomnia is the 
periodic occurrence of a long sleep onset time, on th~ basis of 
which the individual may label himsel£ as an insomniac. Although 
this is a very interesting feature, it presents a problem for the 
objective study of sleep onset insomnia. 
There is no clear indication as to which subjects may elqlerinece 
a long sleep onset on a particular night. This makes it 
impossible for the elqlerimenter to determine whether a sudden 
change in sleep onset time on a particular night is due to 
* The EEG definition of sleep onset insomnia is a sleep onset 
time of at least 30 minutes. The sleep onset time being 
defined as the time from lllights outll until the first 
occurrence of a stage 2 period of at least five minutes duration. 
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the effect of the treatment or due to the symptom insomnia itself. 
It is also likely to be a costly procedure, as several nights 
recording ~y ba required before the occurrence of a long sleep 
onset time. This feature of insomnia was considered previously 
in the subject selection procedure, where five subjects were 
considered unsatisfactory on the basIS"'of one iiight's EEG sleep 
onset time. The point was raised as to whether these subjects 
may have experienced a long sleep onset time if they had been 
studied for several nights. Even if they did, it would be a 
very inefficient and unsatisfactory approach to the objective 
evaluation of "sleeping aids", for the reasons given above. 
6. Consideration must also be given to the fact that insomniacs 
who would satisfy the EEG criteria may not be inclined to 
volunteer to take part in laboratory studies; also many of them 
may be receiving treatment for their sleeping difficulty which 
would prevent them from taking part in' the present study. 
Finally, one of the most interesting observations made during the 
administration of the sleep questionnaire to the 45 self-reported 
insomniacs was that many reported frequently taking Aspirin, which 
they claimed relieved their insomnia. This is quite extraordinary, for 
Aspirin is widely known for its analgesic, antipyretic and anti-inflammatory 
actions, but not for any hypnotic activity. On the contrary, the gastric-
irritation effect of Aspirin might be expected to disturb sleep rather 
than improve it. Clift (1975) listed analgesics amongst a number of 
treatments, such as antihistamines, cough suppressants and nasal 
decongestants, which he had prescribed for various complaints of 
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insomnia. Clift (1975) did not name the analgesics which he prescribed, 
but it is unlikely that Aspirin would be included, except, maybe, in some 
cases where the reported insomniac 1~S suffering from rheumatoid 
arthritis. A doctor would normally prescribe more potent analgesic~. 
However, there is the possiblity that on some occasions insomnia is 
s}'lIlptomatic of an underlying cause such as a headache which could be 
alleviated upon administration of a non-prescription analgesic such as 
Aspirin. It seems unlikely that all those who reported taking Aspirin 
to relieve their insomnia were suffering from an underlying cause 
which could be treated by one dose of Aspirin. It is also possible 
that Aspirin may be acting as a placebo treatment in some cases, but 
it does seem an unusual choice of placebo treatment for one generally 
associates various bedtime beverages with sleep, rather 'than Aspirin 
tablets. Furthermore, there are no published studies upon the effects 
of Aspirin (acetylsalicylic acid) upon sleep. This obserVation therefore 
opened up a new line of inquiry. 
13.0 CONCLUSIONS AND FURTHER RESEARCH 
None of the "sleeping aids" were found to produce any significant 
improvement,. either in·~he.quality or quantity of sleep, ,in the sl~ep 
onset insomniac group studied. This conclusion cannot necessarily be 
applied to the population of sleep onset insOmniacs, since, whilst 
the sleep onset insomniac group studied appeared to s,n'fer from 
sleep onset insomnia as judged by subjective criteria, their sleep 
onset times, according to the EEG criteria, were ,not significantly 
different from the group of good sleepers. In fact, some of the 
self-reported good sleepers actually had longer sleep onset times than 
the sleep onset insomniac group, when measured by means of the EEG. 
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A major component of the complaint of insomnia appears to be the 
individuals~ own attitudes and expectations with respect to sleep rather 
thJ3Cn an absolute. time difference between insomniacs and gocd sleepers. 
Insomnia is therefore predominantly a subjective complaint of sleeping· 
difficulty. This was supported by the fact that the majority of 
self-reported insomniacs overestimated their sleep onset times, according 
to the EEG measure. This phenomenon of overestimation has been reported 
by several investigators. Monroe (1967) found that his poor sleepers 
had a group mean estimated sleep onset time of 60 minutes and a group 
mean objective sleep onset time of 15 minutes. The term objective sleep 
onset time refers to the sleep onset time measured by means of the EEG. 
Freedman and Papsdorf"s (1976) insomniac group had a group mean estimated 
sleep onset time of 81 minutes and a group mean objective sleep onset 
time of 43 minutes. Finally, Carskadon, Dement, Mitler, Guilleminault 
Zarcone and Spiegel (1976) reported that their insomniac group had a 
mean estimated sleep onset time of 62 minutes and a mean objective 
sleep onset time of 26 minutes. In the present study, ·the original 
insomniac group, prior to screening, had a mean estimated sleep onset 
time of 41 minutes and a group mean objective sleep onset time of 
25 minutes, (Table 10, section 14.0, chapter one). There did not appear 
to be a common overestimation factor for the groups of insOmniacs, as 
they overestimated by factors of 4, 2, 2~ and 1~ in each study respectively. 
It can be seen therefore that there is no easy solution for obtaining 
objective sleep onset times from subjective estimates. 
Nevertheless, although the majority of insomniacs of the present 
and previous studies failed to satisfy the EEG criteria for a sleep 
onset insomniac, the fact that they reported sleeping difficulties 
still qualifies them as insomniacs from a subjective point of view. 
-- --- --- - --- -- ---------------
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These individuals do have a problem, for if a.csubjeot reports that . 
he has a sleep onset time of 45 minutes and if this is actually troubling 
~, then he is effectively an insomniac regardlesa of the EEG measure. 
Therefore, the subsequent, logical line of approach would be to 
embark upon a self-report questionnaire study which covered attitudes 
toward sleep, subject expectancies and the subjects· belief in the 
treatment. This would be an interesting line of investigation and 
a self'-report study could be carried out with the "aids" considered in 
the present study, under both positive and counterdemand instruction 
conditions. If the subject reported that he fell asleep faster after, 
for example, a night-time beverage, he is effectively cured of his 
insomnia. However, this line of approach is somewhat outside the 
sphere of competence of the experimenter and although proficiency 
could be gained in this field, the question raised is whether this 
approach would solve the dif'ficulties encountered in attempting to 
evaluate objectively various non-<irug "sleeping aids". In short the 
answer is no. Although the subjective evaluation of the various 
"sleeping aids" would provide some usef'ul inf'ormation with respect to 
the efficacy of an "aid", a major f'ailure of' this approach is that it 
would fail to discriminate between those subjects who were actually 
overestimating their sleep onset times and those who were fairly 
good· estimators. 
In order to illustrate this criticism of'the subjective approach 
the findings of the present study will be employed. Out of the 13 
self-reported insomniacs only three were found to be f'airly good 
estimators of their sleep onset times in comparison with the EEG measure, 
(Table 10, section 14.0, chapter one). It would appear that the 
complaint of sleep onset insomnia by the other ten subjects is 
predominantly psychological, on the majority of occasions. These ten 
subjects might therefore be expected to report improvement: in response 
to almost a:ny "aid", whereas, the other three subjects, whose claim of 
long sleep onset times was confirmed by the EEG, may not report a:ny 
change. Since sleep onset insomniacs who are good estimators of their 
sleep onset times are in the minority, their responses are likely to 
be weakened in a:ny self-report group study. A "sleeping aid" could 
therefore be labelled as an effective treatment for sleep onset insomnia, 
when in fact, it may fail to help those who appear to be most in need. 
As mentioned previously, these "aids" should ideally be evaluated. 
objectively· on a group of insomniacs with longer sleep onset times than 
those of the present study" However, siinilarproblems to those 
encountered in the present study {some of which have been listed below:} 
are likely to be experienced. 
1. Difficulties were encountered in obtaining a group of sleep onset 
insomniacs who satisfied EEG criteria mainly because, in general, 
they tended to overestimate their sleep onset times. Furthermore, 
there does not appear to be a common overestimation factor, so 
there is no easy solution for obtaining objective sleep onset 
times from subjective estimates. 
2. There is also the problem of obtaining drug-free insomniacs. 
Hypnotics and sedatives are the.most widely prescribed treatment 
for insomnia and this treatment may lead to the problem 6f drug 
withdrawal insomnia, which may continue for several days. or weeks 
depending on the type of drug, the dosage level and the duration 
of usage. It is not simply a matter of asking the subject to 
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refrain from taking the drug for a week prior to the commencement 
of the study.· 
3. The sleep of insomniacs has been shown to exhibit a high amount 
of night-to.-nigIitvariability in comparison with a good sleep 
group (Karacan et al, 1973). However, the insomniac group of the 
present study only showed significantly higher night-to-night 
variability than a good sleep group on one sleep parameter, the 
number of stage changes. Various possible reasons for this 
difference are listed in section 12.0, chapter one. 
4. Furthermore, psychological and somatic disorders have been found 
to be associated with some complaints of insomnia. It is 
therefore unlikely that a "sleeping aid" would be able to show 
its potential in such cases, where a treatment for the underlying 
cause of insomnia may be more effective. 
In view of the difficulties which were encountered in the evaluation 
of non-drug "sleeping aids" using a group of self-reported, sleep onsl'lt 
insomniacs, it would be very useful if an EEG model of sleep onset 
insomnia could be created in the laboratory with good sleepers. 
Essentially, the aim of the model would be to provide a long sleep 
latency which would form the basis of the initial evaluation procedure 
for various "sleeping aids", be they drug or non-drug. It was decided 
to follow up this idea by means of a laboratory study. 
One further line of investigation worth pursuing concerns the use 
of Aspirin by insomniacs to relieve their sleeping difficulty, as 
commented upon in the previous section. It;was decided to investigate 
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the grounds, if arty', for the claims that Aspirin aids sleep. It may 
appear rather contradictory that a further research proposal emanating 
from a studY evaluatil:g non-drug "sleeping aids" should be concerned 
with a possible drug "aid"· fo:;:- insomnia. However, these two approaches 
to the treatment of insomnia are not necessarily contradictory. As 
discussed in section 2.1, chapter one, the causes of insomnia are many 
and diverse, therefore, it is possible that drug "aids" may be beneficial 
to some insOmniacs, whilst others may prefer non-drug "aids". 
On the basis of the findings ·of this in! tial study the research 
programme will now proceed along two lines of inquiry: 
1. to create an EEG model of sleep onset insomnia, 
2. to investigate the effects of Aspirin (acetylsalicylic acid) 
upon sleep. 
Secticn 14.0 
RES1JLTS TABLES AND GRAPHS 
FOR 
CHAPTER ONE 
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14.1 . Explanatory Notes for the Results Tables 
All means in the results tables are expressed to the nearest whole number. 
All figures in the results tables are expressed in minutes unless 
otherwise stated. 
Key: 
A.S.A 
B 
c 
H 
R' 
V1 
V2 
Analysed Sleep Time refers to the amount of each sleep record 
analysed from the time of sleep onset. A.S.T. is the lowest 
common measure of total sleep time for all subjects on all 
nights. 
The average score for the two'baseline nights. 
The average score for the two cocoa nights. 
The average score for the two Horlicks nights. 
The score on the recovery night. 
The score on the first cycloid vibration night. 
The score on the second cycloid vibration night. 
V The average score for the two cycloid vibration nights. 
Number of Stage Changes - A stage change was counted each time a subject 
passed from one stage of sleep into another, providing the length of 
time spent in any particular stage was at least two milmtes. 
Results Tables for the study investigat~ the 
effects of Cycloid Vibration upon the s~p 
of Good Sleepers. . 
Stage W+1 Table 2 
Treatment B V1 V2 R Subject 
1 8 15 9 6 
2 41 20 21 8 
3 27 37 21 14 
4 . 35 31 24 42 
5 19 13 22 22 
6 8 11 8 5 
Mean 23 21 18 16 
S.D •. 13.8 10.6 7.1 14.1 
Sta~ 2 Table :2 
Treatment :s- V1 V2 :a Subject 
. 
1 205 22.2 204 222 
2 226 224 222 216 
3 194 181 180 207 
4 188 222 183 172 
5 254 245 219 232 
6 219 191 222 212 
Mean 213 214 205 215 
S.D. 24.1 .23.7 19.~ 24.6 
Stage 2 Table 4 
Treatment B V1 V2 :a Subject 
1 44 30 35 36 
2 28 45 42 28 
3 35 35 33 33 
4 23 31 }3 30 
5 35 38 35 37 
6 25 21 27 20 
Mean 32 33 34 32 
S.D. 7.8 8.1 4.8 3.6 
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A.S.T. for the above three tables is equal to 450 minutes 
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stage 4. Table 5 
Treatment B V1 V2. R Subject 
1 82 99 86 n 
2 75 73 70 89 
3 88 95 97 99 
4 75 75 68 72 
5 51 55 62 44 
6. ~f 1Q2 100 11 Mean 84 81 75 
S.D •. 12.2 20.1 16.1 18.8 
stage 2+4 Table 6 
Treatment B V1 V2 R S1:lbject 
1 126 129 121 113 
2 103 118 112 117 
'3 . 123 130 130 132. -
4 98 106 101 102 
5 86 93 .. ?7, 81 
6 109 1)0 121 101 
Mean 108 118 115 107 
S.D. 15.2 . 15.3 13.7 '7.3 
stage REM Table 1 
Treatment B V1 V2 R Subject 
1 111 84 116 109 
2 80 68 95 109 
3 106 102 119 97 
4 129 91 142 134 
5 91 99 112- 115 
6 123 118 92 101 
Mean 107 ' 97 113· 111 It· . 
S.D. 18.7. 12.3 18.0 1i;Q 
A.S.T. for the above three tables is equal to 450 minutes. 
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SleeE Onset Time TablG 3 
Treatment B V1 V2 R Subject 
1 5 9 5 5 
2 15 13 19 21 
3 14 18 19 13 
4 25 22 16 17 
5 25 24 47 48 
6 2~ 26 20 11 
Mean 18 19 21 20 
S.D. 8.1 6.6 13.9 14.7 
Total Sleen Time Table 2 
Treatment B V1 V2 R Subject 
1 477 463 466 456 
2 467 450 472 453 
3 465 459 456 462 
4 457 467 459 453 
5 451 453 450 460 
6 4~0 ~20 ~68 4:28 Mean 4 5 457 462 457 
S.D •. 9.3 7.1 8.3 3.7 
Subjects 
A 
B 
C 
D 
E 
F 
G, 
H 
I 
J 
K 
L 
M 
Arithmetic 
Mean 
S.D. 
Geometric 
Mean 
EEG Criteria 
11 
25 
17 
26 
48 
8 
11 
23 
26 
8 
40 
63 
13 
25 
16.8 
21 
r = 0.45 raw· scores n.s. 
. Table 10 
Estimate 
45 '- 60 minutes 
One hour or more 
1 - 2 hours 
30 - 45 minutes 
1 - 2 hours 
30 - 45 minutes-
30 - 45 minutes 
30 - 45 minutes 
30 ,..; 60 minutes 
30 - 60 minutes 
30 - 45 minutes 
About one hour 
45 minutes 
41 
32 
r = 0.39 transformed scores (loge) n.s. 
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x 
x 
x 
x 
x 
The subjects marked with a "x" were not allowed to take part in the 
study after the first EEG recording night. 
Resul ts Tables for the study investigatin~ the 
effects of non-drug "sleeping aids" upon he 
sleep of self reported, sleep onset Insomniacs. 
staei2 W+1 Table 11 
. Treatment B" V H C 
Subject 
1 25 15 1 10 
2 26 " 9 14 6 
3 16 4 8 5 
4 12 " 5 9 c; , 
5 24 24 7 63 
6 3" 13 10 11 ' 
7 30 18 21 22 
8 12 . 16 ~ 35 
Mean 19 13 14 20 
S,D, 8,8 6,8 13.3 20.4 
stage W+1 - First Half of Night Table 12 
Treatment B V H C 
Subject 
1 13 7 0 2 
2 13 5 10 4 
3 9 4 5 3 
4 1 2 9 1 
5 7 6 3 11 
6 1 8 9 1 
7/ 12 7 16 9 
8 6 6 22 20 
Mean 8 6 10 6 
S.D. 4.9 1.9 9.1 6.6 
Stage W+ 1 - Second Half of Night Table 12 
Treatment B V lE C 
Subject 
1 12 8 1 8 
2 13 4 4 2 
3 7 0 3 2 
4 11 3 0 4 
5 17 18 4 52 
6 2 5 1 10 
T 18 11 5 13 
8 12 10 12 12 
11ean 12 7 4 13 
S.D. 5.2 5,7 4,7 16.4 
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A.S.T. for the above three tables is equal to 380 minutes 
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Sta~ 2. Table 1~ 
Treatment B V H C 
Subject 
1 154 145 136 183 
2 19.6 187 203 157 
3 177 \ 190 153 173 
4 143 . 171 147 162 
5 173 157 165 138 
6 188 187 160 1.98. 
7 174 216 198 193 
8 166 164 16~ 182 
. Mean 171 177 - 16 173 
. S.D. •. 17.2 22.4 23.5 20.0 
Sta~ 2 . Table 12 
Treatment B V H C 
Subject 
1 14 29 36 27 
2 20 23 19 25 
3 25 43 32 28 
4 32 37 37 44 
5 18 32 32 15 
6 27 21 30 21 
7 34 38 37 38 
8 28 21 22 22 
Mean 25 32 31 28 
S.D. 6.9 7.5 6.8 9.2 
Sta~ ~ Table 16 
Treatment B V H C 
Subject 
1 97 90 82 86 
2 75 79 71 88 
3 93 75 83 84 
4 73 82 92 93 
5 80 84 85 84 
6 90 95 94 81 
7 72 41 50 49 
8 6~ 82 61 56 
Mean 81 79 77 78 
S.D. 11.6 16.4- 15.4 16 
A.S.T. for the above three tables is equal to 380 minutes. 
74 
stage 3+4 Table 17 
Treatment B V H C· 
Subject 
1 111 119 118 113 
2 95 102 90 11) 
3 118· 118 115· 112 
4 105- 119 129 131-
5 98 116 117 99 
6 117 116; 124 102 
7 106 79 81 87 
8 22 112 '82 81 
Mean 105 110 108 106 
S.D. .9.7 13.7 18.1 17.5 
stage REM Table 18 
Treatment B V H C 
Subject· 
1 91 102 125 75 
2 64 83 73 104 
3 70 70 105 92 
4 118 86 95 76 
5 85 84 91 80 
6 73 65 86 69 
7 70 68 72 77 
8 102 88 21 82 
Mean 84 . 81 92 82 
S.D. 18.8 12.4 17.2 11.1 
REM tatencz Table 12 
Treatment B V H C 
Subject 
1 129 65 58 155 
2 154 107 138 49 
3 80 144 92 107 
4 97 93 131 105 
5 109 112 142 123 
6 111 211 134 133 
7 98 75 70 65 
8 88 22 201 112 
Mean 108 108 121 107 
S.D. 23.8 50.1 46 34.9 
A.S.T. for the above three tables is equal to 380 minutes. 
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Number of Stage Changes Table 20 -
Treatment B V H C 
SUbject 
1 28 31 28 39 
2 46 32 47 50 
3 50 45 34 26 
4 54 47 43 46 
5 50 40 55 32 
6 29 46 43 42 
7 82 66 49 59 
8 51 40 22 22 Mean 49 43 42 43 
S.D. ' , 16.8 11 8.6 10.8 
A.S.T. for the above table is equal to 380 minutes 
Total SleeE Time Table 21 
Treatment B V H C 
Subject' 
1 420 429 451 424 , 
2 409 449 400 440 
3 428 437 437 439 
4 453 434 417 408 
5 463 434 454 418 
6 386 389 390 381 
7 463 425 465 418 
8 228 ~OO 226 ~12 
Mean 428 425 426 418 
S.D. 29.7 20.1 29.3 18.7 
SleeE Onset Time Table 22 
Treatment B V H C 
Subject 
1 22 10 8. 22 
2 59 56 60 63 
3 37 23 19 17 
4 50 40 61 56 
5 22 32 16 23 
6 12 11 18 70 
7 22 21 21 21 
8 ~6 22 22 12 
Mean 34 . 28 29 36 
S.D. 16·1 12·2 20·2 22.2 
Geometric 30 24 24 30 ~1ean 
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SleeE Onset Times for Each Treatment Ni~t 
Table 2~· 
Nights E. 1 2. ; 4 5- 6 
Subjec"!;a 
1 . 22 18 10 11 8 5 26 
2. 59 6; 60 6; 61 49 64 ; , ;7 26 . 18 15 22 26 20 
4 50 56 41 4; ;7 61 18 
5 22 ;8 26 12 19 20 25 
6; 12 2; 9 12 126 1; 11 
7 22 28 14 17 25 1; 20 
8 ~6 12 22 22 22 22 11 
Mean ;4 ;; 26 25 42 27 24 
S.D. 16.1 18.1 11.6 18.8 21·2 12.2 16·2 
Geometric ;0 29 22 20 ;1 21 21 Mean 
Mean Baseline Sleep Onset Times for Good Sleep Group and Insomniacs 
Table 24 
Subjects 
1 
2 
; 
4' 
5 
6; 
7 
8 
Mean 
S.D. 
Geometric 
Mean 
Insomniacs 
22 
,59 
;7 
50 
22 
12 
22 
46 
;4 
16.2 
;0 
, t = 0.2" df = 14 n.s. 
Good Sleepers 
60 
.26 
;2 
;6 
21 
;1 
12 
22 
,------- ---- ----
Table 25 
Comparisons Between the Insomniac Group and the Good Sleep Group 
a) The comparison of the inter-subject variability within the two 
groups by means of the between subject variance estimates, 
yielding an F ratio. 
b) The comparison of the night-to-night variability by using an 
unrelated t test, on the logarithmio mean standard deviations 
across the nights, yielding a t value. 
stafi!! W+1 
a) Fm.a.:x: = 1.1, df 2,1 , n.s. 
b) t = 0.6, df 14 , n.s. 
stage 2 
a) F = m.a.:x: 1.1, df 2,1 , n.s. 
b) t = 1.4, df 14 , n.s. 
stage 2 
a) Fm.a.:x: = 1.9, df 2,1 , n.s. 
b) t = 1.1, df 14 ; n.s. 
Stage ~ 
a) Fm.a.:x: = 1.1, df 2,1 , n.s. 
b) t = 1.5, df 14 , n.s. 
stage 2+4 
a) F = m.a.:x: 2.1, df 2,1 , n.s. 
b) t = 0.3, df 14 , n.s. 
stage REM 
a) Fm.a.:x: = 1.1, df 2,1 , n.s. 
b) t = 1.9, df 14 , n.s. 
Total Sleep Time 
a) F = m.a.:x: 1.5, df 2,1 , n.s. 
b) t = 1.2, df 14 , n.s. 
11 
REM Latency 
a) Fmax = 1.8, df 2,1 , n.s. 
b) t = 1.0, df 14 , n.s. 
Number of Stage Changes 
a) Fmax = 1.~, df 2,1 , n.s. 
b) t = 2.4, df 14 , P ... 05, two tailed test 
Sleep Onset Time 
a) Fmax = 4.1, df 2,1 , P';;.05 
b) t = 1.6, df 14 , n.s. 
Comparison of the Slee Onset Time as Measured from the Time of 
3. s Du un 3. e 1me 0 re 0 s ee er e J.rS 
Awakening. and the Estimates of Sleeu Onset Time. 
Table 26 
Estimate 
Subject 
1 195 ~O 
2 ~28 60 
~ 49 ~o 
4 14 60 
5 460 ~O 
6 202 60 
1 ~32 ~O 
,8 303 60 
Arithmetic Mean 243 45 
Geometrio Mean 196 42 
The Em time is the mean of the two baseline nights. 
The estimated time is the lower of the range of the 
sUbjects'estimates of their sleep onset time prior 
. to the commencement of 'the study. 
r = 0.12, n.s., raw scores. 
r = 1.1 x 10 -~, n.s., transformed scores,(loge) 
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A ComEarison Between the First Hour of SleeE of 
Good SleeEers and Insomniacs. 
Table 27 
Good Sleepers Insomniacs 
Mean S.D. Mean S.D. 
First Epoch 
Stage W+1 0.1 0.4 0.3 0.4 ' 
2 1'.8 2.4 8.9 2.9 
3 3.9 1.4 2.5 2.1 
4 3.2 2.9 3.3 2.5 
No. Stage Changes 3.6 1.6 2.1 0.4 
Second Elloch 
Stage W+1 0.1 0.4 0.3 0.5 
.2 1.1 1.6 1.1 1.8, 
3 1.5 1.4 1.3 1.3 
4 12.3 2.6 12.3 2.7 
No. Stage Changes 1.6 1.6 2.1 1.8 
Third EEoch 
stage W+1 0 '0 0.6 1.1 . 
2 2.1 2.9 2.3 3.5 
3 1.5 1.1 0.6 0.7 
4 11.4 3.3 11.5 4.7 
No. Stage Changes 2.4 1.7 1.5 1.7 
Fourth Elloch 
Stage W+1 0.9 0.8 0.6 0.9 
2 4.8 4.0 5.3 5.1 
3 1.3 0.9 1.6 1.4 
4 6.3 4.7 7.5 4.9 
REM 1.7 2.0 0 0 
No. Stage Changes 2.6 1.5 2.3 1.1 
Latency to stage 4 13.8 5.5 14.4 5.4 
. , 
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Chapter Two - Part I 
AN EEG }!ODEL OF SLEEP ONSET INSONNIA 
------------------------.............. 
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1.0 INTRODUCTION 
The previous study (~pter one), which was an objective evaluation 
of ncn~ "sleeping aids" conduoted with a group of self-reported, 
sleep onset insomniacs, revealed some of the many difficulties which 
can be encountered when using insomniac subjects. Briefly, the major 
problems encountered were: 
1. the self-reported insomniacs frequently failed to satisfy the EEG 
criteria for sleep onset insomnia; 
2. many insomniacs were receivinghypnotics or sedatives for their 
,sleeping difi'icul tn 
',.. .,-
,. the sleep onset times of the insomniacs might be expected to show 
a large amount of night-to-night and inter-subject variability 
(Karacan et al., 19D); for example,. if a reported sleep onset: 
" 
insomniac showed a long sleep latency, according'to 'EEG criteria, 
" .(.: 
on one laboratory night, it would not necessarily follow that a 
long sleep latency would be observed on every other night; 
4. psychological and somatic disorders have been found to be associated 
with varicus complaints of insomnia. 
These points were explained in more detail in section 1,.0, ch?pter one. 
For the reasons given above, it l"ould be very advantageous if an 
EEG model of sleep onset insomnia could be created with good sleepers. 
The main aim of the model would be to provide a long sleep latenoy which 
would form the basis of an evaluation procedure for various possible 
treatments of insomnia.' Although it is essential that any potential 
treatment for insomnia should be evaluated with a group representative 
of the population for which it is intended, an EEG model would be very 
useful in the initial eValuation procedure" be 'it fora.possibie 'drug 
or non-drug "a.id"'. If a particular "aid" was found to reduce sleep 
------------------------------............ 
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onset time within the model group, one would then be justified in going 
to the lengths of selecting agroupofirisomn1a.cs which satisfied the 
::::EG criteria. Ka.ra.can, Thornby, :Oooth, Okawa, Salis, !nch and WilliaJllS 
(1975) commented that there was a great need in sleep research for a 
model of insomnia. They proposed the possibility of administering 
pharmacological agents to good sleepers in order to produce model mso"""; a. 
Okuma and Honda (1978) attempted to create such a model by using 
two approaches. One was to pipe white noise into the subjects' bedrooms, 
and the other was to give the subjects the drug methylphenidate, a central 
nervous stimulant. Although both methods increased the sleep onset 
time (baseline group mean of 20.2 minutes), the drug (group mean 
40.8 minutes) being more effective than the white noise (group mean 
31.2 minutes), neither increase was significant when comp~ed with the 
J ' 
baseline., This was rather unexpected, since the increase did appear 
to be high under the drug condition. It may have failed to reach 
statistical significance because of a large amount of inter-subject 
variability. However, the authors did not comment on this point and 
they did not present the standard deviations for the group mean sleep 
onset,'timeil:therefore" the idea of subject variability is only 
speculative. The authors claimed that both methods disturbed sleep, 
as measured by a decreased total sl'eep time, stage 4 and stage REM 
an increased stage W. They reported that this disturbance was reduced 
by the hypnotics Flurazepam and Triazolam. They were, however, 
unsuccessful in producing an EEG model of sleep onset insomnia; but their 
model did simulate,' to sonie extent, the insomnia associated with 
early morning and nocturnal awakenings. One major disadvantage of using 
central nervous stimulants to increase sleep onset times, ,is that 
if one wished to use the model for the initial evaluation of a potential 
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hypnotic/sedative, then a:ny results obtained may be due to the interaction 
effects of the hypnotic/sedative a:nd the stimula:nt, not simply due to 
the hypnotic/sedativc. !1a.nj" drugs produce very u:i1cha.ra.cteristic effects 
under interaction conditions. 
The approach adopted in the present study, in a:n attempt to create 
an EEG model of sleep onset insomnia, was to measure the sleep onset 
times of the daytime naps of good sleepers. This approach was chosen 
on the grounds that as sleep is more difficult to achieve during the 
daytime, then a longer sleep onset time would be expected during the 
day than at night. Agnew a:nd Webb (1971) found that sleep onset -time, 
as measured to the first appearance of stage 1 sleep, was inversely 
-
related to the length of prior wakefulness. When subjects had been 
awake for only four hours prior to their bedtime, the sleep onset time 
was approximately three times greater tha:n normal, with a value of 
36 minutes; alter ·12 hours of wakefulness the mea:n sleep onset time 
decreased. to 18 minutes. However, no clear details of the experimental 
procedure were given. 
A literature search revealed that the majority of daytime sleep 
studies had been primarily concerned with sleep cycling during napping 
(Maron, Rechtschaffen & Wolpert, 1964; Webb & Agnew, 1967) a:nd with 
the e£fects of naps on nocturnal sleep (Ka.ra.ca:n, Williams, Finely & 
Hursch, 1970). Most studies employed subjects who were accustomed to 
napping. Napping sleep did not appear to havebee~ Us~d previously as 
a:n EEG model of sleep onset insomnia. 
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2.0 METHOD 
2.1 Experimental Design 
A total· of ciz nights were to be spent in the laboratory by each 
of eight selected subjects. The first two nights were to allow for 
adaptation effects (Agnew et al., 1966). The remaining four nights were 
all associated with daytime naps. All-night EEG recordings were taken 
on these nights to assess whether or not each subject had a fairly 
typical, gOod night's sleep. It is to be expected that if a subject 
had a particularly poor night's sleep,. this' would'gr~atiy influence 
his sleep onset time during the day. As the subjects were sleeping in 
the laboratory at night, the experimenter was able to keep the subjects' 
retiring and rising times fairly constant from day to day. 
It appeared from the findings of Agnew and Webb ,(1911) that sleep 
, , 
onset time during the day would be related to the length of prior 
wakefulness. For this reason it was decided to have two nap conditions, 
a morning nap and an afternoon nap. It was hypothesised that the sleep 
onset time of the morning nap would be greater than that of the afternoon 
I 
nap. However, this hypothesis was not borne out by the findings of 
Karacan et al. (1910). In this study the group mean sleep onset times 
for one hour nap sessions were six minutes during the morning. and 
seven minutes for the afternoon; both naps were taken on the same day. 
For the two hour nap sessions the group mean sleep onset times were 
13 minutes during the morning and seven minutes during the afternoon. 
Overall, the morning nap sleep onset times did appear to be rather short. 
The reasons for this could be: 
1. the subjects were awoken at 6.00 a.m. every morning and then they 
returned to the laboratory for their morning naps at 8.00 a.m. 
There is the possibility that the subjects were not sleep satiated' 
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prior to their naps. Their group mean total sleep time at night 
was only 372 minutes which is rather low for the subjects' age 
=.ge (21 - 28 years).' According to Roffwarg et al. (1966) 
their total sleep time would be expected to lie within the range 
420 ~ 465 minutes. 
2. Karacan et al. (1970) did not state whether their subjects were 
habitual nappers. Evans, Cook and Cohen (1976) found,. in a study 
of afternoon naps, that subjects who were accustomed to daytime 
napping fell asleep twice as quickly as ±hose who were unaccustomed 
to daytime napping. 
Since a sleep onset time of between 30 and 60 minutes (as defined 
by EEG criteria) is associated with moderate sleep onset insomnia, . 
the napping sessions had to be of about 60 minutes duration. It was 
/; 
eXpected that nap sessions longer than 60 minutes would be very boring 
and monotonous for the subjects. The morning naps were scheduled from 
10.30 - 11.30 a.m. This time was chosen in order to allow the subjects 
sufficient time to wake and organise themselves after rising; also, it 
, 
was not too close to their lunchtime and approximately 2i - 3 hours 
had elapsed since they had arisen. The afternoon naps were scheduled 
from 4.00 - 5.00 p.m.; 8 - Sf hours having elapsed since they had 
arisen. 
The subjects were allowed only five minutes of unbroken sleep 
during any nap session before being awakened by the experimenter. The 
reasons for this were: 
1. if the subjects were allowed only five minutes of daytime sleep, 
it seemed unlikely that this would affect their night-time sleep; 
~--------------------------.......... 
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'2. the aim of the study was to create a long sleep onset time and 
not. to examine the quality of the napping sleep; 
3. if the uuration of the nap was kept short, it may prevent the 
subjects from growing accustomed to napping. 
Sleep onset time, both at night and during the nap sessions, was 
defined as the time from "lights out" until the first appearance of 
stage 2 sleep ,which was of at least five minutes unbroken duration. 
For ,the purpose of data analysis, it was decided that, if the subjects 
did not fall asleep at all during the nap period, this was to be 
expressed as a sleep onset time of 60 minutes. The most suitable 
experimental design which would correspond with the subjects. commitments 
was: 
Night 1 2 3 4 5 6 
Condition Ad Ad B1 B2, B3 l3i4 
Daytime 
2 males + 2 females A1 M1 Mz Az 
" " 
Key: 
Ad - Adaptation 
Bc - Baseline 
M - Morning nap 
A - Afternoon nap 
The subjects were also asked to complete the morning questionnaire upon 
awakening each morning (Appendix Ill) and the daytime questionnaire 
after each napping session (Appendix IV). 
( 
;. 
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2.2 Subject Selection 
The selection procedure was carried out as in section 6.1, chapter 
one. For this particular study it ~~s essential that the subjects were 
good sleepers and not accustomed to daytime napping (Evans et al., 1976). 
Eight, healthy subjects (four males and four females), with a mean 
age of 20.4 years, were selected from the student population. 
2.3 Instructions to Subjects 
, 
The subjects were given the "general instructions to subjects", 
as discussed in section 6.2, chapter one, with the following additional 
instructions: 
1. On the days when the subjects had to return to the laboratory 
they were instructed to refrain from having tea, coffee, alcohol, 
or drinks such as Coca Cola and snacks after breakfast/lunch. 
• !, 
, , 
They were also instructed to have only one weak tea or coffee- with 
their breakfast/lunch and to keep the content of these meals 
fairly constant from day to day. Karacan et al. (1975) reported 
that subjects who drank one cup of coffee 30 minutes before 
, 
retiring at night showed no significant changes in either the 
quality or quantity of their sleep. It was considered, therefore, 
that one cup of weak. tea or coffee, at breakfast or lunch would 
not affect the EEG recorded several hours later. The aim was to 
keep the daily routine of the subjects as'normal as possible and 
if tea and coffee were completely banned some subjects may have· 
been subjeot to stress. 
2. The subjects.were instructed to arrive at the laboratory 
approximately 30 minutes prior to the napping sessions. 
l 
i., 
--------
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". At the commencement of the napping sessions the subjects were 
simPlY'instructed to relax in the quiet, darkened bedrooms. -
. . . . 
They were told that the experimenter would enter the bedroom and 
t= on the light when a sufficient amount of a certain brain 
'.-activity: had been recorded~ The idea of fallirig asleep was not 
suggested to the subjects. 
4. The subjects were told that they would be in the bedroom for no 
longer than one hour. 
5. The subjects were instructed to leave watches and clocks outside 
the bedrooms both at night and during the day. 
2.4 Experimental Procedure 
Each night the subjects arrived at the laboratory approximately 
one hour before their bedtime. The general laboratory procedure was 
carried out (section 6." chapter one), then the subjects prepared 
themselves for bed. The retiring and rising times were kept to 
within :!: 15 minutes each night and morning. On awakening the subjects 
were asked to complete the morning questionnaire (Appendix. IlL). 
During the day the same procedure was employed as at night. The 
subjects retired to the quiet, darkened bedrooms at the scheduled nap 
time. At the end of the napping sessiOns, the subjects completed the 
daytime questionnaire (Appendix IV) and were then allowed to read until 
they were told to leave the bedroom, so that they would not-disturb 
the other subjects. 
-- ------------------------------------------
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2.5 Data Analysis 
The EEG daytime sleep records were scored by the experimenter for 
the time of sleep onset and were checked by another experienced scorer. 
This scoring was done at the time of recording, because the subjects 
had to be awoken after five minutes of sleep. Sleep onset was defined 
as the time from "lights out" until the first appearance of a stage 2 
sleep period, which was of at least five minutes unbroken duration~ The 
results are presented in Tables 28 and 29 (section 11.0, chapter two). 
The original aim was to compare the group mean of the individual 
average sleep onset times for both the morning and afternoon nap 
sessions with the group mean of the individual average sleep onset 
times over the four baseline nights. However, for unforseen reasons, 
which will be discussed later, it appeared that this would not be the 
most suitable method of analysis. Two comparisons were therefore made: 
1. the group mean sleep onset time for the first night-time baseline 
was compared with the group mean of the individual average sleep 
onset times for both the morning and afternoon nap sessions; 
2. the group mean of the individual average sleep onset times for 
the first and second baseline nights was compared with the group 
mean of the individual average sleep onset times for both the 
morning and afternoon nap sessions. 
A related, two-tailed t-test was used for this comparison. 
Pearson's r (correlation coefficient) was computed between the 
group mean objective and subjective sleep onset times of the individual 
. average scores for each nap condition and the four night-time sleep 
onset times. This calculation was performed on·both the raw and 
logari thmic transformed data, because sleep onset time seores ~are not: 
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normally distributed (section 10.3, chapter one). The computation 
was performed according to the method of Meddis (1975, chapter eight). 
With regard to the quality of the night-time sleep, the first 420 
minutes of sleep time from sleep onset were analysed according to the 
standardised criteria of Rechtschaffen and Kales (1968). The records 
were scored blind and independently by two, experienced scorers; if the 
disagreement between them exceeded five per cent of the epochs, it was 
resolved by discussion. The five sleep stages (W+1), 2, 3, 4 and REM 
were all expressed in minutes of the total sleep time of 420 minutes. 
This length of time was chosen as it was the lowest common measure of 
total sleep time, for all subjects on all nights •. The results are 
presented in Tables 30 - 36 (section 11.0, chapter two). ,Each sleep 
stage, over the four nights, was subjected to a two-'"'7Y ANOVA for 
rep.eated measures to determine if there were any significant differences 
for the sleep stages over the four nights (McNemar,1969, page 338). 
The .!NOVA SllllIIllarY' tables are presented in Appendix X. P values equal 
to or less than .05 were considered to be statistically significant. 
3.0 RESULTS 
The individual average sleep onset times of the morning nap 
condition, with a group arithmetic mean of 45 minutes and a geometric 
mean of 41 minutes, were significantly greater than the group mean sleep 
onset time for the first baseline night (arithmetic mean 26 minutes and 
geometric mean 23 minutes), (t = 3.2, df 7, P<,.02~:,~two-tailed test). 
If the group mean of the indiv!dual average sleep onset times for the 
first and second baseline night (arithmetic mean 28 minutes and 
geometric mean 24'minutes) had been used for this comparison, then the 
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increased sleep onset time during the morning was still significant 
(t = 2.7, df 7, p ~ .05, two-tailed test). By the same procedure no! 
significant difference was found between the-group mean sleep onset time 
on the first baseline night (arithmetic mean 26 minutes) and the group 
mean of the individual average sleep onset times for the afternoon nap, 
which had an arithmetic mean of 29 minutes and a geometric mean of 2) 
minutes. The group mean of the individual average sleep onset times 
during the morning was also Significantly greater than the group mean 
of the individual average afternoon sleep onset times (t = 4.8, df 7, 
p ~ .01, two-tailed test); There were no significant differences between 
the group means for the first morning nap and second morning nap when-
compared by the related t~test; the same was true for the first and 
second afternoon nap group means. 
On inspection of'the results table 28 (section 11.0, chapter two), 
it was apparent that the group mean night-time sleep onset times were 
becoming progressively longer from baseline 1 to 4. The first baseline 
night had a group arithmetic mean of 26 minutes and a geometric mean 
, 
of 2) minutes which was significantly lower than the fourth baseline 
night, with a group arithmetic mean of 42 minutes and a geometric mean 
of )6 minutes, using related t-tests (t = 2.5, df 7, P<'.05, two-tailed 
test). The standard deviation of the sleep onset time group means 
also increased after the first baseline'night. 
The sleep onset time results (Tables 61, 72, 91,. section 25.0, 
chapter three and Table 8, section 14.0, chapter one) from other 
studies with good sleepers in this research programme did not show 
such a progressive rise in sleep onset time over the laboratory nights. 
In general, the group mean sleep onset times showed only small, random 
._ • __ 0 
fluctuaticns over the recording nights. However, in the case of the 
placebo contrel group (Table 72, section 25.0, chapter three) there was 
a large increase in the group mean sleep onset time on the fourth 
laboratory night; this was the night when the placebo pill was first 
administered. After this one night, the group mean sleep onset times 
were approximately equal to the baseline Value. Possible reasons for 
this sudden, transient increase will be discussed in section 11.0, 
chapter three. Cauticn must be applied when comparing these varicus 
sleep onset time results, as they may be related to the different 
conditions which each grcup underwent. Nevertheless, the overall 
trend of a progressively increasing group mean night-time sleep onset 
time was not shown by any-other group studied; this indicated that the 
trend may be related to the daytime naps. However, this idea is only 
speculative at present. 
Since the naps appeared to be influencing the night-time sleep 
onset times, it was considered that the first baseline night, which 
was not preceded by a nap, was the only night which could have escaped 
any possible interference from the naps. Therefore, the first baseline 
night is the only night which one can confidently say provided an 
indication of the subjects' normal sleep onset time. However, due to 
night-to-night variabiliy of sleep onset times (Agnew &, Webb, 1971), 
it is usual to base results on the individual averages of several sleep 
onset times. The first and second baseline nights do have similar group 
mean sleep onset times, of 26 and 30 minutes respectively; the 
distinction appeared on the third and fo=th baseline nights. If' the 
group mean of the individual average sleep onset times of the first 
and second baseline nights had been used for the comparison with the 
nap conditions, it was unlikely that they would have altered the 
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results. This was borne out by the results previously reported. 
T"nere was a significant co=elation between the individual averages 
of the four objective sleep onset times, measured by means of EEG criteria 
and the su?jec"fiV'e estimates for the night-time sleep. For the raw 
scores (r = ~.83, N = 8, P ~.01, one-tailed test) and for the 
logarithmic transformed scores (r = 0.86, N = 8, P ~ .01, one-tailed 
test). A one-tailed test was used in this case, because it was 
hypothesised that the good sleepers of the present study would be good 
estimators of their sleep onset times, on the basis of the findings of 
Johns (1977). However, for the nap sessions there were no significant 
co=elations between the objective and subjective sleep onset times: 
Morning nap, raw scores, r=0.41,N=8, n.s. , . 
Morning nap, transformed scores, r = O~M, • N = (I, n.s. 
Afternoon nap, raw scores, r = O.Op, N = 8, n.s. 
Afternoon nap, transformed scores, r =0.14, N = a, n.s. 
For the purpose of comparison with Johns' (1977) findings, graph C 
(section 11.0, chapter two) was drawn, on a logarithmic scale,of:the 
! 
individual average estimated (subjective) sleep onset times against the 
individual average objective sleep onset times over the four baseline 
nights. The regression line was also calculated. 
The ANOVAs (Appendix. X) showed that there were no significant 
differences over the four nights for any sleep stage. 
! , 
.. 
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4.0 DISCUSSION OF RESULTS. 
, 
Since the group mean of the individual average sleep onset times 
fo!: the ~orning r.aps ',/as significantly greater than: 
1. the group mean sleep onset time on the first baseline night, and 
2. the mean of the individual average sleep onset times on the first 
and second baseline nights; 
this approach to creating an EEG model of sleep onset insomnia appeared 
to be successful. The group mean sleep onset time for the morning 
naps was 45 minutes, which was in fact greater than the group mean sleep 
onset time of 34 minutes for the selected group of sleep onset insomniacs 
of chapter one. Furthermore, on the first morning nap ,s.ess10ii; .. s1X '. out 
... ~,,~ ... ~ 
of eight subjects had a sleep onset time greater than 30 minutes, 
whereas, on the first recording night for the self-reported insomniacs 
only three subjects out of thirteen had a sleep onset time greater 
than 30 minutes. The present approach, therefore provided a more 
economical method for obtaining long sleep latencies in terms of subject 
numbers. 
As hypothesised, on the basis of the findiDgs of Agnew and Webb 
(1971), the subjects, in general, fell asleep significantly faster during 
the afternoon nap sessions (group mean sleep onset time 29 minutes) in 
comparison with the morning nap (group mean sleep onset time 45 minutes). 
The afternoon nap, therefore, did no·t effectively.represent an EEG model 
. .",' ~ 
of sleep onset insomnia. There was no significant difference between 
the group mean sleep onset time for the first and second occasions 
of a particular nap session. This indicated that the subjects had not 
grown accustomed to napping over this short period. This is in fact 
a requirement of the model; if the subjects 'did quickly grow·zqcustomed· 
to napping this would limit the usage of the model. 
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The correlation between the objective and estimated sleep onset 
times, at night, for this group of good sleepers was high, Johns (1911) 
reported an r value of .69, using the tra..'lBfornlecf sco"!:'),,; i1'1. the 
present study this r value was .86:. However, Johns (1911) used 28 
subjects, whereas, in the present study only eight were used. From 
the regression line (Graph e, section 11.0, chapter two) it can be seen 
that up to an objective sleep onset time of approximately 30 minutes 
there was, in general, good agreement between the objective and estimated 
sleep onset times, with a tendency for some of the shorter sleep onset 
times to be underestimated. However, for the objective sleep onset 
times greater than about 30 minutes, the subjective estimates tended 
to be an overestimate. For example, on the basis of the regression 
line an actual sleep onset time of 31 minutes corresponded to a subjective 
estimate of 45 minutes. Similar trends were reported by Johns (1911). 
, ' 
When computing the daytime correlations between the objective and 
subjective sleep onset times, it was difficult to decide whether to 
include all the meas=es. In the case of the morning nap sessions only 
44 per cent of the subject sessions resulted in sleep, whereas, in the 
case of the afternoon nap sessions 15 per cent of the subject sessions 
resulted in sleep:- 'these percentages were higher than expected, 
considering that this group were not accustomed to napping at any time 
during the day. It Wasobviouslyea.aielZ.. to est.rina:te. the. tiine 'if one did 
not fall asleep during the hour nap period than if one did. The s~bjects 
were also aided in their estimates by being told that they would be in 
the bedroom for no longer than one ho=. 
It was eventually decided to compute the daytime correlation 
coefficients using all the nap scores, but to take note of these points 
,----------------------------- ----------------
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when interpreting the data. Although no statistically significant 
co=elations.between the objective and 'subjective measureS 6£ sleep 
cn:let'times were f01l.'ld· for ~ithernap condition, the ~orning nap 
session did have a higher correlation coefficient than the afternoon 
nap. This may have been due to a. reason already' mentioned" that is, 
it was easier to estimate time if one did not fall asleep during the 
nap session than to estimate the actual sleep onset time. This idea 
was not supported by subjects 2 and 8 (Table 29, section 11.0, chapter 
two), who both reported falling asleep in 15 minutes during their first 
morning session when, according to, the EEG measure, they did not £all 
asleep at all during that session. When questionned about this at the 
end of the study both subjects reported that on that particular occasion 
they had lost all sense of time. It was unlikely that either daytime 
naP co=elations between the actual and estimated sleep onset times 
" 
" would have been significant, because the subjects were habitually 
non-nappers and the experience of falling asleep during the day would 
have been novel. 
, 
During the afternoon naps the subjects tended to overestimate 
their sleep .onset times. The group mean objective time was 29 minutes, 
whilst the group mean estimated sleep onset time was 42 minutes (Table 29, 
section 11.0, chapter two). It was found from the daytime questionnaire 
responses that during the afternoon nap': sessions, on nine out of the 
16 subject sessions, the subjects felt as though they had not fallen 
asleep, but on oruY three Subject ~~'ssi6ns were:these·;cliima supported, 
, ..- . .. . .. - " . 
by the EEG criteria for sleep onset. Similarily, during the morning 
nap periods on ten out of the 16 subject sessions, the subjects felt 
as though they had not fallen asleep; in this6ase, on seven: subject 
sessions these claima were actually supported by the EEG measure • 
. . -----------------------------------------
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One reason for this marked discrepancy between the objective 
and subjective sleep onset measures, for the afternoon nap sessions, 
may have been that the questi"!,.!lair~responses l{ere susceptible to 
expectancy effeots. Since this group were non-nappers, they did not, 
in general, expect to fall a.sleep a.t anytime during the day. This 
expectation tended to hold more during the morning nap sessions when 
44 per cent of the subject sessions resulted in sleep, than for the 
afternoon sessions when 75 per cent of the subject sessions resulted 
in sleep, due maybe to the increased length of prior wakefulness (Agnew 
& Webb, 1971). 
On inspection of the results Table 29 (section 11~0, chapter two), 
it can be seen clearly that there was a wide variation in 'individual 
sleep onset times: in the morning, the range was from: ,16 to 60 minutes 
. i . 
" 
and in the afternoon, from 8 to 60 minutes.' Eight minutes was a very 
short sleep onset time, in view of the fact that these subjects were 
habitually non-nappers; this was also the first napping,sessiori'for 
this particular subject. One possible way of reducing the range in 
sleep latency for the morning nap condition may be also to employ 
. the Morning Type -,Evening Type questionnaire (Home & Ostberg, 1976) 
in the subject selection procedure. It might be expected that "morning 
types" who are at their peak early in the day would find it very 
difficult to fall asleep during the morning'nap session. This idea 
did not come to mind until after the completion of the subject selection 
procedure for the subsequent study; so it has not yet been applied in 
an EEG model of sleep onset insomnia study. 
--------- ----------- ---- --------------
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There was only one subjeot who did not £all asleep during any o£ 
the £our nap sessions. Exoluding all the subject, sessions which did 
not result in sleep, the longest sleep onset time was 42 minutes; in 
only £our out o£ 19 subject sessions was the sleep onset time greater 
than 30 minutes. In conversation with ,the subjects' at'ter the study, 
the general £eeling seemed to be that i£ they were not asleep within 
about 30 minutes, they £elt bored, restless and wanted to get up. This 
appeared to simulate the £eeling experienced_by sleeP onset insomniacs, 
when they simply abandon all hope o£ being able to £all asleep. However, 
caution must be applied when comparing the ,various psychological 
aspects o£ the EEG model with those o£ actual sleep onset insomnia. 
Firstly, there was no pressure upon the model subjects to £all asleep: 
they had the reassurance that they would be able to sleep that night, 
whereas, the insomniac £eels almost compelled to try arid £all asleep, 
otherwise he will £eel tired the, next day. This point was illustrated 
by the questionnaire responses, in that, on only two o£ 13 subject 
sessions which did not result in sleep, did the subjects report that 
they were worried or anxious about not having £allen asleep during the 
nap period. This aspect may be simulated to some extent by, altering 
the subjects'-response set: I£ they had been instructed that it was 
necessary £or the success o£ the study that they £ell asleep during the 
nap periods, then this may have caused £eelinge o£ anxiety il they had 
been unable to £all asleep. Secondly, the time o£ day is also an 
important di££erence between the model and actual insomnia; being unable 
to sleep at night must be a very di££erent experience £rom that o£ lying 
in a laboratory bedroom, knowing that within one hour the study would be 
£inished. 
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Also of interest is the point, commented upon in the results 
section, that the naps did appear to be lengthening the group mean 
night-tbe sleep onset times, with the fourth baseline night showing 
a significant increase in comparison with the first. However, this 
group trend of a progressively increasing sleep onset time over the 
four baseline nights did not necessarily hold for each individual subject. 
The naps did appear to be generally disrupting the night-time sleep 
onset times. On the fourth baseline night the standard deviation for' 
the group mean sleep onset time: had a value; of 24.2 minutes, which 
was rather high in comparison l~ith the first baseline score of 14.2 
minutes. This may have been partly due to the sheer repetitiono~ 
having to go through all the laboratory procedure twice on one day. 
There did not appe~ t~' be any obvious relationship between whether 
the subjects actually fell asleep during the nap period an~ the lengthening 
of the night-time. sleep onset times. Nevertheless, it was an interesting' 
. 
finding in that it suggested another possible method of creating an 
EEG model of sleep onset insomnia. 
I 
Focusing now upon some of the questionnaire responses, the subjects' 
responses to question 8 on the morning questionnaire (Appendix III), 
"When you awoke this morning, how did you feel?", were 14 tired, 
13 average and 5 rested. By the time the subjects returned to the 
laboratory for each morning session,' on 10 outo! 16 subject sessions 
they reported feeling alert, 3 normal, 2 tired and one anxious. Therefore,' 
the time which had elapsed from awakening until the subjects returned 
to the laboratory had been sufficient to arouse and refresh the majority 
of them. Prior to the afternoon nap sessions a slightly different; pattern 
of responses could be seen;, .. on6 'out of 16· subject .sessions ,they 
reported feeling alert, 2 normal, 6 tired, one relaxed and one anxious. 
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~e trend, therefore, was for fewer of the subjects to feel alert and 
more to feel tired prior to the afternoon nap, in comparsion with the 
questionnaire :::esponses befo:::e the morning naps. ~i3 trend .;"';; borne 
out by the objective findings, as the group mean sleep onset time for 
the afternoon naps was found to be significantly shorter than the group 
mean sleep onset time for the morning naps. After all four naps the 
general comments were that the subjects felt dozy, lethargio and tired.' 
On only four out of the total of 32 subject sessions did the subjects 
report feeling alert after a nap period. These latter four responses 
.were associated with nap periods that had not resulted in sleep; three 
in the. morning and one in the afternoon. 
When subjects were asked to estimate for how long they had been 
asleep, the group mean morning estimate was 21 minutes' and the group 
,d 
mean afternoon estimate was 23 minutes. Both responses are very 
similar, yet in both cases the total sleep time allowed was only five 
minutes. The subjects did, therefore, tend to overestimate the length 
of time they were asleep. No statistical test was performed on this 
data, because of the small number of subjects under consideration, 
especially in the case of the morning naps, where only 44 per cent of 
the subjeot, sessions resulted in sleep. 
Unfortunately, question 8 on the daytime questionnaire (Appendix IV), 
whioh asked for an estimate of how long the subjects had been in the 
bedrooms, turned out to be ambiguous'; Some subjeots' reported 'the time 
from the oommencement of the nap period until the light was switched on, 
whiCh was the response. that had been originally intended. Others reported 
the time from the commencement of the nap session until they actually 
left the bedroom. The daytime questionnaire responses also revealed 
102 
that the subjects, as instrUcted, had attempted to keep the content of 
their meals fairly constant. All their breakfasts consisted of cereal, 
toast and a weak tea or coffee, (the majority of subjects had their 
breakfasts in the laboratory). At lunchtime the subjects had a light 
meal, usually a toasted sandwich or soup, biscuits or f=it and a .Teak 
tea or coffee. 
A further interesting finding was that the nap sessions did not 
significantly change the stages of night-time sleep. Another point 
worthy of note is that for subject 3 the sleep onset for the morning 
nap was characterised by three minutes of stage 2 sleep followed by two 
minutes of stage REM. This sleep patterning is not unusual for this 
time 6f day: Webb, Agnew and Sternthal (1966) found that. sleep during 
the early morning naps contained a high percentage of stage REM and 
-" 
stage 2 sleep, whilst stages 3 and 4 were virtually absent. They also 
reported that the latency to stage REM was only 6.8 minutes for a group 
of habituated subjects. The end of the night and the morning are known 
to be the most propitious hours for REM sleep. Although this pattern 
I 
did not completely satisfy the sleep onset criteria, it was taken as 
indicating that the subject was asleep. 
5.0 CONCLUSIONS AND FURTHER RESEARCH 
The morning nap session provided a reasonable model of sleep 
onset insomnia, according to EEG criteria. This study opened up further 
possible lines of inquiry. 
1. Of further interest was :he observation that the napping sessions 
did appear to be lengthening the group mean night-time sleep onset 
time. This is another possible method of creating an EEG model 
of sleep onset insomnia. An area of further investigation would 
------------
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be to conduct a similar study using only morning nap sessions, 
but to record the sleep onset time of both the nap and night-time 
sleep over a longer period of time. Such a study would have two 
main aims: firstly, to confirm whether an EEG model of sleep 
onset insomnia, at night, could be oreated by this method; 
secondly, to find out, on average, hew many nap ses.sions a subjeot 
.. 
can undergo before he becomes aocustomed to napping. 
2. A further variation of the study proposed above would be to alter 
the instructions given to the subjeots; for example, the subjects 
could be made to feel that they had to fall asleep. This would 
determine whether by instructing the subjects to fall asleep 
and stressing its importanoe, they would be subjected to concern 
about falling asleep, and hence extend the nap sleep onset time. 
I, 
-~ ! 
Alternatively, the reverse oould happen in some cases and a shorter 
sleep onset time result. 
The subjects could be allowed to remain ignorant of the fact that 
, 
the nap session would terminate after 60 minutes, thereby removing 
a time oue which may be affecting the subjects t sleep onset times • 
. H~wever, this proposal was not feasible in the present study, 
because the subjects needed to know for how long they would be in 
the laboratory in order to arrange their daily commitments around 
the laboratory times. 
3. Another aspect of further research would be to test the model with 
a variety of drug and non-drug "sleeping aids", some with known 
sedative properties, in order to determine the sensitivity and 
reliability of the model created in the present study. A set of 
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standards could then be drawn up against which the sedative 
properties of other drugs could. be compared. It may also be 
beneficial, when using the EEG model of sleep onset insomnia 
to evaluate a possible treatment for insOmnia, to increase the 
duration of the actual nap; only by a small amount, however, to 
avoid the risk of interfering with the quality of the night-time 
, 
sleep. For example, the nap could be extended from five to ten 
minutes: thus, not only the sleep onset time could be measured, 
but some indication as to whether the nap could be sustained would 
also be gained. 
It was this last research proposal which was pursued further, (chapter 
two, part II). 
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Chapter Two - Part II 
AN APPLICATION OF THE EEG MODEL OF SLEEP ONSET INSOr~ 
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6~0 INTRODUCTION 
The first two research proposals, which were put forward at the 
end. of chapter two, part I, would have' provided an interesting line of 
investigation, but they were considered to be a deviation from the main 
:path of the research programme. The Aspirin aspect of insomnia was still 
to be investigated and the time was limited. It was the third of these 
research proposals which was studied in this part of chapter two, 
mainly because an approach had been made by Fisons Pharmaceuticals Limited. 
Admittedly, the logical step, after having created this EEG model of 
sleep onset insomnia, would have been to use it for the evaluation of 
the hypnotic potential of the non-drug "sleeping aids" which were 
used in chapter one. The reason for this study would have been to 
determine whether the findings obtained with the model supported those 
l 
previously obtained with the group of self-reported insomniacs. However, 
the Niagara Therapy Company, the manufacturers of the cycloid vibrating 
cushions, were unwilling to provide funding for such a study. Nevertheless, 
as previously mentioned, Fisons Pharmaceuticals Limited were interested 
in the model and were willing to provide both support and funding for 
an investigation to be conducted with the model and one of their compounds, 
which will be referred to as F.P. throughout the text. This offer 
provided an ideal opportunity for using the model that could not be 
missed. This Company were primarily interested in the potential of 
the model for·testing the efficacy of various compounds which were, 
believed to have sedative properties. 
The Company believed that F.P. may have mild sedative properties. 
A known drug, with similar sedative properties, had to be chosen, for 
means of comparison with the unknown effect of F.P. After personal 
, 
;. 
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communication with Max Fink, the drug eventually chosen was Temazepam, 
a member of the benzodiazepine group of compounds. Temazepam is listed 
as a tx-~;uiliscr (Martindale, 1977). The two main r~asons for choosing 
this drug were: 
1. it is relatively fast acting and has a biological half-life of 
5.5 - 8.5 hours (Fuccella, Tosolj~{, Moro & Tamassia, 1972), 
similar to that of F.P., 
2. it was believed to have mild sedative properties. 
Fuccella et al. (1972) reported that their subjects felt drowsy after. 
a dose of Temazepam (30 mg.) and fell asleep for about one hour. HO~lever, 
only four subjects were employed in their study and the time of drug 
, 
administration and whether the study was conducted under double or 
single blind conditions was not made clear in their report". 
{ 
1. 
" 
Temazepam is currently under investigation as a potential hypnotic. 
Two of the self-report studies conducted by Middleton (1978) and 
Fowler (1977) found that Temazepam (10 mg.) was reported as performing 
satisfactorily as an hypnotic. The former used hospitalised geriatric 
patients, and the latter used patients who were ~elected from the general 
practitioner's registers. However, there is some doubt as to the 
effectiveness of Temazepam as an hypnotic when evaluated by means of 
EEG criteria. In a study with six insomniac subjects; Bixler, Kales, 
Soldatos, Scharf and Kales (1978) claimed that Temazepam (30 mg.) was 
found to have no sleep inducing properties and was not effective at 
maintaining sleep, but the number of nightly awakenings were significantly 
reduced. Mitler, Phillips, Billiard., Spiegel, Zarcone and Dement (1975} 
found that' Temazepam (30 mg.) produced a "sig!lificant d~c~ease in the amount 
of time spent awake after sleep onset and an ili.crease" ili.' the total sleep 
. . 
time of a. group of ili.somniaes. Again it was found that Temazepam had no 
. 
\ 
• 
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sleep inducing properties. However, in an earlier study,-Maggini, 
Murri & Sacchetti (1969) reported that Temazepam produced an increase 
in the total sleep time and a decrease in the sleep ons~t time and 
duration of wake periods in a group of insomniacs. These authors 
concluded that Temazepam was effective in the treatment of both initial 
(sleep onset) and middle insomP~a. Some possible re~~ons-forthese 
... . 
d~ffereIlt findings are listed below. 
1. The group mean sleep onset time for the Bixler et al. (1978) 
insomniac group was 27.8 minutes and for the Mitler et al. (1975) 
group only 20.7 minutes, therefore, it is unlikely that any 
hypnotic/sedative would be able to reduce these sleep onset 
times by a large amount. However, in the 11aggini et al. (1968) 
study the group mean sleep onset time was 49.5 minutes ~ there 
was, therefore, more room for improvement in this study. 
" f! 
2. The Bixler et al. (1978) and the Mitler et al. (1975) insomniac 
groups were almost matched for the amount of wakefulness during 
the night, with a mean value of 38.6 minutes for the former and 
40.4 minutes for the latter, but for the }~gini et al. (1968) 
- insomniac group this parameter. had a large group mean value 
equal to 93 minutes. 
3. Bixler et al. (1978) kept the total time that the subjects' spent 
in bed constant from night-to-night,whereas, in the other two 
.. 
studies it was allowed to vary. The group mean baseline total 
sleep time for the }Taggini et al. (1968) insomniac group was 
very short (238 minutes). 
4. The subjects in these three studies were not matched • 
. -~- .. '--
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Maggini et al. (1968) used eight male in-patients from a psyohiatrio 
olinic; five were suffering from neurosis and three from endogenous 
depression. Bixler et al. (1979) used six insomniacs from the 
sleep centre clinic and Mitler et al. (1975) claimed to have 
selected seven idiopathic insomniacs. 
5. Maggini et al. (1968) used 20 second epochs when scoring the sleep 
records, whilst the other investigators used one minute epochs. 
However, in the results tables Maggini et al. (1968) expressed 
the stages of sleep in minutes. 
6. The drug dosage employed is also a further important factor. 
Bixler et al. (1978) and Mitler et al. (1975) both used 30 mg. 
Temazepam. Maggini et al. (1968) simply stated .that by the 
.. 
." 
fourth night the total dosage administered was 300 mg. Temazepam; 
by the eighth night, 680 mg. Temazepam had been administered. 
It is therefore difficult to infer from these figures the 
actual dosage they employed, but it would appear""to be higher 
than that used in the other two studies. 
7. Both the Bixler et al. (1978) and Mitler et al. (1975) studies 
were relatively long term, lasting for 49 and 54 nights respectively, 
in comparison with the Maggini et al. (1968) study which continued 
for eight nights. 
8. Both the Bixler et al. (1978) and the Hitler et al. (1975) studies 
incorporated a placebo condition into their experimental designs, 
whereas, Maggini et al. (1968) used the placebo days to screen for 
placebo responders prior to measuring the baseline. The 
,-------- -- ------------- ---------------
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Maggini et al. (1968) results were therefore not compared with 
the placebo condition and the study was single-blind. 
It would appear, from the reasons listed above, that Temazepam 
has not been satisfactorily evaluated as a sleep inducing agent. Although 
Maggini et al. (1968) claimed that Temazepam was effective in inducing 
sleep, this study has many shortcomings, as mentioned above, and no 
firm conclusions can be drawn from their findings. Nevertheless, it 
was hypothesised that Temazepam would reveal sedative properties when 
tested with the model, because there was prior indication that it 
had sedative propeties (Fuccella et al. 1972) and it is likely to 
haveprop~;ties· similar to other members of thebenzodiazepine group, 
which are known to bring about sedation •. F.P. was expected to reveal 
Iledativeproperties similar to those of Temazepamwhente~ted with the 
..... 
model, on the basis of the claims of Fisons Pha.:rma.ceuticals Limited 
" 
that F.P. may have mild sedative properties. 
7.0 METHOD 
7.1 Experimental Design 
It was necessary to change the original model slightly, for with 
drug studies it is important to examine the effects of the drug over 
time. This necessitates performing repeated measures on the "sedating 
potential" of the drugs during each nap session. It was connnented 
in the previous discussion (section 4.0, chapter two), that after 
approximately 30 minutes in the bedrooms during the day, the subjects 
became bored and restless. For this drug study, it was therefore 
decided to reduce the, length of the nap periods to 30 minutes each and 
to have four of these nap periods, during which EEG recordings were 
made. There was a 30 minute break between each EEG recording period 
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during which time the subjects were allowed to read some light material. 
The experimental protocol was: 
0900 Dosed; electrodes applied 
0930 start of: Period 1: 30 minutes of ,"":G recording 
1000 30 minutes of reading 
1030 start of Period 2: 30 minutes of EEG recording 
1100 30 minutes of reading 
1130 start of Period 3: 30 minutes of EEG recording 
1200 30 minutes of reading 
1230 start of Period 4: 30 minutes of EEG recording 
1300 End 
The first nap period commenced at 9.30 a.m., 11hich was approximately 
2t hours ~t_~:;,_ the subjects had arisen from their nightl~ 'sleep • 
. ,. ,. 
Another deviation from the original model was that due to various 
domestic commitments, the subjects were unable to sleep in the laboratory 
on the nights associated with the nap periods. However, in an attempt 
I 
to compensate partly for this, the subjects were asked to complete the 
morning questionnaire - (Appendix Ill), upon awakenmg each morning at 
home: ·tllO'questionnaire responses would give some indication as-to 
whether the subjects were sleep satiated prior to the nap periods. The 
subjects were also asked to complete this questionnaire on the mornings 
after they had been in the laboratory. As mentioned in the research 
proposal (section 5.0, chapter two), the subjects were to be allowed 
ten minutes sleep dur~--any nap period;-before being awoken by the 
experimenter. They were then allowed to return to sleep and the· 
procedure repeated if they fell_asleep again for more than ten minutes. 
The reason for this was to investigate whether the naps could be sustained 
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and to give some indication of the "pressure" forcing· the subject. to 
return to sleep after·he had been awoken. 
Each subject underwent all three conditions, namely, Temazepam, 
F.P. and placebo, on separate occasions, one week apart. The reasons 
for the laboratory sessions being one week apart was to allow a wash 
out period for the drug and to also prevent the subjects from acquiring 
the napping habit. The treatments were administered in a randomised 
order according to a replicated, latin square design. The treatments 
were all administered under double blind conditions. The compoimds: 
were presented in rice paper cachets, because the form of Temazepam 
used was like a syrup. However, it was impossible, to distinguish 
between the three treatments. The dosage of Temazepam employed was 
20 mg.; this was the mid-point of the recommended dosage, ; (10 - 30 mg.). 
.,1 
The pattern of drug administration was: 
Week 1st. 2nd. 3rd. 
Subject 
1 B A C 
2 C B A_ 
3 A C B 
4 B A C 
5; c B A 
6 A C B 
Key: 
Treatment A = F.P. (50 mg.) 
Treatment B = Placebo 
Trea.tment C = Temazepam (20 mg.) 
The same pair of subjects attended the labora.tory on the same day each 
week. 
-------c----------- --
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7.2 Subject Selection 
The six subjects were selected from· the Fisons Pharmaceuticals I 
volunteer pa..~el, \li th the aid of the sleep questionnaira (Appendix II), 
according to the procedure of section 6.1, chapter one. The subjects 
had to satisfy the general requirements for subjects selected for a 
sleep study (section 6.1, chapter one:) and they also had to be unaccustomed 
to daytime napping.. The subjects, (average age 31.5 years) were all 
healthy males and self-reported good sleepers. 
7.3 Instructions to Subjects 
The subjects were given the "general instructions to subjects"; 
section 6.2, chapter one. They were also instructed to have a light. 
breakfast plus onS' weak: tea or coffee: and not to have any additional 
. snacks or drinks between then and a=iving at the laboratory. They 
were asked to keep the content, of their breakfasts. constant during 
the course of the study. For ethical reasons, the whole procedure 
was carefully explained to all the subjects and they knew which drugs 
were to be employed, but they did not know the order of presentation. 
, 
As for the initial model study, the subjects were simply instructed to 
relax during the EEG recording periods and no sUggestion of falling. asleep 
was made. 
7.4 Experimental Procedure 
The subjects were studied in pairs. Each pair a=ived at the 
laboratory between 8.45 a.m. - 9.00 a.m. The subjects l'Tere given the 
rice paper cachet, which contained the drug or placebo, at 9.00 a.m. 
The electrodes were then applied, according to the general laboratory 
procedure (section 6.3, chapter one). Each subject retired to his 
respective bedroom at 9.25 a.m., where he remained for 3i hours. 
---------------------- -- -- ---
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Any subject who fell asleep during the EEG recording periods was 
allowed ten minutes of unbroken sleep from the time of sleep onset and 
~hen, if still asleep, he was gently aroused by the experimenter until 
clearly awake. The experimenter then withdrew from the bedroom. If 
sleep returned,then the ten minute_ time. restraint. was again applied. 
If the subject awoke for more than one minute during any ten minute 
sleep period' it, in effect, eliminated the preceding minutes of sleep 
from a scoring point of view. The ten minute time restraint was again 
applied from the time of the subjects' next sleep onset. The sleep 
* onset criteria were the same as for the model study in part r. 
Subjects were not allowed to fall asleep during the reading 
periods. The experimenter periodically observed the subjects to' 
ensure that they were still reading. If the subjects appeared as though 
, . 
. " 
they might have been about to fall asleep, then the experimenter chatted 
to them. In a few cases it was extremely difficult to keep the subjects 
awake. As these subjects were accustomed to having a morning tea break, 
they were given a drink of diluted orange squash and a plain biscuit 
at 11.00 a.m. 
At the request of Fisons Pharmaceuticals Limited a check was 
made, by means of self-report data, on the general health and well-being 
of the subjects, at the end of the morning session and on the sub~equent 
morning. 
* The time to sleep onset: was defined as the time from "lights out" 
until the first appearance of a stage 2 period,· which was of at 
least five minutes unbroken duration. 
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7.5 Data Analysis 
The EEG records for each reco~period were scored in one 
minute epochs and classified under tha following headings: stage 
drowsy + 1 (D+1), 2, 3, 4 and REM. This was done according to the 
standardised criteria described by Rechtscha£fen and Kales (1968). The 
EEG records were assessed blind and independently by two, experienced 
.. 
scorers. Tt the disagreement between. the scorers exceeded five pe~ cent 
of the epochs, it was resolved by discussion. Total sleep time, sleep 
onset time and the number of sleep onsets were also determined. Initially,. 
the term "number of sleep onsets" was intended to refer to the number 
of times, during one recording period, that the subject, having been 
asleep for ten minutes and then awoken, returned to sleep again. However, 
considering the definition of sleep 'onset employed in this research 
. programme, any amount of time greater than five minutes spent asleep 
' . 
.. (t 
should be classed as a sleep onset. For example, if a subject awoke 
after seven minutes of stage 2 sleep, it should still be classed as a 
sleep onset. This explanation accounts for subject 5 (Table 43, 
section 11.0, chapter tWo) having four sleep onsets during the first 
I 
reco~ period of the placebo condition. Any further research With 
this model will have to make provision in the data analysiS for a 
distinction to be made between these two types of sleep onset in order 
to aid the interpretation of the results. 
The data were tabulated over all the four periods (Table 37, 
section 11.0, chapter two) and for periods 1 - 4 individually (Tables 
38 - 41, chapter two). The individual subject data are presented 
in Tables 42 - 50 (section 11.0, chapter two). A three-way !NOVA, 
with repeated measures on two factors, was computed for the sleep 
stages (D+1), 2 and for the sleep onset time, total sleep time. 
,-------- - --- - -- -- -
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and the number of sleep onsets (~liner, 1971, page 5,9). This analysis 
was not performed on stages " 4, (;+ 4) and REM, as it can be seen 
.tr~m'Tables '47- 50, (section 11.0, chapter two), that many of the scores 
for these parameters were equal to zero. The !NOVA would, therefore, 
have little meaning. A three-way AHOVA enables one to examine the d:i:ug 
and period effects simultaneously. If the A1:TOVA gave a significant F 
value, it was followed by a Hewman-Keuls IIlUltiple comparison test 
(Winer, 1971, page 191), in order to determinecwhich components of 
the factor contributed most to the significant F value. Summary 
!NOVA and Newman-lCeuls tables are presented in Tables 42A -' 46A' (section 
11.d~ ,chB.;t~;: tW~r. Vaiues of F which yieled aP. valueequru. t~ or less 
"thail'-~g5were cofuJ'idired' t~-bE!' statisti~iy'sig;;i ii~imt. 
8.0 RESULTS 
A significant drug (F = 7.1, df 2,10, P " .025) and period 
(F = ,.9, df ,,15, P ~ .05) effect were found for sleep onset time -, 
(Table 42, section 11.0, chapter two). The Newman-Keuls IIlUltiple 
comparison test showed that Temazepam produced a significantly shorter 
group mean sleep cnset time than both placebo and F.P., (P -< .05). F.P. 
was not significantly different from placebo for this measure. , The 
significant period effect indicated that regardless of the treatment 
condition there were some other factors operating. The IIlUltiple 
comparison test revealed that the second period produced a significantly 
shorter group mean sleep onset time than the first, third and fourth 
, {P ~ .05), .. ,an<1. that' there w~re ;0 significant differe~ces between the 
other periods. 
For total sleep time there was both a significant d:i:ug (F = 15." 
df 2,10, P ~ .001) and period (F = ,.4, df ,,15, P ~ .05) effect (Table 44, 
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section 11.0, chapter two). From the multiple comparison test, it was 
apparent that it was Temazepam which produced this significant result, 
because Temazepam produced a significantly longer group mean total 
sleep time than both F.P. and placebo (p ~ .01); there was no 
significant difference between F.P. and the placebo for this measure. 
With regard to the period effect, it was the second period which 
produced a significantly longer group mean total sleep time, regardless 
of the treatment condition, in comparison with the first and fourth 
periods (p ~ .05). 
There was a significant drug effect for stage 2 (F = 20.3, df 2,10, 
P <; .001), Table 46 (section 11,.0, chapter two). The multiple comparison 
test showed that Temazepam produced a significantly greater group mean 
increase in stage 2 than did both placebo and F.P. (p" .ch). H()\.ever~ 
" 
for this sleep parameter there was also a borderline significant difference 
between F.P. and placebo (p ~ .05). A Significant drug effect was also 
found for the number of sleep onsets (F= 16:,.0, df 2,10, P ~ .001), 
Table 43, (section 11.0, chapter two). Once again, it was found to be 
I 
Temazepam which produced a greater number of sleep onsets than both 
F.P. and plcebo (p ~ .01). 
9.0 DISCUSSION OF RESULTS 
From the results section above it is apparent that almost all the 
significant drug effects were attributable· to the action of Temazepam. 
Temazepam produced a significant increase in:,' total sleep time, number 
of sleep onsets and stage 2 sleep when compared with the placebo and the 
cJ.:r.oug;F~P.- F.P. was only found to be significantly different from 
placebo for stage 2 sleep. There was a slight tendency for F.P. to 
increase total sleep time in comparison with the placebo, "but this 
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did not reach statistical significance. 
Th& question now raised iSiwhat do these significant changes in 
the various sleep parameters, produced by the administration of these 
treatments, indicate? Since Temazepam produced a significant decrease 
in the group mean sleep onset time and an increase in the total sleep 
tilliEi ~:-in"coinParisori"wHh the"othertreatments , it demonstrated that L 
.-< ' • --. ,.-. 
the model was sensitive to the sedative properties of this drug. It 
was hypothesised that Temazepam would bring about sedation in the model. 
This hypothesis was based on the findings of Fuccella et al. (1972) 
and the fact that this drug is a member of the benzodiazepine.group of 
compounds. This. sedative potential was also revealed by the finding 
that with Temazepam on only 6 out of the 24 subject sessions did the 
subjects fail to fall asleep, "hereas, for the placebo' and F.P. conditions 
. ;, 
.. 
these values were 15 and 13 ~espectively. This sedative potential' 
was especially prevalent in the oase of subjects 1 and 5'for the second 
period, when their sleep onset times were zero and one minute respectively 
(Table 42, section 11.0, chapter two). A significant increase in the 
, 
total sleep time and the number of sleep onsets (Tables 44 and 43, 
section 11.0, chapter two) produced by Temazepam shO\,ed that even after 
being awoken after ten minutes sleep, there was a strong tendency for 
the subjects to return to sleep; much more so thaJi"wiiil either F.P. 
or placebo. In some cases, when Temazepam had been administered, this 
tendency was so great that the subjects had difficulty in remaining 
awake dUring the reading periods. 
Temazepam also produced a significant increase in stage 2 sleep, 
in comparison "ith the other treatments (Table 46, section 11.0, chapter 
two). This ~las to be expected due to the increase in total sleep time. 
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F.P. also brought about a significant increase in stage 2 sleep, in 
comparison with the placebo. Such an effect may be linked with the slight 
tandency ef F.P. to inc:rease total sleep time and is indicative of only 
a very slight sedative potential, particularly as F.P. did not produce 
a significant decrease in the parameter of major interest in, this 
particular case, namely, sleep onset time. 
Another interesting observation (Table 49, section 11.0, chapter 
two) was that Temazepam produced a marked increase in the amount of 
stage (3+4) during the second period. This may have been because 
this second period corresponded to the time of peak activity for Temazepam. 
The second period commenced at 10.30 a.m., one and a half hours after 
drug administration. FUccella et al .. (1972) found that 30 mg. Temazepam, 
when administered in a liquid form to four subjects, reached peak plasma 
" "~ I 
levels approximately 40 - 60 minutes after administration. However, 
their subjects had been starved since the previous night. Therefore, 
even 'though a lower dose of Temazepam was employed in the present study, 
(20 mg.), because the subjects were not starved the peak plasma level 
I 
would be expected to be delayed slightly. This effect may also be 
linked with the finding that the second period, regardless of the 
treatment condition, appeared to be more conducive to sleep than the 
others. However, this effect is only speculative, because no statistical 
analyses were performed on stage (3+4). The group mean amount of 
stage (3+4), during the second Temazepam period was 4.5 minutes, which 
on first consideration appeared rather small. However, it must be borne 
in mind that only ten minute sleep epochs were allowed during the EEG 
recording periods. 
· ........ ------------------~----------
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Also worthy of comment is the statistically significan~period 
effect, which was found for sleep onset time and total sleep time. In 
both cases, it was the second period which p::'oduced the ::ignificant 
change, regardless of the treatment. One possible explanation for 
J 
this effect may be associated with adaptation effects. The subjects 
might not have been adapted to the laboratory setting by the time of 
the first recording period, because only approximately 15 miIiutes prior 
to the first rest period they. had had electrodes applied for the first, 
time; and only five minutes prior had entered the., darkened, bedroom. 
... '. . .' . 
Whereas, prior to the second recording period the subjects had been 
reading and they had been in the bedroom for one hour. In the previous 
EEG model insomnia study the subjects had slept in the laboratory for 
three nights prior to the first nap. These subjects were 'therefore 
adapted. to the laboratory setting. In view of the present findings, 
the subjects of the present study should have attended the laboratory 
on four occasions, the first being for adaptation purposes. Alternatively, 
the first and second periods may have been made equally conducive to 
sleep by allowing the subjects to read for the first 30 minutes in the 
bedroom and then to have commenced the first recording period at 10.00 a.m. 
The disadvantage of this time scale was that any possible effects of 
the drug, evident after approximately 30 minutes, would be missed: . 
. the-refore" the dosing would have to take place at 9.30 a.m. However, 
- .. - . '-', 
this alternative has its disadvantages as well, for in order to be able 
to examine the effects of drugs over four recording periods at 30 minute 
intervals the fourth period would then'commence at 1.00 p.m. This would 
lead to another confounding effect, namely, that of boredom of the subjects 
and the feeling that their lunchtime was near. On the time scale used 
in the present study, there was an indication that even by 12.30 p.m., 
the subjects were anxious to be returning home for their lunch and were 
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b'ored with the experimental procedure. 
This p~~blem of boredom is very difficult to overcome in a repeated 
. ,-
measures study such as this. One possible way to overcome this effect 
may be simply to record for three periods; but since the third period 
would then be the last, the same boredom factor may then apply to 
this period as it did to the fourth. However, the laboratory session 
would then finish earlier at 12.00 p.m. One disadvantage with recording 
for only three periods is that some of the effects of the drug may be 
missed. Another alternative may be to reduce the. length of the reading 
periods between each recording period. 
Another factor contributing to the significant period effect may 
have been that, if a subject fell asleep in one period~' this may have 
,.,',! 
interfered with his chances of fal11o€ asleep in a subsequent period. 
Since it appeared to be the second period which was conducive to sleep, 
regardless of the treatment, the third and fourth periods were the ones 
most likely to be affeoted by this faotor. An alternative way to 
overoome ·this period effect may be to adopt a different experimental 
design. For example, a much larger sample of matohed subjeots, divided 
into four groups, could be used, each group of subjeots representing a 
particular :time period. All groups would be dosed at the same time, 
and each group would be allowed one hour of rela.:xa.tion in the bedrooms, 
oommencing at their time period. This.design would enable the study 
of possible longer sleep onset times. However, this approach also 
introduces variablility due to the different groups of subjects 
employed. 
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It was interesting to note that 38 per cent of the subject sessions, 
for the placebo condition, resulted in sleep. For the previous model 
study the proportion was 44 per cent. These percentages are similiar, 
and both are higher than was initially expected. In consideration . 
of the fact that these subjects were all unaccustomed to daytime napping, 
one would ideally expect these percentages to equal zero. The morning 
.. 
questionnaire responses by the subjects of the present study indicated 
that the majority of subjects felt "average" upon awakening (Table 51, 
section 11.0, chapter two). However, prior to all conditions the group 
mean estimated total sleep time was approximately 390 minutes, which 
was less than would be expected for this age group. A group mean total 
sleep time lying within the range 420. - 465 minutes (Roffwarg et al., 1966) 
would be expected. Only two subjects claimed. that they felt as if they 
had not had enough sleep; subject 6, prior to the Temazepam and F.P. 
~ : 
treatments and subject 1, prior to the F.P. treatment. It is possible 
that not all of the subjects were sleep satiated prior to the morning 
laboratory sessions. Although the experimental design may have randomised 
the effects of any prior sleep deprivation, this procedure would not 
, 
have been entirely effective with this relatively small sample size. 
Following the experimental days, there was a slight tendency for an 
increased feeling of tiredness (Table 52, section 11.0, chapter two), 
but there was no obvious treatment associated trend. There was also 
indications of a slightly lengthened night-time sleep following Temazepam. 
Scrutiny of the EEG traces for unusual or abnormal activity produced 
only one finding. This was an increase in duration and amplitude of 
12-14 Hz. spindle activity in two subjects following the administration 
of F.P. in one subject and Temazepam in the other. 
12:3 
From Tables 5:3 and 54 (section 11.0, chapter two), it would appear 
that with regard to the subjects' general health and well-being, only 
subject :3 under the F.P. condition experienced any undesirable side-effects, 
namely, slight stomach discomfort, which did not persist into the next 
day. 
Before. attempting to draw any conclusioris from the findings reported, 
it is necessary to be aware of some of the shortcomings of this study: 
1. As mentioned previously, ~here was some indication that the subjects 
were not sleep satiated· prior to each morning session in the 
laboratory. This could have been better controlled if the subjects· 
night-time sleep had been recorded in the laboratory. 
i 
2. There was a significant period effect, regardless of the treatment 
, 
condition. ·It was the second period which was significantly more 
conducive to sleep 1;han. the others. Various suggestions were made 
to overcome this. problem •. 
:3. In Order to. carry out a repeated measures study of reasonable 
duration, the nap period was reduced to :30 minutes. Thus, the 
maximum sleep onSet time which could possibly be achieved was 
:30 minutes. Ideally, a longer period time should have been used, 
for example, 45 minutes. 
With the above points in mind, some conclusions will be drawn from 
the findings concerning the sedative potential of the two .drugs. 
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10 .• 0 CONCLUSIONS AND FURTHER RESEARCH 
Temazepam, as hypothesised, clearly revealed its sedative properties 
when evaluated with the model, primaril;r tllrough the significant 
decrease in sleep onset ,time and increase in total sleep time brought: 
about by this drug. Temazepam was significantly more effective than 
both F.P. and the placebo at producing sedation'in the model. F.P. 
showed only one effect which was significantly different from the placebo 
condition, namely an increase in stage 2 sleep. This effect of F.P. 
may be linked with the, slight tendency for an increased total sleep time 
upon administration of this drug, but the increase was not statistically 
significant. F.P. did not bring about a significant reduction in sleep 
onset time in comparison with the placebo. This measure was of major 
importance in the present study. The evidence in support of the claim 
\ 
that F.P. may have mild sedative properties was very weak.' With only 
one significant effect, one can only cautiously conclude that F.P. 
appeared to have very mild sedative properties in comparison with the 
placebo, but it failed to match the sedative potential shown by Temazepam. 
, 
The question now raised is, "Why is there such a marked difference 
between the two drugs when tested upon the model, when they were initially 
believed to have similar sedative properties?" At present, there appears 
to be two alternative, possible answers: 
1. Temazepam may possess much stronger sedative powers than was 
initially believed. As mentioned in the introduction, the studies 
which have previously investigated this action of Temazepam are 
themselves open to criticism. There is also the possibility that 
F.P. has even less sedative potential than the Company believed. 
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'2. The. model itself may be tlextra-sensitivetl at discriminating 
between the sedative potential of various compounds. Therefore, 
there may only be slight differences between the sedative potential 
of these two drugs, but this evaluation procedure may be very 
sensitive, and as a result amplified this difference. 
Although the second alternative is a possible explanation, there is little 
evidence to support it, since the present study is the first conducted 
with this model. The sensitivity of the model will have to be determined 
in a series of further· studies with compounds of known sedative potential. 
Nevertheless, on the basis of the present findings, it would appear that 
Temazepam (20 mg.) has marked sedative properties. 
In order to aid in the interpretation of the results from such 
·model insomnia studies, a table of results must be draWn up of the 
action of known sedative compounds upon this model; this would then 
serve as a reference table against which drugs of unknown sedative 
potential could be compared. This is an important series of further 
studies which ought to be conducted before the model is again employed 
in studies with drugs of unknown sedative potential. These proposed 
studies will also give some indication of the sensitivity of the model. 
It would also be interesting to use the model to examine drug 
interaction and multiple dosing effects. However, as mentioned in the 
previous discussion (section 9.0, chapter two), it is necessary to try 
to ma.k~' all. the recordiDg periods equally conducive to sleep. -Various 
suggestions were made, for example, to reduce the length of the reading 
periods which were interspersed between the recording periods and 
employing four groups of subjects, each corresponding to a particular 
time period. Some of these suggestions could be tested experimentally. 
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Any further research with this model should ideally. require the subjects 
to attend the laboratory at night as well as during the day. If this 
is not pcssible, then a ~orning session should be allowed for adaptation 
purposes. 
Another line of investigation would be to select,a group of sleep 
onset insomniacs, according to EEG criteria, for the purpose of a 
double-blind assessment of Temazepam at night. The results of the 
present study indicated that Temazepam has stronger sedative properties 
than was initiallyexpeoted: it may, therefore; be a usefUl "aid" for 
sleep onset insomniacs. Also, on the basis of the results of the present 
study one would feel justified in going to the lengths of selecting a 
group of sleep onset insomniacs to satisfy EEG criteria. The three 
studies already conducted in this area were discussed in the introduction 
. i, 
and it ~Ias clear that, to date, Temazepam has not been satisfactorily 
evaluated by EEG criteria as a sleep inducing agent. 
Although the EEG model of sleep onset insomnia study opened many 
, 
avenues of further inquiry, they were not pursued at present, mainly 
.because of time limitations. The experimenter was still interested 
in determining the rationale, if any, behind the claim made by many of 
the self-reported insomniacs that Aspirin helped them to sleep (chapter 
one). The following chapter will therefore focus upon this aspect of 
insomnia. 
Section 11.0 
RESULTS TABLES AND GRAPHS 
FOR 
CHAPTER TWO 
i, 
., 
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11.1 Explanatory Notes for the Results Tables" 
All means in the results tables are expressed to the nearest whole number. 
All figures in the results tables are expressed in minutes unless 
otherwise stated. 
Key: 
A - Afternoon Nap Session 
A.S.T. Analysed Sleep Time refers to the amount of each sleep record 
analysed from the time of sleep onset. A.S.T. is the lowest 
common measure of total sleep time for all subjects on all 
nights. 
Av - Average 
B - Baseline 
M - Morning Nap Session 
X"" - Sleep onset time as measured by the EEG criteria 
Y - Sleep onset time as estimated by the subjects '" ." 
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Results Tables for Sleep Onset Times at Night and during the Day .. 
SleeE Onset Time at Nisht Table 28 
Night B1 B2 B3 · B4. 
X Y X Y X Y X Y 
SUbject 
1 19· 20 11 20 15 15 18 20 
2 21 20 32 30 32 25 33 15 
3 20 30 9 30 61 60 24 30 
4 36 60 15 45 21 30 86 120 
5 14 15 18 15 28 20 32 30 
6 12 10 27 10 46; 30 21 30 
7. 35 30 81 80 57 60 64 45 
8 ~t ~o 21 60 ~1 ~~ :1:1 20 Mean 27 30 36 38 :3 42 48 
SIDs'· 1~.2 1:1.2 22.8 2~ 16·2 11·1 2~.2 21·1 
Geometric 
Mean 23 24 24 30 35 32 36 38 
!, 
" 
" 
Sleell Onset Time during the DaI Table 22 
Nap 
. Session; A1 A2 
X Y X Y X Y X Y 
Subject 
1 60 60 60 60 14 10 60 60 
2 60 15 34 15 26 60 . 15 60 
3 32 60 60 60 15 60 22 60 
4 60 60 60 60 60 60 . 60 60 
5 16 60 30 60 8 60 12 60 
6 21 15 37 20 16 15 20 30 
7 60 60 60 60 60 20 42 30 
8 60 1:1 16 10 1~ 1:1 10 10 
Mean 46 43 45 43 27 38 30 46 
S.D. 12.6 22·2 11·:1 22·~ 21.2 2~.2 20·2 20 
Geometric 
Mean 41 36 ' 41 35 21 30 24 41 
----~------~------------....... 
, 
.. 
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Results Tables for the EEG Model of Sleep Onset 
Insomnia stuCly 
Stage 1f+1 • Table 20 
Night B1 B B B4 
Subject 2 3 
1 22 9 15, 12 
2 23 '9 19 25 
3 12 29 2 27 
4. 4 10 39 13 
5 14 8 16 17 
6 5 5 5 3 
7 11 15 7 2.2 
8 19 12 18 14 
Mean 14 12 15 16 
S.D. 7.2 7.4 11.6 7.9 
stage 2 Table 21 
Night B1 B2 B3 B' 
, 
.4 ; Subject 
1 219 219 226 . '223 
2 238 235 218 202 
3 223 211 228 203 
4 270 232 205 240 
5 204 186 184 184 
6 198 201 207 184 
7 190 206 209 180 
8 171 181 112 161 
Mean 215 210 206, 197 
S.D. 29.6 18.5 19.6 25.4. 
, 
Stage 2 Table 22 
Night B1 B2 B' B 
Subject 3 4 
1 32 35 24 27 
2 10 13 13 16 
3 32 29 22 29 
4 29 29 18 35 
5 27 37 29 20 
6 19 22 21 22 
7 18 22 24 27 
8 22 22 22 22 }!ean 25 28 23 25 
S.D. 8.3 8.3 6.2 5.8 
A.S.T. for the above three tables is equal to 420 minutes. 
,---------------------- -
( 
1, 
stagoe !l: 
Night 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
Mean 
S.D. 
stagoe ~+4 
Night 
Subject 
1 
2 
3 
4 
5 
6 
7 
8 
Mean 
S.D. 
stai?!! REl1 
Night 
Subject: 
1 
2 
3 
4 
5 
6 
7 
8 
Mean 
S.D. 
B1 
60 
75 
51 
30 
65 
115 
76 
82 
70 
25.4 
B' 1 
92 
85 
83-
59 
92 
134 
94 
121 
95 
23.2 
B1 
87 
74 
102 
87 
110 
83 
125,: 
1~g 
16.6 
----------........ 
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Table ~~ 
B' 2 B3 B4 
76 70 76 
62 74 73 
62 59 52. 
60 54, ' 30 
62 61 76 
101 98 118 
72 73 72 
12 14 28 
71 70 74 
13.6 13.5 26.6 
Table ~ 
B 2 B' 3 B4 
111 94 103 
75 87 89 
91 81 '81 
89 72 65 
99 90 96 
123 11~ 140 
94 97 99 
101 101 12:2 
99 93 '100, ' 
14.9 14.7 2,3.4 ' 
Table 22 
B" 2- B3 B4 
81 85 82 
101 96 104 
89 109 109 
89 104 102 
127 130 123 
91 89 93 
105 101:' 119 
11:2 12:2 122 
100 105 107 , 
15.1 15.6 14.6 
A.S.T. for the above three tables is equal to 420 minutes. 
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Total SleeE Time Table 26 
-
Night :81 :82 :83 :84 S'.:object 
1 487 480 420 483 
2 486 454 461 467 
3 505 504· 460 486 
4 478 496, 499 432 
5 513 492 492 490 
6 424 446 423 420 
7 434 423 429 429 8 4:26 ~~2 ~21 ~20 Mean 473 49 451 457 
S.D. 32.1 28.5· 31.6 28.1 
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Means and Standard Deviations of the Total Amounts of the 
Sleep Stages over· all Four Half-Hour Recording Periods, 
in =tes. . - . - , -- . _ 
Table 37 
Temazepam F.P. Placebo 
Sleep Onset Time 18.6 23.5 25.0 (10.4) (8.2) (7.6) 
Stage D+1 10.7 5.4 6.6 (6.9) (4".5) (6.6) 
stage' .2 9.7 6.2 3.5 (6.8) (7 •. 1) (5.9) 
stage 3 1.0 0.3 0.3 (1.6) (1.0) (0.7) 
stage 4 0.8 0 0 (2.7) (0), : (0) 
i 
stage 3+4 1.8 0.3 (, 0.3 ' , (3.7) (1.2) (0.7) 
Stage REM 1.1 0.1 0 (3.6) (0.6) (0) 
Total Sleep Time 12.3 6.7 3.8 (8.5) (7.4) (5.9) 
Number of Sleep Onsets 1.5 0.9 0.6: (0.8) (1.1) (1.0) 
The figures enclosed in brackets are the standard deviations 
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Means and standard Deviations of the Sleep stages in the 
First Half-Hour Recording Period, in minutes. 
Table ~8 
Temazepam F.P. Placebo 
Sleep Onset Time 20.0 25.8 26.0 
(11.1) (5.9) . (7.6) 
stage D+1 12.2 6.7 6.8 
(7.4) (5.1) (6.3) 
stage 2 8.7 5.2 3.5 
(8.6) (5.2) (6.4) 
stage 3 0.8 0 0.2 
(2.0) (0) (0.4) 
stage 4 0.5 0 0 (1.2) (0) . (0) 
-stage 3+4 1.3 0 0.2 
(3.3) (b) (0.4) 
i, 
"~ : 
stage REM 0 0 0 
(0) (0) (0) 
Total Sleep Time 10.0 . 5.2 . 3.7 
(9.9) (5.2) (6.5) 
NUmber of Sleep Onsets 1.2 0.7 0.8 
(0.8) (9.8) (1.6) 
The figures enclosed in brackets are the standard deviations 
Means and Standard Deviations of the Sleep S~s in the 
Second Half-Hour Recording Period, in minutes. 
Table 22 
Temazepam F.P •. Placebo 
. Sleep Onset Time 12.5 19.5 21.0 
(11.5) (9.6) (10.8) 
Stage D+1 10.2 6.3 6.8 
(7.0) (2.0) (6.9) 
Stage 2: 11.3 9.5 6.2 
(6.1) (7.8) (8.8) 
stage 3 2.0 0.8 0.3 
(1.7) (2.0) (0.8) 
stage 4 2.5 0.2 0 
(5.2) (0.4) (0) 
stage 3+4 4.5 1.0 , ' 0.; 
(6.0) (2.4) f,' (0.8) , ; 
Stage REM 1.; 0.5 0 
(3.3) (1.2) . (0) 
Total Sleep Time 15.8 11.0 6.5 
(8.1) (7.4) (8.7) 
Number of Sleep Onsets 1.8 , ~7 0.8 
(0.8) (1.2) (1.0) 
The figures enclosed in brackets are the standard deviations 
Means and Standard Deviations of the Sleep stages in the 
Third Half-Hour Recording Period, in minutes. 
Table ~O 
Temazepam F.P. Placebo' 
Sleep Onset.Time 1S.3 21.7 29.0 (11.1) (9.3) (2.4) 
s ta.gl;! ll+ 1 9.7 5.5 4.S (9.S) (6.2) (7.5) 
stage :t 9.0 7~0 1.3 
(S.2) (S.2) (2.2) 
Stage 3 0.7 0.2 0.3 (1.6) (0.4) (o.s) . 
sta.gl;! 4 0 0 0 (0) (0) . (0) 
stage 3+4 0.7 0.2 ,. ' 0.; (1.6) (0.4) " (o.s) , , 
stage REM 3.2 0 0 
(6.4) (0) (0) 
Total Sleep Time 12.S 7.5 1.7 
(10.5) (S.7). (2.9) 
Number of Sleep Onsets 1.5 1.0 0.3 (o.s) (1.3) • (0.5) 
The figures enclosed in brackets are the standard deviations 
--------------------------_. _.- --_.-
Means and Standard Deviations of the Sleep Stages in the 
Fourth Half-Hour. Recording Period, in minutes. 
Table ~1 
Temazepam F.P. Placebo 
Sleep Onset Time 24.0 27.0 24.0 
(6.3) (7.3) (7.5) 
stage D+1 10.7 3.2 a.o 
(4.0) (4.0) (7.1) 
stage 2 9.7 3.0 3.0 
(5.5) (7.3) (4.3) 
stage 3 0.6 0 0.5 
(1.0) (0) (o.a) 
Stage 4 0.2 0 . 0 
(0.4) (0) . (0) 
, 
Stage 3+4 o.a 0 !! 0.5 
(1.3) (0) ,c,: (o.a) 
Stage REM 0 0 o. 
(0) (0) (0) 
Total Sleep Time 10.5 3.0 3.5 (5.9) (7.3) (4.4) 
NUmber of Sleep Onsets 1.5 0.3 0.5 (o.a) (O~a) (0.6) ". 
The figures enclosed in brackets are the standard deviations 
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Sleep Onset Time Table 42 
Drug Placebo Temazepam F.P. 
Period 1 2 3 4 1 2 3 4 1 2 3 4 
.. 
Subject 
1 25 20 24 23 6 0 4 22 26 15 15 30 
2 30 30 ,0 ,0 ,0 17 30 3.0 30 30 30 30 
3 30 8 30 19 16 27 24 13 30 17 10 30 
4 30 30 30 30 30 23 10' 30 30 30 30 30 
5 11 8 30 30 9 1 12 22 15 5 15 12 
6 30 30 30 12 29 7 30 24 24 20 30 30 
-
Mean 26.0 21'.0 29~0 24.0 20.0 12.5 18.3,24.0 25.8 19.5 21.7 27~0 
S.D. 7.6 10.8 2.4 7.5 11.1 11.5 11.1 6.3 5.9 9.6 9.3 7.3 
Summa~ ANOVA Table Table'~2A 
Source S.S. d.f. M.S. F P df1,df2 
I 
'I' 
Drug 540.8 2 270.4 7.1 2.5% 2,10 
Period 559.2 3 186.4 :3.9 5.00!o 3,15 
Subject 2034.4 5 406.9 
Drug x Period 246.6 6 41.1 0.8 n.s. 6,30 
Drug x Subject 379.8 10 38.0 
Period x Subject 720.3 15 48'.0 
Drug x Period x Subject 1471.5 30 49.1 
Total 5952.6 71 
Newman-Keuls Multiple Comparisons 
~ Period 
TemazePalll F.P. Placebo 2nd 3rd 1st 4th 
Temazepam ,5"/0 5% 2nd 5% 5% 5% F.P. n.s. 3rd n.s. n.s. 
1st n.s. 
t 
i' 
Number of Sleep Onsets Table 43 
--Drug Phcebo Temazepam F.P. 
'-,' 
Period 1 2 3 4 1 2 
Subject 
1 1 1 1 1 2 2 
2 0 0 0 0 1 1 
3 0 2 0 1 1 1 
4 0 0 1 0 0 2 
5 4 2 0 0 2 3 
6 0 0 0 1 1 2 
Mean .8 .8 
.3-- .5 1.2 1.8' 
S.D. 1.6 1.0 .5 .6 .8 .8 
S~ ANOVA Table 
Source S.S~ d.f. 
Drug 9.5 2 
Period 4.7 3 
Subject 26.4 5 
Drug x: Period 3.6 6 
Drug x Subject 2.8 10 
Period x Subject 8.6 15 
Drug x Period x: Subject 17.4 30 
Total 73.0 71 
Newman-Keuls Multiple Comparisons 
Plaoebo F.P. Temazepam 
Plaoebo 
F.P. 
n.s. 
3 4 1 2 3 
2 2 1 2 2 
0 1 0 1 0 
2 2 0 3 1 
2 0 0 0 0 
2 2 2 3 3 
1 2 1 1 0 
1.5 1.5 .7 1.7 1.0 
.8 .8 .8 1.2 1.3 
" . 
Table:43A 
M.S. F P 
4.8 16.0 0.1% 
1.6 2.8 n.s. 
5.3 
0.6.- 1.0 n.s. 
0.3 
0.6 Q.6 
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4, 
0 
0 
0 
Q. 
2 
0 
.3 
.8 
.df1,df2 
2,10 
3,15 
6,30 
-------------------- - -
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Total Sleep Time Table 44 
Drug Placebo Temazepam F.P. 
Period 1 2 3 4 1 2 3 4 1 2 3 4 
Subject 
1 6 5 7 5 21 28 . 24 15 6 15 16 0 
2 0 0 0 0 4 10 0 8 6 4 0 0 
3 0 13 0 11 10 8 11 16 0 16 10 0 
4 0 0 3 0 0 10 20 0 0 0 0 0 
5 16 21 0 0 23 23 . 21 13 14 19 19 18 
6 0 0 0 5 2 16 1 11 5 12 0 0 
Mean 3.7 6.5 1.7 3.5 10.0 15.8 12.8 10.5 5.2 11.0 7.5 3.0 
S.D. 6.5 8.7 2.9 4.4 9.9 8.1 10.5 5.9 5.2 7.4 8.7 7.3 
Summary ANOVA Table Table ~A 
" 
" Source S.S. d.i. M.S. F P df1,df2 
Drug 889.7 2 444.9 15.3 0.1% 2,10 
Period 321.9 3 107.3 3.4 5.0% 3,15 
Subject 1737.2 5 347.4 
Drug x Period 88.6 6 14.8 0.5 n.s. . 6,30 
Drug x Subject 291.2 10 29.1 
Period x Subject 471.6 15 31.4 
Drug x Period x Subject 833.1 30 27.8 
Total 4633.3 71 
Newman-Keuls Multiple Comparisons 
Placebo F.P. Temazepam ~th 1st 2rd 2nd 
Pla.cebo n.s. 1% 4th n.s. n.s. 5% 
F.P. 1% 1st n.s. 5% 
3rd n.s. 
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stage DrOlVsy+1 Table 45. 
Drug Placebo Temazepam F.P. 
Period 1 2: 3 4 1 2 3 4 . 1 2 :2 4 
. 
Subject 
1 4 13 3 6~, 5 2 5 10 14 5 4 Q; 
2 o· 3 0 0 10 13 0 9; 9 5 1 0 
3 14 16 0 16 18 22 15 7 2 10 17 3 
4 0 0 7/ 0 13 11 7 12 0 6 1 0., 
5' 12 9 19 15 4 r: 4 8 8 5 8 9 
6 11 0 0 11 23 6 27 18· 7 7 2 7 
. 
. 
Mean 6.8 6.8 4.8 8.0 12.2 10.2 9.7 10.7 6.7 6.3 5.5 3.2 
S.D. 6.3 6.9 7.5 7.1 7.4 7.0 9.8 4.0 5.1 2.0 6.2- 4.0 
SummarY ANOVA Table Table ~~A 
Source S.S. d.!. M.S. F P df1,df2 
Drug 362.9 2 181.5 2.8 n.s. 2,10 
Period 34.5 3 11.5 0.5 n.s. 3,15 
Subject 559.2 5 111.8 
, 
Drug :x: Period 62.4 6 10.4· 0.3 n.s. 6,30 
Drug :x: Sub ject 657.8 10. 65.8 
Period :x: Subject 344.0 15 22.9 
Drug :x: Period :x: Subject 902.9 30 30.1 
Total 2923.7 71 
stage 2 
Drug Placebo 
Period 1 2 3 4 1 
Subject 
1 5 3 5 1 13 
2 0 0 0 0 4 
3 0 13 0 11 10 
4 0 0 3 0 0 
5 16 21 0 0 23 
6> 0 0 0 4 2. 
Mean 3.5 6.2 1.3 3.0 8.7 
S.D. 6.4 8.8 2.2 4;3 8.6 
S~ AlTOVA Table 
Source S.S. 
Drug 459.1 
Period 160.4 
Subject 1531.4 
Drug x Period 74.3 
Drug x Subject 113.3 
Period x Subject 410.6 
Drug x Period x Subject 742.7 
Total 3491.8 
Newman-Keuls Multiple Comparisons 
Placebo F.P. 
Placebo 5% 
F.P. 
Table 46 
Temazepam F.P. 
2 3 4 1 2 3 
12 8' 12 6 9 16 . 
8 0 8· 6 1 0 
8 8 16 0 16 9 
6 16 0 0 0 0 
23 21 13 14 19 17 
11 1 9 5 12. 0 
11.3 9.0 9.7 5.2 9.5 7.0 
6~1. 8.2 5.5 5.2 7.8 8.2 
Table 46A 
f, 
d.i. M.S. F' P 
2 229.6 20.3 0.1% 
3 53.5 2.0 . n.s. 
5 306.3 
6 12.4 0.5 n.s. 
10 . 11.3 
15 27.4 
30 24.8 
71 
Temazepam 
1% 
1% 
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4 
0 
0 
o. 
0 
18 
0 
3.0 
7.3 
2,10 
3,15 
;" ;'. 
~--~--------------............... 
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stage 3 Table 47 
Drug Placebo Temazepam F.P. 
Period 1 2 3 4 1 2 3 4 1 2 3 4 
Subject 
1 1 2 2 2 5 3 0 2 0 5 0 0 
2 0 0 0 0 0 2 0 O. 0 0 0 0 
3 0 0 0 0 0 0 0 0 0 0 1 0 
4 0 0 0 0 0 4 4 0 0 0 0 0 
5 0 0 o. 0 0 0 0 0 0 0 0 0 
6 0; 0 0 1 0 3 0 2 0 0 0 0 
Mean .2 .3 .3 .5 .8 2 .7 .6 0 .8 .2 0 
S.D. .4 .8 .8 .8 2.0 1.7 1.6 1.0 0 2.0 .4 0 
. 
stage 4 Table' 48 
Drug Placebo Temazepam F.P. 
Period 1 2 3 4 1 2 3 4 1 2 3 4 
Subject I 
1 0 0 0 0 3 13 0 1 0 1 0 0 
2 0 0 0 0 0 0 0 0 0 0 0 0 
3 0 0 0 0 0 0 0 0 0 0 0 0 
4 0 0 0 0 0 0 0 0 0 0 0 0 
5 0 0 0 0 0 0 0 0 0 0 0 0 
6 0 0 0 0 0 2 0 0 0 0 0 0 
Mean 0 0 0 0 
.5 2.5 0 .2 0 .2- 0 0 
S.D. 0 0 0 0' 1.2 5.2 0 .4 0 .4 0 0 
~----------------------------.......... .. 
stage 3+4 
Drug Placebo 
Period '1 2 3 4 1 
Subject 
1 1 2 2 2 8 
2 0 0 0 0 0 
3 0 0 0 0 0 
4 0 0 0 0 0 
5 0 0 0 0 0 
6 0 0 0 1 0 
Mean .2 ' .3 .3 .5 1.3 
S.D. .4 .8 .8 .8 3.3 
stage REl-! 
Drug Placebo 
Period 1 2 3 4 1 
Subjeot 
1 0 0 0 0 0 
2 0 0 0 0 0 
3 0 0 0 0 0 
4 0 0 0 0 0 
5 0 0 0 0 0 
6 0 0 0 0 0 
Mean 0 0 0 0 0 
S.D. 0 0 0 
, 
0 0 
Temazepam 
2 3 4 
16 0 3 
2 0 0 
0 0 0 
4 4 0 
0 0 0 
5 0 2 
4.5 .7 .8 
6.0 1.6 1.4 
Temazepam 
2 3 4 
I 
0 16 0 
0 0 0 
0 3 0 
0 0 0 
0 0 0 
8 0 0 
1.3 3.2 0 
3.3 6.4 0 
Table 49 
- 1 
0 
0 
0 
0 
0 
0 
0 
0 
-
t-,· 
-, 
Table' 50 
1 
0 
0 
0 
0 
0 
0 
0 
F.P. 
. 
2 
6 
0 
0 
0 
0 
0 
.3 
.8 
F.P. 
2 
0 
3 
0 
0 
0 
8 
.5 
0 1.2 
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3 4 
0 0 
0 0 
1 0 
0 0 
0 0 
0 0 
.2 0; 
.4 0 
3 4 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
0 0 
S1lmmary o£ some o£ the Mornin~ ~estionnaire ResEonses 
Prior to the Morning NaEs. 
Table :21 
Subject Number . Temazepam F.P. Placebo 
1 AV/6hr Tired/ 
~ 
AV/6hr 
2 AV/~ AV/7Jzhr AV/61zhr 
3 AV/6hr AV/7~ AV/61zhr 
4 AV/tJzhr AV/6hr AV/7hr 
5 AV/7hr Av/6hr AV/6hr 
6 Tired/ Tired/ AV/8hr 
~hr 7hr 
Summary of some of the Morning ~estionnaire Responses 
on the Morning Following the NaE Sessions. , 
., 
Table :22 
Subject NU!Ilber Temazepam F.P. Placebo 
1 Tired/ Tired/, Tired/ 
6-~hr ~hr 7hr 
2 AV/7hr AV/7Jzhr AV/6hr 
3 AV/7hr AV/7hr AV/7hr 
4 AV/7hr Tired/ Tired/ 
7hr 7~ 
5 Tired/ . 
7~ 
AV/7r.hr AV/7hr 
6 Headachy/ AV/4~ AV/ry~hr 
7hr 
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The General Health and Well-Being of the Subjects immediatell 
Following the Nap sessions. 
Table 22 
Subject Number Temazepam F.P. Placebo 
1 OK OK OK 
'2 OK OK OK 
3 OK stomach OK 
discomfort 
4 OK OK OK 
5 OK OK OK 
6 OK OK OK 
U In (y) = 0.61 In(x) + 1.28 
.~ 67 
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148 
Chapter Three·- Part I 
THE EFFECTS OF ACETYLSALICYLIC ACID UPON SLEEP. 
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1.0 INTRODUCTION 
This aspeot of the research programme emanated from the oomment 
made by many of the self-reported', sleep onset insomniaos in ohapter 
. ."". " one, that they frequently took Aspirin to relieve theIr insomnia~ 
Initially, a literature searoh was carried out in order to determine 
if there was any evidenoe for the olaims that Aspirin aids sleep: Only 
two studies of direct relevance were discovered. 
Soldatos, Kales, Bixler, Soharf and Kales (1918) investigated the 
effects of sodium salioylamide (650 mg. and 1,300 mg.) upon the sleep of 
insomniacs; neither dose had a significant effeot"upon the sleep stages 
or latency to sleep onset, but with the higher dosage there was a " 
declinini trend in sleep latenoy upon drug administration, which was 
also reported by the subjeots. This trend was indicative of a slight" 
sedative effeot. Some shortcomings of this study whioh are worthy of 
r 
• • 
note are: 
1. 'there were only four subjeots in each dosage group, 
2. the time of drug adminIstration was not olearly stated, but simply 
refe=edto as "at night", 
3. the total sleep time was not indicated in the results tables, 
4. the percentage of stage 4 sleep, approximately zero for the groups 
of insomniaos, appeared to be rather low, b~t it is difficult to 
estimate by how muoh, sinoe only the age range of the subjects 
was given (28 - 54 years), and not the group mean age, 
5. no oomments were made as to whether there was" any~ inter-subject 
• It is necessary to explain the terminology to be used. Although 
the insomniacs reported taking Aspirin, very few, in fact knew 
what form of the drug they were taking. Aocording to them Aspirin 
refers both to aoetylsalicylio acid (A.S.A.) and its derivatives. 
However, throughout this text acetylsalicylio aoid will be refe=ed 
to as A.S.A. and its derivatives individually Da.IIled. 
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variability in response to the drug; nor were the standard 
deviations presented in the results tables. 
The second study by Pfeiffer, Goldstein, Murphee and Hopkins (1967), 
which examined the possible sedative properties of A.S.A. and its 
derivatives, was conducted during the day; te,n minute EEG recordings 
were taken every hour over a period of seven hours. A.S.A. (1 gm.) was 
found to induce changes in the EEG, characterised by a decrease in the 
"mean energy content" and an increase in the "coefficient of variation" 
of the EEG signal. The authors claimed that upon visual inspection of 
I 
the EEG records, their reported EEG changes would be represented by 
"EEG drowsiness", that is, "flattening o,f the amplitude of the alpha 
waves with sporadic occurrence of waves corresponding to light sleep and 
even some high amplitude slow waves", (Pfeiffer et al., 1967). They 
,y 
emphasised the similarity between their reported EEG changes brought 
. , 
about by A.S.A. and those brought about by some' of the minor tranquilisers, 
such as chlorodiazepoxide. The authors suggested that A.S.A.,may be 
effective in relieving some of the anxieties of everyday life. This 
study gave some indication that A.S.A. may have a sedative effect. 
Sodium salicylate, sodiUm salicylamide and acetaminophen were found to 
have negligible effects upon the EEG under the same experimental conditions. 
This study is open to the following criticisms. 
1. The timing of the whole study was unclear; for example, whether 
all the drugs and plaoebo were administered to the subjects at 
the same time and whether all laboratory sessions commenced at 
the same time. Time of day effects. are a very ,important variable 
when measuring sedation, as shown in the EEG model of insomnia. 
study (chapter two). The subjects in the model study fell 
. , 
asleep significantly faster during the afternoon than during the 
. ~ , 
morning. 
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2. No check was made as to whether the subjects were sleep satiated 
prior to the commencement of the study. This is another important 
variable which may have caused some subjects to show signs of 
3. 
drowsiness, regardless of the: treatment. This may be reflected 
in the different:. "mean energy content" values for the subjects:, 
which :ranged from 38 - 84 •. It was not clear whether this .initial 
difference in baseline values was taken into account during the 
data analysis. 
The subjects were in the laboratory for seven hours, during which , 
time they may have had refreshments. This is another variable 
which was not mentioned in the report. 
It is also interesting to note that the EEG changes were observed 
approximately t\{O hours after A.S.A. administration. If these changes 
are an. indication of a sedative effect, it is unlikely that it would 
be beneficial. to the sleep onset insomniac who takes the Aspirin just 
before retiring. 
Soldatos et al. (1978) examined the effects of sodium salicylamide, 
an A.S.A. derivative, upon sleep. However, there were no published 
studies which had investigated the effects of A.S.A.upon sleep. It 
was therefore decided to continue the literature search fUrther to 
determine whether any other properties of A.S.A. may be expected to 
affect sleep. Apart from its common effects, A.S.A. has a wide variety 
of lesser known effects at therapeutic doses, some of which are listed 
below: 
1. Respiration - Full therapeutic doses of A.S.A. increase oxy~n 
; 
consumption and carbon dioxide production. 
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'2. Acid-Base Balance and Electrolyte Pattern - In view of the 
previous point, equilibrium is maintained by the renal excretion 
. of bicarbonate ions,' 'accompanied by sodium and potassium ions. 
3. Gastrointestinal Effects - The ingestion of A.S.A. may result in 
gastric bleeding, nausea, vomiting and gas tric ulceration. Al thcugh 
scme of these effects are experienced by some people at therapeutic 
dosages, in general, the dosage at which these effects are 
experienced varies widely from individual to individual. 
4. Effect on Platelets - A.S.A.,. at a dose as low as 0.3 gm., can 
cause prolongation of bleeding time. 
(Goodman & Gilman, 1970) 
However, the aspects which were of particular interest were some cf 
the proposed mechanisms by which A.S.A. is believed to exert some of 
its effects. One proposed mechanism is via the inhibition of prostaglandin 
synthesis. The prostaglandins are believed to play an important role 
in neurotransmission. "They are thought to function postsynaptically 
by inhibition or facilitation of neurotransmission through cyclase 
inhibition or activation and by means of a negative feedback loop to 
inhibit further release of the neurotransmitter from the presynaptic 
nerve", (Gross, Dunner, Lafleur, Meltzer, }'luhlbauer & Fieve, 1977). 
1.1 Inhibition of Prostaglandin Synthesis by A.S.A. 
Many of the studies demonstrating the inhibition of prostaglandin 
formation by A.S.A. have been conducted in vitro and with tissue 
preparations. from animal species. For example, Vane (1971) found that 
A.S.A •. prevented the,syiithe~"is:of prostaglandins in, tissue homogenates 
from guinea pig lung. 
Considering the human studie"s, Smith and Willis (1971) found that 
A.S.A. taken orally (600·mg., three times per day) inhibited the 
production of prostaglandins in the platelet.system. However, they 
only experimented with three subjects. Koscis, Herna.ndovich, Silver, 
Smith and Inge:rman (1973) in a similar study, found that A.S.A. (13 mg. 
per kg.) produced marked inhibition of prostaglandin formation in the 
, 
platelet system and that the prostaglandin formation in the platelet 
system did not return to control levels for at least 72 hours. Hamberg 
. '_ .. 
(1972), by measu;t'ing the' major urinary metaboli tes of prostaglandins·in, 
Man, found that A.S~A. (4 x 0.75 gm.). produced strong inhibition of " 
the metabolites for 48 hours after cessation of A.S.A.:adIDinistration. 
: , 
This evidence indicated thatA.S.A., at therapeutic doses, inhibited , 
~l ' _. . 
prostaglandin formation in Man and that this i~bition remained after 
the drug had been metabolised and removed from the body. However, 
" " I 
reported I50 values for prostaglandin" inhibition vary widely between 
different animal species and even between different enzyme preparations 
from the same species. This may be due to the following reasons: 
1. Methods of Handling Tissue - Prostaglandin release, in some cases, 
can be brought about simply by handling the tissue. 
2. Methods of Prostaglandin Analysis - There are a wide variety of 
assay techniques, for example, bioassay, radio-active tracers and 
gas-liquid chromatography. Furthermore, some experimenters 
examined. the formation of the prostagla.~dins per 'se, whilst 
others looked at the prostaglandin metabolites. Koscis"et al. (1973) 
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. and Smith and Willis (1971) examined the formation of prostaglandins 
in the platelets by means of a bioassay, whereas, Hamberg (1972) 
examined the prostaglandin metabolites in the urine, using a 
radio-active tracer assay. 
3. There is a whole family of prostaglandins; drugs may react 
differently to each subclass studied. 
The inhibition of prostaglandin synthesis is not peculiar to the 
drug A.S.A.; Gross et al. (1977) compiled a list of some of the 
, 
anti-depressant, anti-anxiety and anti-psychotic drugs which also inhibit 
prostaglandin synthesis to varying degrees. 
1.2 Functions of Prostaglandins 
I,)' 
Res~arch in the prostaglandin field has advanced rapidly since 
1962, ·when Bergstiom defined their chemical structure. Since then the 
prostaglandirishave been implicated in many areas, for example, they are 
thought to play some role in pain, to contribute to the autoregulation 
of renal blood flow and to have various functions in the central nervous 
system. It is the latter function which is of major interest. The 
prostaglandins have been found to interact with brain neurotransmitter· 
substances, such as, dopamine, noradrenaline and 5-hydroxytryptamine.and 
they may well have an important role to play in the effectiveness of 
these neurotransmitters (Gross et al., 1977). For example, Bergstrom, 
Farnebo and Fuxe (1973) £o~d that PGE2 reduced the amounts of dopamine 
and norepinephrine that were released fro~ the rat neostriatum and 
cerebral cortex following nerve stimulation. 
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1.3 Prostadandins and Sedation 
The prostaglandins have been f'ound to bring about sedation in a 
wide variety of animal species. Horton (1964) observed in cats, that 
after intraventricular injection of prostaglandins of the E series 
(7 - 20jhg. per kg.), the cats showed signs of sedation and stupor. 
Horton and Ma~ (1965) extended Horton's earlier work by demonstrating 
that PGF2.,.<..did not bring about sedation in cats or chickens. PGE1, E2, 
F1 and F2 have all been identified in the dog brain and f'ound to be ,,,... .... 
distributed throughout all regions of the central nervous system (Holmes 
& Horton, 1968). On the basis of the findings of Horton and Main (1965) 
I 
and Horton (1964), it would appear that it is the prostaglandins of' the 
E series which are involved in sedation. Some investigators have 
qualified their behavioural observations with EEG and biochemical 
measures. 
" 
" " 
Haubrich, Perez-Cruet and Reid (1973), using rats injected with 
PGE1 (1 mg. per kg., i.p.), found that sedation was evident'within 
15 minutes and persisted for about one hour. The period of' sedation 
was reported to be characterised by a desynchronised EEG pattern, similar 
io that of the normal, waking rat, and a diminished IllUScular tone of'the 
neck muscles; the rats could easi17 be aroused by gentle ~dling. 
The authors commented that these EEG and behavioural changes were 
indicative of' REI1 sleep. The turnover rate of brain 5-h7droxytryptamine 
was found to increase following the administration of PGE1• Furthermore, 
the behavioural effects of PGE1 were blocked by drugs such as 
pa.ra.chlorophenylaJaniDe (PCPA), which lowers the levels of 5-hydroxyindole-
acetic acid (5HIAA), a breakdown product of' 5-hydroxytryptamine. 
Administration of PGE1 (two doses of' 1 mg. per kg., i.p., 45 ~utes 
apart) was also found to increase the brain acetylcholine concentfation 
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by ~O per cent. Prior administration of atropine (20 mg. per kg.) failed 
to block the sedation produced by PGE1• The placebo group of rats who 
received four per cent ethanol in saline did not show any of these 
physiological or behavioural changes. The authors concluded therefore, 
that PGE1 probably does not produce its sedative effect by increasing 
the brain acetylcholine concentration.Vlhereas, Perez-Cruet~ Haubrich 
and Reid (1971) found.that seruation in rats, produced by PGE1 (1 mg. 
per kg., i.p.), was completely blocked by atropine (50 mg. per kg., i.p.). 
It would therefore appear that the dose of atropine used in their 197~ 
study was insufficient to block the production of acetylcholine 
completely. Prostaglandins may exert their sedative effects vii both 
the 5-hydroxyi;r,yptamine and acetylcholine pathways. 
Gilmore and Shaikh (1972) reported:that PGE1 and PGE2 exerted a 
!f 
sedat~ve<effect when administered subcutaneously in the rat (approximately 
2.5 mg. per kg.) and also caused flushing, increased respiration and 
diarrhoea.' The authors found that the effects of theprostaglandins were 
not blocked by prior administration of Aspirin.' This is to be expected, 
since Aspirin is believed to inhibit prostaglandin syntheSis, but this 
, does not necessarily imply that Aspirin will inhibit the action of . 
administered prostaglandins. These results are therefore not contrary 
to the idea that the prostaglandinsare involved in sedation. Gilmore 
and Shaikh (1972) concluded that the prostaglandins exerted their 
sedative. effects by restricting blood flow to the brain (Yamamoto, 
Feindel, Woli'e, Katoh & Hodge, 1972). 
Potts and East (197~) examined the sedative properties of the 
prostaglandins by another method, the response to a conditioned avoidance 
task. They also, made EEG recordings., PGA2, PGE1, E2 and arachidonic acid 
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(a precursor of prostaglandins) caused dose related decreases in 
avoidance responding, in: the rat. The researchers reported that this 
behaviour was typical of that observed with general sedatives, such as, 
barbiturates. The EEG changes were less clear: PGE2, administered 
intraventricularly, caused an increase in the low frequency activity 
of the power spectrum. Potts and East (1973) also reported that these 
changes were indicative of a "sleep like" state~ When PGE2 was 
administered either intraperitoneally or intragastrically, a decrease 
in the power of the EEG was evident, which indicates an alerting type 
of effect. These differences may be due to the various routes of 
I 
administration employed,which results in difficulty in equating 
the dosages. There is also the possibility that the "alert type" of 
EEG, induced by PGE2, was indicative of a REM like state of sleep, 
\~hich is characterised by a low voltage, mixed frequency EEG, similar 
, , 
to that of the waking EEG. Haubrich et al. (1973) found that PGE 
. . 1 
induced a state of sedation in the rat characterised by a de synchronised 
EEG pattern, I'Ihich they claimed was indicative of REl1 sleep. 
Nistico and Marley (1973), experimenting with adult fowls, 
concluded that PGE1 (1 - 3gms.), infused into the hypothalamus, resulted 
in behavioural and electrocortical sleep. Desiraju (1973) showed that· 
PGE1 (50 mg. per kg.), administered into the cerebral ventricle of an 
unanesthetised monkey, caused tremor, disturbance of posture and stupor 
for several minutes, followed later by somnolence; the EEG was 
desynchronised. Lower doses (25 mg. per kg.) caused drowsiness and 
facilitated sleep behaviour. 
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Hovlever, it is very difficult to compare the fiDdings of these 
animal studies because: 
1. different animal species were used, 
2. not all of the studies employed EEG measures, 
3. various routes o~ administration, a range of doses and different 
members of the prostaglandin family have been used. 
4. Consideration must also be given to the fact that when the 
prostaglandins are injected directly into the brain areas they 
vlill result in abnormally high prostaglandin concentrations, since 
they are normally present in the brain in concentrations of the 
order of.10-9gm. 
It is difficult to extrapolate these animal findings to humans. 
HOv/ever, there is sufficient evidence to suggest that prostaglandins 
in animals' bring about sedation by means of interactions with brain 
neurotransmitter substances. It must be appreciated that the 
prostaglandins have a wide variety of effects and, at present, the 
sedative effect is being examined in isolation. Nevertheless, if the 
overall effects of prostaglandins in animals are taken as being 
indicative of their role in humans, then they might be expected to play 
some rele in the sleep mechanisms of Man. This idea is admittedly 
rather speculative, but appears vlorthy of further investigation~ 
Section 1.1, chapter three, provided evidence that .therapeutic doses 
of A.S.A. administered orally to humans were able to inhibit the 
formation of prostaglandins in the platelets. If this inhibition can 
be assumed to hold for the brain areas as well, then A.S.A.,. rather than 
promoting sleep as the irisomniacsbelieved, may instead have an 
arousing effect!· It must be stressed that this proposed link between 
A.S.A., prostaglandins and sleep is only tentative and it is quite 
; 
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possible that if A.S.A. is found to affect sleep in humans, it may be 
due to its actions on some entirely different mechanism. 
1.4 The Relationship Between Aspirin and Tryp'tophan Binding 
Another interesting property of A.S.A. is its capacity to bind 
to serum albumin, thereby causing the release of other bound molecules, 
such as tryptophan., Free, circulating tryptophan is the precursor 
of'5-hydroxytryptamine, which is believed to be one of the major 
neurotransmitter substances involved in sleep (Mendelson, Gillin & Wyatt, 
1977). In rats, sodium salicylate (50 - 450 mg. per kg., i.p.) has 
I 
been'shown to increase serum free tryptophan, which then res]1l ted:,', :, " 
in an increase in both the central nervous system uptake of tryptophan 
and the central nervous system turnover of 5-hydroxytryptamine (Tagliamonte, 
Biggio, Vargiu & Gessa, 1973). Guerinot, Poitou and Bohuon (1974) 
.")' 
reported~imilar findings to those of Tagliamonte et al. (1973), but 
Guerinot et al. (1974) found that the lowest dose employed ( 50 mg. 
per kg., orally) did not increase brain tryptophan levels. This 
difference between the two studies may be due to: 
1. Tagliamonte et al. (1973) used sodium salicylate, whereas 
Guerinot et al. (1974) Used A.S.A., 
2. different routes of administration of the drugs were employed, 
3. the drugs were administered at different times of day in the two 
studies, 
4. different strains of rats were used, 
5. tryptophan binding is very susceptible to changes in pH and 
temperature, therefore, any differences in handling techniques 
may have introduced another variable. 
The comparable dose in humans to that employed in these two studies is 
approximately 17 times the recommended therapeutic dosage., The 
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equivalent study does not appear to have been performed on primates. 
However, McArthurand Dawki11s (1969) found that 10 mg. sodium 
salicylate in 50 mls. of human serum brought about a considerable 
release of tryptophan from its binding'site. Smith and Lakatos (1971) 
found that in humans, after ingestionofA.S.A.,the, ooncentration of bound 
tryptophan was decreased and the mean free tryptophan concentration 
increased. A tryptophan loading study enabled the authors to demonstrate 
that a relatively high concentration of salicylate ion was required to 
produce a marked displacement of tryptophan. The increase, in free 
tryptophan is therefore, likely to be short lived: it will only be 
elevated for as long as there is a sufficient salicylate ion concentration 
in the plasma to compete successfully with tryptophan for the binding 
site on albumin. Since tryptophan is thep;ecUrsor of the neurotransmitter 
5-hydro~tamine, which is believed to be involved in the sleep 
mechanisms (Mendelson et al. 1977), this action of A.S.A. was considered 
relevant. However, other drugs, such as,the benzodiazepines, have 
also been shown to displace tryptophan from its binding site (MUller & 
Wollert, 1975). The pharmacological significance of this drug action 
is not yet fully understood. 
1.5 Summary of the Literature 
There has been no investigation into the effects of A.S.A. upon 
human sleep. Nevertheless, the literature suggested several A.S.A. 
actions which may affect sleep. However, caution must be applied when 
interpreting the experimental evidence for the various A.S.A. pathways, 
because the majority of studies nave been conducted with different 
animal species or in vitro. 
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From the studies considered in the previous section, the link 
between A.S.A., prostaglandins and sleep is not absolutely clear. If 
A.S.A. does inhibit prostaglandin synthesis in the brain, one may have 
expected the results of the Guerinot et al. (1974) study to have shown 
the increased brain tryptophan content, but not the increased 
5-hydroxytryptamine turnover rate. Haubrich et al. (1973) found that 
increased prostaglandin levels brought, about an increased 5-hydroXytrypt-
amine turnover rate. Subsequently, if the prostaglandins do play a 
major role in the pathways associated with the turnover of 5-hydroxytrypt-
amine, when the prostaglandins are supposedly inhibited by, for example, 
I 
A.S.A. administration as in the Guerinot et al. (1974) study, the 
turnover rate would be reduced. However, this discrepancy does not 
necessarily mean that the hypothesised link between prostaglandins, 
brain neurotransmitters and sleep no longer holds. It could be that 
the pros~landins are exerting their sedative effects via the 
acetylcholine pathways, which were not examined by Guerinot et al. (1974). 
Haubrich et al. (1973) found, however, that prostaglandin administration 
was able to increase acetylcholine levels in rat brain. 
There is also the possibility that the prostaglandins are involved 
in a regulatory r~le, maintaining a balance between the various 
neurotransmitters. In the Haubrich et al. (1973) study,. the increased 
prostaglandin level may have indicated some neurochemical imbalance, 
which resulted in an increased turnover of 5-hydroxytryptamine and an 
increase in brain acetylcholine concentration. However, in the 
Guerinot et al. (1974) study this regulatory effect may have been lost 
due to prostaglandin inhib;''t~oj\. by A.S.A.', but the actual pathways for 
the conversion of tryptophan to 5-hydroxytryptamine may have b~en 
unaffected, resulting in an increased turnover rate. These ideas' are , 
162_ 
only speculative and much research is being conducted with the _ 
prostaglandins at present to determine the precise rele of prostaglandins 
in neurotransmission,. 
There is sufficient evidence to suggest that prostaglandins play 
some r81e in sedation in animals. There is also evidence to suggest 
that A.S.A." inhibits prostaglandin production in both animals and Man. 
Caution must be applied here, because the evidence indicated prostaglandin 
" inhibition in the periphery, but not necessarily in the brain areas. 
However, if brain prostagliixidiIl synthesis is also inhibited, and if the 
" I prostaglandins are involved in the sleep lIlechanisms of Ha.n, then one 
might expect A.S.A. to have an arousing effect upon sleep in Man. This 
idea is in fact contrary to the findings of the Pfeiffer et al. (1967) 
study, which indicated that A.S.A. has sedative properties; the results 
of this study were, however, inconclusive, because of "the criticisms 
made in section 1.0, chapter three." 
This proposed mechanism, involving the prostaglandins, does not 
elilIliriate the _possibility that A.S.A. may exert an effect upon sleep 
by means of other pathways and actions. A.S.A. has a wide variety of 
effects, and it is possible that any one of them may produce a change 
in sleep,al though the mechanism of_ action may not be clear at present. 
A.S.A. has also been shown to release tryptophan from its binding site, 
which, in turn, may bring about a change in sleep via. the 5-hydroxytrypt-
amine pathway. However, it appeared that this A.S.A. action is likely 
to be short lived, effective only whilst the plasma concentration of 
A.S.A. could successfully compete with tryptophan for its binding site. 
The pharmacological significance of these two A.S.A. actions, tryptophan 
release and prostaglandin inhibition, is not yet clear. 
--------------------------------........... 
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The intial interest in the effects of A.S.A. upon human sleep 
stemmed from the comment made by the self-reported insomniacs of 
chapter one, that they frequently took Aspirin to relieve their sleeping 
difficulties. However, the literature search revealed that, apart from 
the findings of the Pfeiffer et al. (1967) study, which are open to 
criticism, A.S.A. is not reported as having sedative properties. 
Nevertheless, the literature search revealed other interesting aspects 
of the drug A.S.A., and although the evidence for A.S.A. having any 
effects upon sleep in }~ was far from complete, it was decided that 
there were sufficient grounds to warrant a pilot study • 
. { 
The aim of the pilot study was to investigate the effects of A.S.A. 
upon human sleep. It may seem that the most logical step would have 
been to evaluate the sedative potential of A.S.A. with a group of sleep 
l' 
onset insomniacs or by means of the EEG model of sleep onset insomnia 
(chapter two). Although both of these alternatives would have been 
very interesting lines of investigation, the literature revealed little 
evidence to support the claims that therapeutic doses of A.S.A. would 
have sedative properties: To the contrary, if some of the proposed 
mechanisms of A.S.A. action are correct, then one might expect A.S.A. 
to have an arousing effect upon $leepl It was therefore decided that 
priority ought to be given to the investigation of the effects of 
A.S.A. upon the sleep of ncrmal, good sleepers before looking at its 
effects upon abnormal sleep. 
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2.0 PILOT STUDY 
The aim of the pilot study'was to investigate the effeots of a 
normal, therapeutio dose of aoetylsalioylio aoid (A.S.A.) upon sleep. 
3.0 METHOD 
3.1 Experimental Design 
The experimental protoool was: 
~" Night 1 2 3 4 5 6 7 8 9 
Treatment Ad Ad E1 ' E2 E3 A1 A2 R1 R2 
Key: 
Ad - Adaptation 
E - Easeline 
A - A.S.A. (2 x 300 mg., three times per day) 
R - Reoovery 
Two adaptation nights, during whioh no EEG reoordings were made, allowed 
, , ' 
for the adaptation effeots desoribed by Agnew et al. (1966). In this 
study three baseline nights were taken, in order to obtain a good, 
average measure of a typioal night's sleep for each subjeot, for i'l; 
was expeoted that any ohange brought about by A.S.A. may be slight. 
A.S.A., at a dosage of 2 x 300 mg., three times per day, was administered 
over a period of two days in order to determine if there was a 
oun:rulative effeot of the drug. The reoovery nights allowed for any 
ohanges in sleep upon drug withdrawal to be-examined. The form of 
Aspirin ohosen was A.SeA., beoause Pfeiffer et al. (1967) had found 
A.S.A. to be more effeotive at, produoing sedation than its derivatives, 
suoh as,sodium sa.lioylate. 
For ethioal reasons the dose of A.S.A. was limited to within' 
the recommended range, 0.3 - 1.0 gm., taken orally every three or, four 
,----------------------- -----------
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hours (Goodman & Gilman, 1970). The timing of,A.S.A. administration for 
this study was 10.00 a.m., 4.00 p.m. and 10.00 p.m.Soldatos et al. (1978) 
appear to have given the total dose of sodium salicylamide just prior 
to the subjects I retiring time; however, it was considered. that it 
may be rather disturbing for the subjects to have to take two tablets 
just as they were retiring. Therefore, 10.00 p.m. was the time chosen 
for the last dose, because this was only approximately one hour before 
the subjects retired; it also enabled the possible short term effects 
of A.S.A. to be observed. The dosage times were spaced at regular 
intervals during the day. No placebo control condition was incorporated 
, 
into this experimental design, as it was simply a pilot study. 
3.2 Subject Selection ,-, 
. The subject selection procedure was as described in section 6.1, 
I" 
chapter orie. The subjects had to satisfy the general criteria of 
section 6.1, chapter one and in addition they had to be able to take 
A.S.A. without experiencing any unusual or marked side-effects. Eight 
subjects, (four males and four females), were selected from the student 
population. The females were all in the first half of their menstrual 
cycle at the commencement of the study. 
3.3 Instructions to Subjects 
The "general instructions to subjects" of section 6.2, chapter 
one, also applied to this group, along with the additional instruction 
that they must not take Aspirin or related drugs,- 'such as Paracetamol 
and Disprin, for one week prio= to the commencement of the study and 
during the course of the study, except when administered by the. 
experimenter. The subjects were also instructed.that if they had to' 
, 
take any medication for any reason during this time period, they were 
I 
I 
I 
I 
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to report it to the experimenter. The subjects were informed as to 
the dosage of A.S.A. to be used and of the timing of the dosages • 
. 3.4 ExPerimental Procedure 
The subjects were studied in pairs. They arrived at the laboratory 
approximately one hour before retiring. The general laboratory procedure 
was carried out, as described in section 6.3, chapter one •. The retiring 
and rising times for each subject were kept constant (:!: 15 minutes) from 
day to day. 
I 
A daily check was made, by means of self-report responses, on the 
general health and well being of each subject, to determine if they 
were experiencing any obvious adverse side-effects. The subjects were 
also instructed to report to the experimenter, if at any .time during the 
oourse of~.the study they eXperienced gastric discomfort or nausea. 
3.5 :ria. ta Analysis 
The EEG records. were scored, in one minute epochs, according to 
the standardised criteria. of Rechtschaffen and Kales (1968). The 
records were scored blind and independently by two, experienced scorers. 
If disagreement between the scorers exceeded five per cent of the epochs, 
it was resolved by discussion. 
The amounts of each sleep stage, (W+1), 2, 3, 4, (3+4). and REM, 
were all expressed in absolute minutes of 420 minutes, which was the lowest 
common measure of total sleep time for all subjects, on all nights. Total 
sleep times, sleep onset tj:mes and REM latency were also determined. 
The amount of each sleep stage,· over the three baseline nights~ for each 
subject· was expressed as a mean; The results are presented in 
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Tables 55 ~ 63,s~ction 25~0, chapter three. 
A two way ANOVA with repeated measures on one factor was carried 
out for each sleep stage, tot~l sleep" time and sleep onset time, in 
order to determine if there were any significant differences between 
the nights for these parameters (McNemar, 1969, page 338). The 
Greenhouse-Geisser degrees of freedom correction factor was applied, 
(Winer, 1971, page 523): .This correction factor lowers the degrees of 
freedom and makes the F test more conservative. An F value which 
yielded P levels of equal to or less than .05 was considered to be 
I 
statistically significant. The significant ANOVA summary tables are 
presented"in section 25.0, chapter three and the non-significants~ 
tables are presented in Appendix XI. If the ANOVA gave a significant 
F value if was followed by a Newman-Keuls multiple comparisons test, 
in order "-i:'~ determine which component of that factor contributed most 
to the significant F value (Winer, 1971, page 191). 
Graphs D, E and F were drawn for both the whole group and the 
male and female groups independently,: (section 25.0, chapter three). 
They are an illustration of nights against the group mean difference 
score for each sleep parameter. The difference scores were obtained 
by subtracting the value of a particular sleep parameter on each night 
from the baseline value. This enabled the changes from the baseline 
to be more clearly observed. 
4.0 RESULTS 
A significant F value for stage 4 sleep was found between the 
nights, (F = 7.9, df 1,7, P ~ .05, conservative test, Table "631, " 
'" 
section 25.0, chapter three). The Nel-nnan-Keuls multiple comparisons 
; 
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test revealed that the group mean amount of stage 4 on nights A1,R1 
and ~ was significantly reduced in comparison ,with the baseline, but 
, 
there was no significant difference between the baseline and A2• , On 
the second A.S.A. night, the group mean amount of stage 4 sleep returned 
• 
to slightly above baseline Values., Graph D (section 25.0, chapter three) 
clearly showed these trends. A trend test showed that a cubic trend 
was a very good fit for ,this data, (p~, .001), as illustrated with 
graph G (section 25.0, chapter three), (Meddis, 1975, 'page 143). 
5.0 DISCUSSION OF RESULTS" 
The major significant finding was the decline in stage 4, which 
reached its lowest value, compared with the baseline, on the first 
recovery night. There was also ,a marked decline in stage (3+4), which 
followed a similar pattern to stage 4, but failed to reach statistical 
,,1'" 
significance. From graph E, for the male and female groups independently, 
it is 'interesting to note that for the males, by the second recovery night 
both stages 4"and (3+4) had returned to slightly beyond baseline values, 
whereas, in the case of the female group, both stages 4 and (3+4), were 
still markedly depressed in comparison with the baseline. Also of 
interest was the declining trend in stage 3 sleep for the female group, 
while the male group showed only a slight decline in stage 3 on the 
,second A.S.A. night. Graph D (section 25.0, chapter three) revealed a 
marked increase in stage 2 sleep for the whole group on the first 
recovery night; as, stage 4 was significantly reduced, it :rollows that 
one of the other stages would show an ,increase. 
Since there were only four subjects in the male group and four 
in the female, group, caution should be applied when interpreting the 
individual group findings. However, the general trend of a decl1D.e in 
169 
stages 4 and (3+4) did appear to be more marked in the female group, 
but, in fact, this general trend did not hold for all the females. With 
reference to Table 63 (section 25:0, chapter three), . subject 5 did 
not show a decline in stage 4 on either A1 or A2, and only a slight 
decline on R1 and R2 : there appeared to be a"large 'amount of inter-
subject variability in response to A.S.A. .ThiS might have been expected. 
for a drug such as A.S.A., which has such a wide variety of effects, 
thereby increasing the number and degree of responses which each, 
individual could show upon A.S.A. administration. The overall difference, 
between the response of the male and female groups to A.S.A. may have 
been due to the differences in body size; or maybe, if A.S.A. is exerting 
its effects upon sleep via. the prostaglandin path\;ay;' higher doses of 
A~S.A. may be required to block prostaglandin synthesis in males,' 
because men produce larger amounts of prostaglandins (50 - "Oy g per day) 
, 
than femaies (20 - 40 pg per a1y), (Hainberg, 1972). 
It is not clear why the effect of A.S.A. upon stage 4 sleep should 
sho\1 a cubic trend. One, explanation may be that on the first A.S.A. 
night, the stage 4 decline is due to an initial "shock" response by 
the system. Perhaps by the second night of A.S.A. administration 
, 
compensatory changes have been made, but on the recovery nights the 
system cannot cope, possibly due to a build up of some metabolites or 
due to some long lasting inhibitory effects of the drug. This is only 
a hypothetical explanation. 
One, maY' argue that the changes in sleep observed were simply due 
to placebo effects; however, the results of previous studies on the 
effects of placebos on sleep showed that this explanation seemed unlikely. 
Adamj-:-Adamson, lli'~zino~ and Oswald (1976); Touyz, Beum?nt, Saaymim, -'stern 
~----------------------------............ 
170 
and Zabow (1978) and Kales et al. (1971) all found that a ~lacebo had 
no effects u~on sleep. To the contrary, Hartmann and Cravens (1973) 
reported that a placebo did have a significant effect upon slee~. 
There was no dramatic effect when the placebo was first given, but 
several days after the discontinuation of the placebo, there was a 
distinct increase in REM sleep and total sleep time. Since total 
sleep time increased, one would expect REr-! sleep to increase, but 
the increase in HEt-! sleep, did a~pear to be greater than could be 
explained solely by an increased sleep length. This result is rather 
unusual and has not been reported by other researchers. The aim of 
the Hartmann and Cravens (1973) study was not primarily to evaluate 
the effects of placebos upon sleep; the placebo study was only one of 
six, 60 day drug studies with the same group of 14 subjects undergoing 
each condition. This may, in some way, have contributed to this 
unusual p~acebo response. Nevertheless, none of the placebo studies 
considered have reported effects similar to those of the present study. 
In fact, the group mean amount of REM sleep, for the present study, 
showed only minor fluctuations after A.S.A. administration: a slight 
decline on the second drug night and a small increase on the first 
recovery night. It is unusual that A.S.A. did not significantly reduce 
stage REM in the whole pilot study group, since this appears to be a 
common effect of many drugs upon sleep (Kay, Blackburn, Buckingham & 
Karacan, 1976). However, the male group did show a marked decline in 
stage REM, see graph' F (section 25.0, chapter three), in com~sion with 
the female group. 
A.S.A. did not have any significant effect upon sleep onset times 
, 
or total sleep time. However, since these subjects were self-reported 
good sleepers, with a mean. baseline sleep onset time of 21 minute~ and 
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a group mean total sleep time equal to 455 minutes, it is unlikely 
that any drug would be able to either reduoe the sleep latenoy or, 
inorease the total sleep time. FUrthermore, A.S.A. did not prevent the 
subjeots from falling asleep as quickly as they normally did no~ did 
it cause them to wake earlier. 
6.0 CONCLUSIONS 
There was evidence from the pilot study to indicate that A.S.A. 
was having an effeot upon sleep. stage 4 was significantly depressed 
on nights R1, R2' and A1, in comparison with the baseline. It also 
I 
appeared that the general, overall declining trend in stage 4 was more 
marked in the female group. The stage 4 response to A.S.A. followed a 
oubic trend. There was also an increasing trend in stage 2 sleep 
for the whole group, reaohing a peak on the, first recovery night, but 
i )~ 
this trend did not reach statistical significanoe. There were no 
statistically significant changes in stage REM for the whole group, 
after A.S.A. administration. 
7~O MAIN A.S.A. STUDY, 
8.0 INTRODUCTION 
The findings, of the pilot study provided a suffioient basis for 
pursuing this line of investigation further. The next step was to 
investigate the effeots of A.S.A. upon sleep by means of a larger, 
well controlled study. 
-
§ , 
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9.0 l'IETHOD 
9.1 Experimental Design . 
The basic design was split plot with repeated measures on one 
factor (Winer, 1971, page 525), comprising of eight females in the 
A.S.A. group and eight in the placebo group. The study was conducted 
under double-blind conditions. 
On the basis of the findings of the pilot study, it was decided 
to use only female subjects, because the overall trends did appear to 
be more marked in this group. Since there was quite a wide variation 
in response to A.S.A. in the pilot study, with respect to sleep patterns, 
an all female study may help to reduce some of this variability. It 
was decided to extend the period of A.S.A. administration from two 
to four consecutive days; the aim of. this was to enable further 
investig!!;t1on of the previous observations of an increasing trend in 
stage.4 sleep towards baseline values on the second A.S.A. night and 
to observe whether this increasing trend in stage 4 continues with 
repeated A.S.A. administration. Furthermore, since stages 3 and 4 
had not returned to baseline values by the second recovery night, for.' 
the female group, it was decided to extend the recovery period to six 
nights, by which time these stages may have returned to baseline 
values. 
All subjects were required to attend the laboratory for 15 
consecutive nights. The experimental protocol was: 
Night 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
A A' A R 234 1 
, 
'. ; 
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Key: 
Ad - Adaptation 
B - Baseline 
A - A.S.A. (2 x 500 mg., three times per day) 
R - Recovery 
The first two nights in the laboratory were for adaptation purposes 
(Agnew et al., 1966) and no EEG recordings were made. Similarly, on 
the third A.S.A. night and fourth recovery night no EEG recordings were 
made. It ,~ould have been very costly to hitve recorded on all 15 nights 
and it was considered that sufficient knowledge could be gained about 
, 
,the activity of A.S.A. even if nights A5 and R5 were not recorded. 
This also gave the experimenter time to relax. However, the subjects 
were led to believe that recordings were made on every night; the 
reason for this was to keep the subjects· set fairly constant from 
night tonight and to avoid the risk of some of the subjects'failtng;. 
to observe some of the "instruc.tions to subjects". if they had known 
that no recordings were being made. 
The same dosage of A.S.A. (2 x 500 mg."three times per day) and 
the times of administration (10.00 a.m., 4.00 p.m. and 10.00 p.m.) were 
employed as in the pilot study. The placebo tablets were supplied by 
drug manufacturers and were made to match the A.S.A. tablets in shape, 
colour and consistency. They did, however, differ with respect to 
taste. This difference could only be detected if the tablets were 
broken down whilst still in the mouth, 'the subjects were therefore 
instructed to swallow the tablets whole. The contents of the placebo 
tablets are listed in Appendix XVII. The dosage of placebo administered 
was identical to that for A.S.A. 
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9.2 Subject Selection 
The subjects were selected according to the general procedure of 
section 6.1, chapter one. The subjects had to satisfy the general 
criteria for good sleepers and they had to be able to take A.S.A. 
without experiencing any adverse side-effects. Sixteen females were 
selected, mean age 19.8 years. They were all in the first half of 
their menstrual cycle at the commencement of the study. The subjects 
were matched for age and body size; they were all drawn from the student 
population. 
9.3 Instructions to Subjects 
The subjects were given the "general instructions"'of section 6.2, 
chapter one, plus the additional instruction that they must not take 
Aspirin or related drugs, such as Paracetamol and Disprin, for one week 
prior to ihe commencement of the study and also during the course of the 
. , ' 
study,' except; when administered by the experimenter. The subjects were 
also instructed that if they had to take any medication, for any reason 
during this time period, then they were to report it to the experimenter 
The subjects were informed as to the dosage of A.S.A. to be used and 
the timing of the dosages, but the subjects were not told that half of 
them would be on placebo., It was considered that this information may 
lessen any placebo response. This comment was also made by Kales et al. 
(1971). 
9.4 Exnerimental Procedure 
The subjects ,~ere studied in pairs, one of each pair rGc"iving 
A.S.A. and one receiving placebo, under double-blind conditions. The 
subjects were allocated at random to either the drug or'placebo group. 
, 
The subjects who attended the laboratory on the same nights were matched 
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for similar retiring and rising times. They arrived at the laboratory 
approximately one hour before retiring. The general laboratory 
procedure was carried out as in section 6.3, chapter one. The retiring 
and rising times of each subject were kept constant to within :!: 15 minutes 
over the 15 days. 
A daily check was made, by means of self-report data, as to the 
general health and well being of the subjects. The subjects were 
instructed to report to the experimenter if, at any time during the 
study, they experienced gastric discomfort or nausea. The subjects 
were also asked to complete the questionnaire shown in Appendix V on the 
last morning of the study; the reason for this was to obtain some 
estimate of how frequently the subjects would normally take a drug 
such as A.S.A. 
" .1; 
.;, 
• 
" 
9.5 Data AnalysiS 
The EEG records were scored, in one minute epochs, according to 
the standardised criteria of Rechtschaffen and Kales (1968). The records 
were scored blind and independently by two, experienced scorers. If 
the disagreement between the scorers exceeded five per cent of the epochs, 
it was resolved by discussion. Each sleep stage, (W+1), 2, 3, 4, (3+4) 
and REM, was expressed in absolute minutes' out' of a total sleep time ,,' ., 
of 400 minutes, this was the lowest common measure of total sleep time, 
for all subjects on all nights. The baseline values for each sleep 
parameter over the three nights were expressed as a mean. Total sleep 
time, sleep onset time, REM,latency, REM periodicity a.~d the Ir~ber,of 
stage changes were also determined for all subjects on all nights. The 
results are shown in Tables 64 - 14, (section 25.0, chapter three). 
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Initially, the two groups, A.S.A. and placebo, were tested for 
homogeneity cfvariance according to the method of Winer (1971, page 527). 
The F value was calculated for'each sleep parameter, for both "subjects 
max 
~Ii thin groups" and "nights :x: subjects \{i thin groups", over the drug 
and recovery nights (Table 80; section 25.0, chapter three): Only . 
7 out of the 40 F values reached significance. Therefore, it is 
max 
reasonable to assume that the two groups were drawn from populations 
with equal variances. Since the F test has been sho1m to be robust 
(Boneau, 1960; Ravlicek & Peterson, 1974), it would be expected to 
accommodate the ~jority of these unequal variances. However, since. 
, 
sleep onset time scores had previously been shown to be severely 
skewed (section 10.3, chapter one), .the significant F value for 
max 
sleep onset times over the drug nights did give cause for concern. This 
parameter was, therefore, Violating two of the underlying assumptions 
of the F test. Therefore, for this particular parameter it was decided 
" 
to perform the ANOVA on both the raw and transformed scores for means 
of comparison~ 
Before the statistical analysis could be embarked upon, the problem 
of unmatched baseline scores for each sleep stage, for the two groups 
had to be resolved. Unrelated t-tests revealed that there were no 
significant differences between the baseline means for each sleep 
parameter, for the" two groups. However, it was felt that this problem 
could not be overlooked simply because the difference was not significant, 
as any changes observed after drug administration may simply be due to 
the fact that the two groups had different values initially. The 
difference between the two groups was most marked for stage 4 sleep, 
with a value of 15 minutes. It is difficult to explain this ~ge 
difference in baseline scores, as the subjects were matched for age, 
; 
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sex and body size and were randomly assigned to either group. Furthermore. 
within each group there was a large amount of inter-subject variability 
fer the baseline values of several sleep parameters. notably stages 
2 and 4. In an attempt to overceme this problem of unmatched baseline 
scores for the two groups. it was decided to perform the main analysis 
on the difference scores. that is. .the scores for each sleep parameter. 
on every night were expressed as the difference from the baseline. 
The recommended statistical analysis for the experimental design 
employed in this study is a multivariate methed (Thernby. 1976). However. 
after consultation with the program advisors. it was discovered .that 
the package programs available would be unable to handle a multivariate 
analysis on this data. because ef the large number of parameters. The 
best approach which they ceuld recommend. was to use the GENSTAT package 
(Nelder •. ~977). This would. in effect. perferm a univariate ANOVA. but 
would censider all the sleep stages at once. GENSTAT has only been 
available for a few menths. therefore considerable difficulty was 
experienced in trying to run the program. Whilst serting out the problems 
an alternative analysis was carried out. 
A three facter. split plot ANOVA was performed on each sleep 
parameter's difference score. over the drug and recovery nights : 
independently (Winer, "1971. page 525). The Geisser-Greenhouse correction 
factor for censervative degrees of freedom was applied where appropriate. 
accerding to. the precedure in Winer (1971. page 523). The ANOVAs which 
gave significant results were examined. when applicable, by means of 
the Newman-Keuls multiple cemparisen test (Winer. 1971, page 191). P 
levels which were equal to. or less than .05 were considered to be 
statistically significant. The significant ANOVA S1ll!lllla.rY tables are 
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'p:resented'in se;tIon~25:0~' Tables 75 - 79,and'the non-significant 
ANOVA s~ tables are presented in Appendix XII fcr the drugs nights 
and .AppendixXIII fcr the recovery nights. 
The standard deviations across the drug and recovery nights were 
computed for each subject, for each stage' of sleep, and the geometric 
means of the standard deviations for the two groups were compared by 
means of an unrelated t-test. The reason for this procedure was to 
determine whether A.S.A. significantly increased the variability of 
the sleep stages across the nights, in comparison with the placebo., 
"'--.'-
Graphs (H, I, J and K) were drawn for the A.S.A. and the placebo 
groups of nights against the group mean difference scores, for each 
sleep stage. The cumulative graphs (L and M) were also dralID for the 
second drug night, because this appeared to be the night which Showed 
the most prominent changes in stages 2 and 4. These graphs are a 
plot of half-hour epochs throughout the night against the accumulation 
of the stages in minutes. The reason for these graphs was to determine 
whether A.S.A. was affecting the distribution and build up of these 
sleep stages throughout the night. All these graphs are included in 
section 25.0, chapter three. 
10.0 RESULTS 
The three-way, split plot AlTOVA gave the following significant 
results: 
Drug Nights 
stage 2 - A significant difference be~jeen the A.S.A. and placebo 
conditions, over the drug nightsl· A.S.A. produced a significant increase 
in sta.ie 2 (F = 14.5" df 1,14, P ~ .01, conservative test), (Tables 65 
a.nd75, section 25.0). 
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Total Sleep Time - A significant difference between the three drug nights, 
~lhich is independent of the treatment condition (F = 9.4, df 1,14, P';; .01, 
conservative test): the second drUg night showed a significantly lower 
total sleep time than either the fourth drug night (p ~ .05) or the first 
drug night (p ~'.01), (Tables,"73 and 76, section 25.0). 
Sleep Onset Time - A significant difference between the drug nights 
(F = 10.8, d£ 1,14, P ,,-,.01 1 conservative test, raw scores; F = 6.4, ' 
df 1,14, P ~ .025, conservative test, transformed scores), with a 
drug by night interaction effect (F = 8.7, d£ 1,14, P~, .01, conservative 
test, raw scores; F = 5.3, df 1,14, P ~,.05, conservative test, 
transformed scores). The group mean sleep onset time was significantly 
increased on the first placebo night in comparison with the A.S.A. 
group (Tables 72, 77 and 78, section 25.0). 
Recovery Nights 
REl-! Latency - A significant difference between the two drug c,ondi tions, 
,=-, 
~ ,. . . , . '. '. 
(F = 5.5, d£ 1,14, P~, .05, conservative test): . the: A.S.~!, group showed a 
significant decline in REM_latency in. comparison with the placebo group, 
(Tables 70 and: 79, section 25.0). 
A.S.A. was found to increase significantly the night-to-night 
variability of stage REM over the recoverY nights (t = 2.9, df 14, PE:;,.02) 
and of stage 3 over both the drug and recoverY nights (t = 2.6, d£ 14, 
p ~ .02 and t = 4.4, d£ 14, p~ .01, respectively), in comparison with 
the placebo grouP. using a two-tailed test. 
The Al~OVA summarY tables from the GENSTAT analysis are p~esented 
in Appendix XIV for the drug nights and Appendix XV for the recovery 
, 
------------------------------------------------------------------~ 
( 
, 
, 
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nigilts;, this analysis revealed the,.same e£i'ects as were reported above. , 
11.0 DISCUSSION OF RESULTS 
The significant increase in stage 2 sleep ~Iith A.S.A. administration 
can be clearly seen from graph H,' the increase reaching a maximum on 
the second A.S.A. night. From the same graph it can also be seen that 
there was a slight declining trend in stage REl1;'this ',was' not :, 
statisticallY-Significant. Also of interest is the declining .trendin 
stage 4 sleep during A.S.A. administration (graph I). This trend wasc 
not statistically significant, but was greater that the decline in stage 
REM. In the pilot study a significant, decline in stage 4 was found 
on nights A1, R1 and R2, in comparison with the baseline. In the main 
study, however, stage 4 was found to return to baseline values on R1 
, \ 
and R2 and to increase slightly above on R3 and'R4• 9;Verall, the 
_('I 
general trend in the stage 4 findings was similar to those of the pilot 
study, but they were not as marked;, this maY,be due to the fact that, 
for the pilot study, the results were compared with the baseline and 
not with a placebo control group. Another possible reason for this 
, , 
difference in results may be the large amount of inter-subject variability 
shown by stags 4 sleep in response to A.S.A. administration: for 
example, on the second A.S.A. nigilt the range in difference scores for 
stage 4 sleep was -51 minutes to +3 minutes. This wide variation in 
response may, in part, be attributable to: 
1. the dosage level of A.S.A. used may not have been sufficiently 
higil to bring about a consistent response in all subjects, 
2. the range in individual tolerance levels to A.S.A., 
3. the degree of response of each subject to the large number of A.S.A. 
actions. 
Another.indication of the large amount of inter-subject variability in 
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response to A.S.A. can be seen on the recovery:.ru.ghts:_ subject 6 showed 
her lowest decline in stage 4 on R and subject 3 on R • 
3. 4 
Also worthy of comment is the fact that three of the placebo 
subjects, namelY~ 11, 12 and 16, showed a marked decline in stage 4 sleep 
on the second placebo night, but this decline was not revealed for the 
group as a whole, because two subjects showed a marked increase. It 
is difficult to explain these changes in the placebo group subjects' 
sleep over and above that due to nightly variation;· This observation does 
weaken the findings of the A.S.A. pilot study l-lith respect to stage 4 
sleep: . they may have been artefacts due to.the lack of a placebo,contJ;ol 
group. In the pilot study data analysis, the sleep parameter scores 
on the drug and recovery nights were compared with the baseline scores 
and not l-li th a placebo control group; since the subjects cif the present (/ '.' ,. 
" placebo group showed a. considerable amount of inter-subject variability 
in response to placebo administration, it appears necessary to compare 
all the results obtained upon A.S.A. administration with a placebo 
control group. 
Upon withdra'.;al of A.S.A. a significant reduction in REM latency 
was found. This appeared to be most marked on the second recovery night 
and raises an interesting possibility: since this reduction in REl1 latency 
was not observed until the recovery nights, it indicated that the 
effect was not due to A.S.A. per se, but maybe to one of its metabolites 
which may have still been left in the body. This decrease in REl1 
latency could be classed as a qualitative change in REl1 sleep and did 
not appear to be linked l-li th a statistically significant quantitative 
change in m! sleep. HOl-lever, the night-to-night variability of m! 
sleep ~~s significantly increased for the A.S.A. group, in comparison 
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with the placebo group over the recoverY nights. This increased 
variability may, in some way, be linked with the decline in REM latency.: -. 
if the REM periods commenced earlier, there is the possibility that 
some subjects may have had lengthened REM periods on some nights, which 
may have been compensated for by a decrease on the next,' thereby 
increasing the night-to-night variability. A possible explanation for 
the decrease in REM latency, is that some A.S.A. metabolites may have 
interfered with a REM triggering mechanism, but mechanisms which controlled 
the absolute amounts of REM sleep were not Significantly altered •. These 
suggestions are only tentative. 
Also worthy of comment is the fact that REM sleep underwent no 
significant changes during, A.S.A. administration, in comparison with 
the placebo group. This was a rather Unexpected result, a.s REM sleep 
is considered to be a fragile type of sleep which can easily be 
disrupted by a variety of factors, such as, drugs and anxiety. If A.SeA. 
was affecting one of the major neurotransmitter pathways or maybe, even 
if it was producing unpleasant side-effects, then one might expect REM 
sleep to decline. 
The remaining significant fincU.ngs were not· simply due to the 
drug effects. Over the drug nights there was a Significant night and 
night x drug interaction effect, for both the raw and transformed sleep 
onset time scores. Inspection of Table 72 (section 25.0, chapter three), 
clearly shows that'it was the first plaoebo night which showed a 
significant increase in the group mean sleep onset time. The multiple 
comparison test revealed that the placebo group mean sleep onset time 
on A1 ,was significantly higher than on A2 and A4" Only three of the 
eight subjects failed to show a large increase in sleep onset time on 
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this night. There was no obvious reason for this large increase on the 
first placebo night. Although the subjects were allocated at random 
to tee grcu~s, it may be that, by :hance, subjects who were ar~ous 
about taking tablets were in the placebo group, but this idea was not 
bo=e out by the questionnaire responses. A significant night effect 
was also f01lIld for total sleep time; the second drug night for both 
A.S.A. and placebo groups showing a decreased total sleep time in 
comparison with the first and fourth drug nights. Once again there, was 
no obvious reason why this effect should be observed, as the retiring 
and rising times of a.:),l subjects were kept to within :!: 15 minutes of 
their normal times each day. These changes may be due to the fact 
that the second drug night was a Sunday night, which may have caused 
the subjects to wake earlier in anticipation of "Monday mo=in.g". The 
other Sunday night spent in the laboratory was R5 which was not recorled., .. 
, 
therefore, there is no other data available from this study to support 
this idea. However, the significant changes in total sleep time will 
not affect the results, because only the first 400 minutes of sleep time 
for each subject were analysed. 
The cumulative graph (L) revealed little change in the distribution 
of stage 2 sleep over the second drug night. However, graph M revealed 
that the accumulation of stage 4 sleep levelled off earlier on the second 
A.S.A. night in comparison with the A.S.A. baseline night and the second 
placebo night. This levelling off occurred after approximately 2! hours. 
A.S.A. did, therefore, appear to be having a slight suppressing effect 
on stage 4 sleep after the first ~ hours of sleep. 
On the basis of the overall questionnaire responses, neither group 
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oould be olassified as regular users of A.S.A. Only two subjeots from 
the A.S.A.group and three from the plaoebo group reported taking 
Aspirin. Other oompounds taken by the subjeots, as determined by the 
questionnaire, inoluded Paraoetamol, Panadol and Phensio. Two weeks 
was the shortest time interval between a subjeot taking an analgesio 
and oommenoing the study, the longest was approximately six months 
(subjeot 5), the average time interval being 1 - 2 months. With regard 
to reported side-effeots, only one subjeot-in the A.S.A. group and two 
in the plaoebo group reported slight stomaoh disoomfort. Three subjeots 
(1, 4 and 6) in the A.S.A. group and one in the plaoebo group reported 
that A.S.A. made them feel drowsy and one subjeot (7) reported that 
A.S.A. made her feel lively. Five subjeots reported being slightly 
anxious about taking A.S.A. for four days: three in· the· A.SeA. group 
. -
and two in the plaoebo group. All subjeots oonsidered that they 
oonsumed the same amOunt or slightly lesscoarbohydrate than the rest of 
the student population. 
Having oonsidered both the statistioally significant findings and 
the trends observed from the graphs, it is neoessary to determine whether 
there is a link between them. Although this study showed tb.at A.S.A. 
did have an effeot upon sleep, no indication was given as to why; but 
some speoulations will be made. The only statistioally signifioant.. 
fiDding for the sleep stages was the inorease in stage 2 sleep shown 
by the A.S.A. group on the seoond drug night, in oomparison with the 
plaoebo group. A ohange in stage 2 sleep is generally viewed as being 
seoondary to a ohange in one ~f the other sleep stages whioh are believed 
to be assooiated with more important funotional roles, suoh as, stage 4 
and REM sleep. There is, however, the alternative view that the ohanges 
in stage 2 sleep may be the primary effeot and the other ohanges 
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seconda.:ry' to those obserVed'for s~ 2 sleep. Adopting the approach 
of the first view point, the overall impression gained from the results 
is that A.S.A. is having a slight disruptive ,effect upon sleep which 
is buffered by a significant increase in stage 2 sleep. This disruptive 
effect is reflected over the drug nights by the declining trend in ' 
stage 4 sleep, the slight decline in REM sleep, the significant increase 
in the night-to-night variability of stage , and the .reduction in the 
accumulation of stage.4 after approximately 2! hours of sleep on the 
second drug night. A.S.A. did not appear to have a marked disruptive 
effect upon sleep, otherwise REM sleep would have been expected to show 
a significant decline in comparison with the placebo. 
One may speculate therefore, that A.S.A. is not acting via one 
of the major neurotransmitter ~athways associated with sleep, because 
a more dramatic change in the sleep stages would be expected. The effects 
of A.S.A. upon sleep appear to be rather subtle and may be brought about 
by the influence of A.S.A. upon subsidiary pathways which regulate 
the amounts of the various sleep stages. This might be achieved by the 
, 
interactions of A.S.A. or its metabo1ites with various catalysts and 
co-enzymes, or mayb.e even via. pros taglandin inhibition. However, it; 
must not be over1ooked.that A.S.A. may not be affecting sleep by its 
direct action on neural transmitter pathways associated with the sleep 
mechanisms, but by such actions as its effects upon respiration. 
It was suggested in an earlier section (1.5, chapter three), that 
A.S.A. may have an arousing effect upon sleep. The reasoning behind 
this hypothesis stemmed from the evidence, revealed by the literature 
search, which indicated that prostag1andins produce sedation in animals. 
If the prostaglandins have a similar function in Man, and the dosage of 
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A;.S.A. used was sufficient to block: prostaglandin synthesis in the brain 
areas, then one might expect A.S.A. to exert an arousing effect. A.S.A. 
did not interfere with the sleep induction process, as the sleep onset 
times were not significantly increased upon A.S.A. administration. This 
hy,pothesised arousing effect was, therefore, not so strong as to delay 
sleep onset; neither did it bring about .. an increased amount of stage. 
(\01+1) or a decreased total sleep time. However, this idea was partly 
borne out by the significant increase in stage 2 sleep, which is a light 
stage of sleep:· A.S.A. does, therefore, appear to have only a slight 
arousing effect upon sleep.· It could be that A.S.A. is affecting 
some regulatory mechanism controlling the ratio of light to deep sleep 
during the course of the ni~t. If this were· the case, one might expect 
stage 2 sleep to show its largest increase during the first half of the 
night, when the deeper stages of sleep are most prominent,'- but this 
suggestion is not supported by graph L (section 25.0, chapter three), 
which shows ;that the increase in stage 2 sleep is fairly evenly 
ditributed throughout the night. Therefore, some control mechanism 
which may-regruate the :i:at10of llEM sleep to stage 2 may also have 
been affected by A.S.A. administration. These ideas are only speculative • 
. There is also the possibility that the action of A.S.A. upon 
respiration (increased oxygen consumption and carbon dioxide production) 
may have caused this significant shift to the lighter stage of sleep, 
(stage 2). The increased carbon dioxide production may have caused 
an unbalancing of the homeostasis, resulting in EEG arousal. However, 
it is unlikely that the total daily dosage of A.S.A. used in the present 
study would have a marked effect upon respiration:. Goodman and Gilman 
(1970) reported that a full therapeutic dose of·A.S.A. (4 gm.) produced 
these respiratory changes, which was ~ore than twice the dose of.A.S.A. 
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used in the present study" (1'''8 gm): 
The decline in REl1 la:~enoy,' observed upon wHhd:ra.wal of A.S.A., 
was previously discussed in this section and it was tentatively 
suggested that this effect of A.S.A. may have been brought about by the 
action of some A.S.A. metabolites upon a REM triggering mechanism. 
In the introduction to this chapter various A.S.A. actions were 
put forward as possible mechanisms by which A.S.A. may affect sleep. 
The tryptophan releasing effect does seem Unlikely in this case, as 
there is evidence to suggest that high doses of A.S.A. are required to 
bring about a substantial release of tryptophan (Smith & Lakatos, 1971). 
There may be a transient rise in free tryptophan when the plasma 
concentration of A~S.A. is relatively high~ this effect is likely to 
" /1 
be short lived. With regard to the prostaglandin pathway, from the 
studies of Koscis et al. (1973) and Hamberg (1972), the dosage of 
A.S.A. used in the present study appears to be sufficient to block 
prostaglandin synthesis. The available evidence indicated inhibition 
, 
of protaglandin synthesis in the periphery, but one cannot:necessarily 
conclude that, in Man, oral administration of a therapeutic dose of 
A.S.A. blocks the synthesis of prostaglandins in the brain areas. Also, 
Hamberg (1972) claimed that A.SeA. produced marked inhibition of 
prostaglandin syntheSis upto 48 hours after cessation of the drug. 
If the significant rise in stage 2 sleep were due primarily to the 
inhibition of prostaglandin synthesis, one would have expected it to 
have remained substantially elevated on the first two recovery nights; 
but only a slight increase was observed on R1 and R2t This may be due 
to a progressive decline in prostaglandin inhibition. 
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Another mechanism by which A.S.A. may be exerting its effects 
upon sleep has been suggested by Traynor (1978, personal communication). 
The acetyl moiety-of A'.S.A. my cause acetylation of important 
plasma proteins or may interfere with the amino-acid,transport 
mechanism by which means tryptophan and related compounds gain entry 
to the brain. There is also the possibility that some side-effects 
of A.S.A., such as. gastro-intestinal bleeding may bring about changes 
in sleep. 
Consideration must also be given to the fact that the results 
'" 
obtained from this study did not replicate those of Soldatos et al. 
(1978) who reported no statistically significant changes in the sleep 
stages of insomniac subjects, who had been ac1miliistered sodium 
salicylamide (650 and 1,300 mi~). a derivative of A.S.A. There are 
;, 
, , 
several possible reasons for this: 
1. Soldatos et al. (1978) investigated the effects of sodium 
.... 
salicylamide upon sleep, whereas. in the present study, A.S.A. 
was the drug used. It was reported by Goodman and Gilman (1970) 
that sodium salicylamide, under double blind conditiOns, did not 
demonstrate analgesic or anti-rheumatic properties even at high 
doses which caused a high percentage of gastro-intestinal and 
other side-e£fects. Sodium salicylamide does, therefore, ,appear 
to be a weaker analgesic and anti-rheumatic agent thanA.S.A. 
It does not bind to plasma proteins, to any great extent, at 
therapeutic doses. These differences in drug action may bring 
about different effects upon sleep • 
2. Soldatos et al. (1978) appear to have given a single dose of 
the drug prior to retiring on each of the three drug nights, 
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whereas, in the present study, the drug was administered three 
times per day, at six hourly intervals oVer a period of four 
days. 
3. Soldatos et al. (1978) used insomniac subjects, whereas, 
good sleepers were used in the present study ... 
Furtherinore, since the completion of this research programme, an 
abstract of a paper presented by Hauri and Silberfarb (1978) at th~ 
eighteenth Association of the Psychophysiological Study of Sleep meeting, 
at Stanford, California, has been. published recently •. " These authors 
have studied the effeots of A.S.A. on the sleep of insomniacs; they 
had also noted that A.S.A. is taken as an hypnotic by many insomniacs, 
which supports the olaims made by the self-reported, .13~eep onset 
insomniacs of chapter one that Aspirin relieved their sleeping difficulties. 
They examined the effects of a single dose of A.S.A. (650 mgs.) upon 
the sleep of a group of eight insomniacs. They reported that the 
total sleep time was significantly increased and that the amount of 
, 
wake time after sleep onset and the amount of total wake time were both 
significantly reduced in comparison with the placebo baseline, after 
A.SeA. administration. These changes were most marked during the first 
three days of A.SeA. administration. A.S.A. was reported as having no 
significant effect upon any of the sleep stages, REM latency, sleep 
onset time and the number of stage changes. The results of this study, 
therefore, did not support the idea put forward by the self-reported, 
sleep onset insomniacs of chap~er one that A.S.A. aids sleep. However, 
the baseline group mean sleep onset time for the insomniacs of the 
Hauri: and Silberfarb (1978) study was only 30.9 minutes; so A.S.A. may 
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not have been given sufficient opportunity to reveal its full sedative 
. potential. Furthermore, no standard deviations were given in the 
abstract; so there is the possibility that only one or two subjects may 
have had a relatively long sleep latency. Nevertheless, the results 
of this study did indicate that A.S.A. may be a useful, non-prescription 
hypnotic for those insomniacs whose primary complaint is early mcrning 
or frequent nocturnal awakenings. Hauri and Silberfarb (1978) found 
A.S.A. to be as effective as some other prescription hypnotics, such as, 
chloral hydrate.; (ICales, Bixler, ICales & Scharf, 1977), on the variable 
, 
, 
of total wake time. The authors failed to define the type of insomnia 
". 
they were investigating, that is, whether the subjects complaints were 
primarily a long sleep latency, early morning awakening or frequent 
nocturnal awakenings. 
The results of the Hauri and Silberfarb (1978) study did not 
support those of the A.S.A. study conducted in this research programme. 
The reasons for this could be: 
1. Hauri and Silberfarb (1978) used insomniac subjects, whereas, 
healthy females who were all good sleepers were used in the present 
study. 
2. Hauri and Silberfarb (1978) examined the effects of a single dose 
of A.S.A. (650 mgs.) upon sleep. Although the time of drug 
administration was not stated, it is likely to have coincided 
with the subjects' retiring times, as this is the time when 
insomniacs would consider taking a "sleeping aid". The present 
study examined the effects of a normal, daily therapeutic dose 
of A.S.A. upon sleep, that is, 2 x 300 mg. tablets administered 
three times per "day, at 10.00 a.m., 4.00 p.m. and 10.00 p.m., a 
, 
\ , 
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total daily dose of 1.8 gms. 
3. A dif£ersnt experimental design ;;as employed in both studies. 
!fauti: and Silberfarb (1978) used each subject as their own placebo 
control. Their study lasted for 21 days, the A.S.A. being given 
for 14 days. The subjects slept at home from the fourth to the 
tenth drug nights. The present study used two groups of ,matched, 
subjects::' one a placebo group, 'the' other'receiving A.S.A. under 
double blind conditions. The study continued for 14 consecutive 
laboratory nights, with no break. A.S.A. was taken for four days. 
Regardless of these differences an interesting finding common to both 
studies was the large individual differences found in response to 
A.S.A. This may be due to the range in individual tolerance levels to 
./1 
the drug and how accustomed the subjects were, to taking A.S.A. and 
related drugs.' Also, A.S.A~ is a drug with a wide variety of actions, 
and each subject may respond to different degrees to each A.S.A. action. 
OVerall, the results of the !fauri and Siiberfarb (1978) study indicated 
that A.SeA. may be a useful hypnotic for some insomniacs. 
12.0 CONCLUSIONS AND FURTHER RESEARCH 
The results showed that A.S.A., ata dosage of 2 x 300 mgs., three 
times per day, does affect sleep. The major finding was an increase 
in stage 2 sleep which reached statistical significance on the second 
drug night, in comparison with a placebo group. There was also a 
declining trend for stage 4 sleep during A.S.A. administration, but 
this did not reach statistical significance. The cumulative graph (M) 
revealed that on the second A.SeA. night the accumulation of stage 4 
sleep was suppressed after 2! hours of sleep, in comparison with the 
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.,lacebo group. On withdrawal of A.S.A., there was a significant decline; 
in REM latency and an increase in the night-to-night variability of 
stage REM and stage 3 sleep. Overall, these results were considered 
as being indicative of A.S.A. exerting a slight disruptive effect upon 
sleep. 
Raving found out that A.S.A. has an effect upon sleep the question 
now raised is "why?" Although various specul.8.ticins have been made, 
there is little evidence for these various, possible mechanisms of A.S.A. 
action in humans, at the dosage employed in the present study. It was 
felt that some attempt ought to be made to determine a possible mechanism 
by which A.S.A. may be exerting its effects upon sleep. Two, general 
approaches to this problem were envisaged. One was a biochemical 
approach, with the aim of examining the effects of A.S.A. 'upon various 
. - . il - . ... .. 
neurotransmitter substances, for example,5-hydroxytryjrtallline and other,. 
neurochemical substances, such as the prostaglandins., 5-hydroxytrypt8mine 
is believed to be one of the major neurotransmitters involved in sleep 
(Mendelson et al. 1977). The prostaglandins are believed to play an 
important role in neurotransmission (Gross et al'. 1977). The link 
between A.S.A. and 5-hydroxytryptamine is: if the dosage of A.S.A. used 
was sufficiently high to bring about the release oftryptophan,'the 
precursor of 5-hydroxytryptamine,' from its binding,site, an increased 
5-hydroxytryptamine concentration or turnover rate should result. 
Although this association appears quite straightforward when examined 
in isolation, when the body as a whole is considered the link is 
rather more complicated. Many other factors such as diet and free 
fatty acid concentrations can influence the ratio of free to bound 
tryptophan. One must be aware of these other factors which may be 
operating, for any assay technique for 5-hydroxytrytamine or its 
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metabolites can only serve as an indication of the effects of A.S.A.; 
it cannoit necessarily show that it is A.S.A. alone which is bringing 
about a change in the levels of 5-hydroxytryp~3 cr its metabolites. 
The assay techniques available were limited by the equipment and 
reagents at the experimenter's disposal and by the fact that it was not 
feasible to use a technique which involved invasive procedures. This, 
therefore, eliminated the possiblity of dete~ the concentrations 
of. 541ydroxytryptamine in the blood. The most sui table assay technique 
available at the time was the urinary analysis of 5-hydroxyindolea.cetic·· 
acid, according to the method of Udenfriend, Weissbach and ~rodie (1958). 
5-Hydroxyindoleacetic acid (5HIAA) is the major end product of 
5-hydroxytryptamine metabolism. 
,. 
" 
" The other approach was to examine the effects of other analgesics 
upon sleep. The analgesic chosen was. Paracetamol (acetaminophen), 
because: 
1. it shares many common properties with A.S.A.. They are both effective 
analgesics and antipyretic agents at therapeutic .. doses. 
2. Paracetamol has been found to inhibit prostaglandin synthesis from 
in vitro enzyme preparations (Flower & Vane, 1972). It has.been 
found to be as effective as A.S.A. in the inhibition of prostaglandin 
syntheSiS in preparations from the dog, rabbit, mouse and gerbil 
brain, but less effective than A.S.A. against enzymes from the 
spleen. 
3. Unlike A.S.A., Paracetamol, at normal, therapeutic doses does not 
release tryptophan from its binding site (Gazzard, Ford-Hutchinson, 
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Smith & Williams, 1913). If Paracetamol is found ;to have an 
effect upon sleep, different to that found for A.S.A., it may 
indi:::ate that this pathway is involved. 
4. Paracetamol has less overall toxicity and side-effects thall A.S.A.;. 
Paracetamol does not produce gastric irritation, erosion and 
bleeding which may occur after A.S.A. administration. Paracetamol 
will, therefore, serve also as a comparison to determine if the 
effects of A.S.A. upon sleep may simply be attributable to its 
adverse side-effects. 
The reason for this second approach was to determine whether the 
effects produced by A.S.A. upon sleep are common to some related compovn~~ 
or peculiar to A.S.A. An alternative choice of drug c~uld have been 
.. 
to have used a drug such as indomethacin which, on a weight basis, is 
23 times more potent than A.S.A. as an inhibitor of PGE2 synthesis from 
an enzyme preparation from guinea pig lung (Vane, 1911). However, on 
ethical grounds, the use of indomethacin would not be allowed as it 
.. . I 
has severe side-effects, with complaints of headache, naUsea, abdominal 
pain and diarrhoea (Goodman & Gilman, 1910) •. 
, . 
The following two studies in this research programme will be pilot 
studies investigating; 
1. the effects of a therapeutic dose of A.S.A. (2 x 300 mgs., three 
times per day, a total daily dose of 1.8 gms.) upon the amount 
of 5-hydroxyindoleacetic acid (5HIAA) excreted each day, 
2. the effects of a therapeutic dose of Paracetamol (1 x 500 mgs., 
four times per day, a total daily dose of 2.0 gms.) upon human sleep. 
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Chapter Three - Part II 
" SUPPLEl1ElITARY PILOT STOJ)IES' 
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13.0 URINE ANALYSIS OF 5-HYDROXYINJ)()LEACETIC ACID 
-14.0 INTRODUCTION 
The aim of the present study was to obtain some indication as 
to whether A.S.A., at a dosage of 2 x 300 mgs., three times per day, 
was able to bring about changes in the urinary excretion of. one of the 
.. 
metabolites of the tryptophan pathways. As considered in section 1.4 
(chapter three), A.S.A. is known to compete with plasma tryptophan for 
its binding site to human serum albumin. However, Smith and Lakatos 
(1971) showed that the concentration of A.S.A. required to compete 
successfully with tryptophan for its binding site was high. Consideration 
must also be given to the fact that other factors such as diet may be 
operating: to produce a change in the ratio of free to bound tryptophan: 
therefore;. any changes found after A.S.A. ~dministration does not 
necessarily show that A.S.A. is releasing tryptophan. 'The results of 
the assay will simply provide an overall view of the changes connected 
with the trypt9Phan pathway. 
, 
The pathway of particular interest is the .formation of, 
5-hydroxytryptamine from tryptophan, as it is 5-hydroxytryptamine and 
its breakdown prodUcts which are believed to play a major rSle in sleep 
production and maintenance (Mendelson et al., 1977). 5-Hydroxytryptamine 
is oxidised to 5-hydroxyindoleacetic acid, which is excreted in the 
urine. The relationship between tryptophan and 5HIAA is represented 
below: 
Tryptophan Hydroxylase MAO 
~ 5-HTP decarboxylase ~ 
Tryptophan ) 5-HTP .J, ) 5-HT --~;;-7) 5HIAA I .,. 
PePA I'fAOI 
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Key: 
5-RTP 5-Hydrcixytryptophan 
PCPA - P3richl;ropheny~l3nirie 
MAOI Monoamine OXidase Inhibitor 
5-RT 5-Hydroxytryptamine (serotonin) 
This tryptophan pathway isa minor one, as the bulk of tryptophan 
.. 
metabolised is acted upon by the enzyme tryptophan pyrrolase, eventually 
yielding such products as anthronilic acid, xanthurenic acid and nicotinic 
acid. 
As mentioned in section 11.0, chapter three, the choice of assay 
techniques was limited by the equipment and reagents available at the 
time and the fact that any technique which involved invasive procedures 
was not feasible. In view of these points, the most suitable assay 
" 
" 
technique was the analysis of 5-HIAA. in the urine by colormetric means. 
However, 80 to 90 per cent of the 5-HIAA. excreted in the urine will be 
from the alimentary tract and only a small proportion from the brain 
areas. Therefore, urine analysis will only provide an overall view of 
the amount of 5-hydroxytryptamine in the body prior to, 'during and after 
A.S.A. administration, rather than giving specific details about the 
5-hydroxytryptamine content in various areas. Nevertheless, it was 
considered that if A.S.A. was having a marked effect upon the formation 
of 5-HIAA., it would be detected,in the urine. 
15.0 EXPERIMENTAL DESIGN AND PROCEDURE 
Three female subjects, who were able to take A.S.A. without 
experiencing any adverse side-effects were selected. The experimental 
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protocol was: 
Day 1 2 , 4 5 6 1 8 9 10 11 12 
Condition ]1 ]2 A1 A2 A, A4 R1 R2 R, R4 R5' R6 
Key: 
] - J3aseline 
A - A.S.A. (2 x ,00 mgs., three times per day) 
R - Recovery 
On days three to six the subjects were administered 2 x ,OO'mgs. of A.S.A., 
- .. ~ 
three times per day,' at 10~-OO a.m., 4.00 p.m. and 10.00 p.m., as for 
, 
the previous study. The subjects were required to collect all the 
urine for each day. The volume of urine excreted upon awakening was 
combined with the urine of the previous day., The subjects were ' 
instructed to store their collecting bottles in a cool place. The total 
urinary output was collected each day apart from days.,R2, .~. and R5, 
as it was considered that R1, R, and RG; would give sufficient 
indication of any recovery trends which may be present. The imPortance 
of keeping their daily dietary intake constant was stressed to the 
subjects. 
In order to check the sensitivity of the assay technique, one 
subject;: approxima.tely.four weeks a.1'ter the study, supplemented her" 
'normal diet with two foods relatively high in tryptophan content, namely, 
the tomato and the banana. The approximate tryptophan contents o.f these 
.foods are 9 mg. per 100 gms. and 13 mg. per 100 gms., respectively (Food 
and Agricult=e Organisation, 1912). The subject ate 400 gms. o.f each 
food during the course of the day. The urine was collected and analysed 
as for the other days. The aim of this procedUre was to determine whether 
the assay used was sufficiently sensitive to indicate the rise in dietary 
tryptophan. 
, 
, 
; 
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For both parts of the study, the urine was analysed daily, 
according to the standard method of Udenfriend et al. (1958). This is 
a colormetric method:-theextracted 5-HIAA yields a violet colour on 
interaction with nitrosonapthol reagent. After extraction and 
treatment with ni trosonapthol reagent, the Tl"inal aqueous layer was 
transferred to a microcuvette, and the optical density was measured at 
540 m/,. The reagent blank was pre:pared by treating 6 mls. of distilled: 
water in the same manner as the 6 mls. urine sample. The ether used 
was washed with a dilute solution of i'e=ous sulphate to remove 
im:purities. Each'sam:ple was assayed in triplicate~ 
The standard curve was compiled from the optical densities 
measured on 6 mls. of standard solutions containing 8, 14.5, 29, 44.5, 
58 and 66 r i. of 5-HIAA treated in the same manner a~: the urine 
samples. The standards were assayed in duplicate. A standard was also 
assayed every day along with the samples as a check. The standard was 
stored in the refrigerator. 
16.0 RESULTS 
The standard curve was plotted, and the line of best fit calculated, 
(graph N, section 25.9. chapter three). The urinary excretion of 5-HIAA 
for each subject, for each day is shown in Tables 81 and 82 (section 25.0, 
chapter three). The 5-HIAA output is expressed both in mg. per day and 
per 1,000 mls. of urine, for ease of com:parisori'1iith previous studies. 
Although N is too small for accurate statistical analysiS, it can be 
clearly seen from Tables 81 an9- 82 that A.S.A. administration had little 
marked-ei'fect upon the urinary output of 5-HIAA. When the tryptophan 
load was given there was a marked increase in the amount of 5-HIAA in 
the urine. The 5-HIAA concentration increased from a baseline mean of 
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5.7 mg. per day to 17.9 mg. per day or when expressed per 1,000 mls. 
of urine from 3.1 to 7.0. Graph 0 (section 25.0, chapter three) has 
been plotted. liith days against the group mean 5-HIAA concentration, 
expressed both as mg. per day and per 1,000 mls. of urine. 
17.0 DISCUSSION OF RESULTS 
Firstly, mention must be made of the fact that there was 
variability in the 9ptical density readings for the standard from 
. + 
day to day, the range was 0.15 - 0.02. The error was thought to be 
due to the spectrophotometer. To allow for this error, the recorded 
excretion of 5-HIAA was adjusted according to the percentage error 
associated with the standard for that particular day. In applying this 
correction factor, the assumption was made that the standard had not 
undergone any change during the course of the study; this 'seems 
,.!f 
reasonable, as it was stored according to the drug company's instructions 
and the standard values did not simply show a progressive decline during; 
the course of the study, but a random fluctuation. This indicated that 
the standard was not undergoing progressive degradation. 
Tables 81'and 'Siand graph 0 (section 25.6, chapter three) clearly 
show that there was no marked change in urinary output of 5-HIAA during 
A.S.A. administration. This may be because: 
1. the dosage of A.S .A. used may have be~n insufficient to compete· 
successfully with tryptophan for its binding site, 
2. the effect of A.S.A. may be slight; more subjects or a more 
sensitive assay technique may be required in order to detect any 
change, 
3. inaccuracies exist within the assay technique, 
( 
i, 
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4. there is also the possibility that A.S.A. may be successfully 
competing with tryptophan for its binding site to human serum 
albumin, but another mechanism, 'such as a decrease in free:' 
fatty acid concentrations may be causing an increase in tryptophan 
binding, with the net result of no change in the free tryptophan 
concentration. 
However, the assay technique was sufficiently sensitive to detect the 
increased urinary output of 5-HIAA due to, the , tJ:Y'ptoph2.n' supplemented 
diet. Wyatt, Engelman, Kupfer, ]'ram, Sjoerdsma and Snyder (1970) also 
found that this assay teohnique was sensitive to a tryptophan load 
(7.5 gms. per day). Wyatt et al. (1970) reported that the 24 hour 
urinary 5-HIAA ooncentration increased from a placebo mean of 
6.2 mg'. per day to 19.6 mg. per day. Worthy of comment is the fact 
that, although the amount of tryptophan administered ,~ the diet, 
in the present study, was only approximately 90 mg., in comparison 
with the 7.5 gms. per day of the Wyatt et al. (1970) study, the increase 
in 5-HIAA concentration in the urine reported for both studies was 
almost equal. There are several reasons for this: 
, 
1 • The conversion of tryptophan to 5-hydroxytryptamine and then to 
5-HIAA is only a minor tryptophan pathway}' there is the possibility 
~ -
that this pathway may quickly become saturated, resulting in the 
excess amounts of tryptophan passing along alternative pathways. 
2. The tryptophan administered in the present study was of the order 
of that likely to be encountered in practice (90 mgs'.). 'lhereas, 
in the Wyatt et al. (197P) study a very large tryptophan load was 
given, 7.5 gms. In the present study, the tryptophan was 
'., administered by means of high tryptophan foods, in the Wyatt et 
al. (1970) study the tryptophan was administered as a drug and it 
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is regarded as being very unpalatable. The extreme conditions 
of the Wyatt et al. (1970) study may have caused some of the 
bodily systems to reac\; atypically. 
3. In the Wyatt et al. (1970) study the urine was analysed over three 
days. In the present study the urine was only analysed on one 
day for the high tryptophan diet condition. 
It is also interesting to note that the two graphs 0, one with 
5~ concentration expressed in mg. per day and the other per 1 ,000 ml~. 
of urine, show slightly different trends. This may be due to the wide 
variation in the daily urinary volumes for each subject. ~or example, 
one subject had a range of daily volumes from 1,214 mls. to 3,065 mls. 
Also, with N = 3, variations in the urinary volume are,;likely to 
,{' 
affect the group results. The subjects were not instructed to keep 
their daily fluid intake cons;tant; this was a shortcoming in the 
instructions given to the subjects.· The slight fluctuations in both 
graphs are likely to reflect normal daily changes in 5-HIAA excretion. 
I 
The concentrations of 5-HIAA excreted were within the range quoted by 
Udenfriend et al. (1958) of 2 - 8 mg. per day. 
18.0 CONCLUSIONS AND FURTHER RESEARCH 
Th1spilot study indicated that A.S.A., at a dosage of 2 x 300 mg., 
administered three times daily, does not markedly effect the urinary 
excretion of 5-HIAA, as measured by the colormetric assay technique 
of Udenfriend et al. (1958). ~is finding suggests that the dosage of 
A.S.A. administered in the main study did not have a major effect upon 
tryptophan metabolism. 
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This study was essentially a pilot study, but further research 
in this area is not justif'ied at present; £irstly, because the 
fluctuations in the standa=d measu.~mcnt !rcm day to day throws 
suspicion on the reliability of this assay technique,.' indicating that 
another assay technique ought to be tried before e~ the responses 
of more subjects to A.S.A. administration. A possible alternative 
assay is to use a flurometric technique (Udenfriend et'al., 1958). 
However, the spectrophotoflurometer was under repair at the time. 
Secondly, this biochemical aspect of the research programme is a side-
track and runs the risk of becoming divorced from the main theme. 
19.0 PARACETAMOL (ACETAMINOPHEN) PILOT STUDY , 
20.0 INTRODUCTION 
(' 
The aim of this pilot study was to determine whether a drug with 
similar analgesic and antipyretic activities to A.S.A. produced the same 
effect upon sleep. The drug chosen was Paracetamol (Acetaminophen). 
The reasons for choosing Paracetamol were listed in section 11.0, chapter 
, , 
three. In brief, the reasons were primarily that A.S.A. and Paracetamol 
are both effective analgesics and antipyretic agents at therapeutic 
doses and both drugs have been found to inhibit the synthesis of 
prostaglandins from in vitro enzyme preparatiOns (Vane, 1971; Flower &, 
Vane, 1972). They do differ in some respects:" Paracetamol does. not 
release tryptophan from its binding site to serum albumin, at therapeutic 
doses (Gazzard, Ford-Hutchinson, Smith & Williams, 1973). Furthermore, 
Paracetamol does not produce gastric irritation, erosion and bleeding 
that may occur after A.S.A. administration (Goodman & Gilman, 1970). 
Therefore, the comparison of the effects of these two drugs upon sleep, 
in view of theix properties, both similar and dissimilar, may aid in 
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determining the pathway v~ which A.S.A. exerted its effects upon sleep. 
21.0 !1ET!!OD 
21.1 Experimental Design 
Four female subjects were selected according to the procedure of 
section 6.1, chapter one. The subjects were given the same, instructions 
as for the A.S.A. main study. The only changes being that the subjects, 
had to be able to take Paracetamol without experiencing any adverse 
side-effects and the subjects were told the dosage of Paracetamol to 
be used. The dosage of Paracetamol administered was 1 x 500 mgs., four 
times per day, at 10.00 a.m., 2.00 p.m., 6.00 p.m. and 10.00 p.m., 
yielding a total daily dosage of 2.0 gms. This dosage was within the 
therapeutic mnge quoted by Goodman and Gilman (1970), 0.,' - 0.60 gms., 
every four hours. f{ 
" 
The experimental protocol was the same as the A.S.A. main study: 
'Night 1 2 , 4 5 6 7 8 9 10 11 12 13 14 15 
Treatment Ad Ad. B1 B2 B, P 1 P2 P, P 4 R1 R2 R3 R.4. R5 R6j 
Key: 
Ad - Adaptation 
B - Baseline 
P _ Paracetamol (1 x 500 mgs., four times per day) 
R. - Recovery 
Each subject attended the laboratory for a total of 15 nights. As for 
the A.S.A. study no EEG recordings were made on P, or RS:, 
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21'.2 Experimental Procedure 
The subjects attended the laboratory in pairs and arrived at the 
laboratory approximately one hour before retiring. The general laboratory 
procedure of section 6.3, chapter one was carried out. The retiring 
and rising times for each subject, on every night were kept to within 
+ . 
-15 minutes. A daily check was made on the general health and well 
being of.the subjects by means of self-report accounts. 
21.3 Data Analysis 
The EEG records were scored in one minute epochs, according to 
the standardised criteria of RecHschaffen.and Kales '(1968) •. The . 
records were scored blind and independently by two, experienced scorers; , 
if the disagreement between them exceeded five per cent of the epochs, 
, 
it was resolved by discussion. The stages of sleep; (W+1), 2, 3, 4, 
, , 
(3+4):iina. REM, were all expressed in minutes out of a'total sleep t~e 
400 minutes. This length of time was chosen in order that the resultS 
would be directly comparable with tho'se' of the A.S .A. study. Sleep onset 
time, total sleep time, REM latency and REM periodicity were also 
calculated. The values for each sleep parameter, over the three 
baseline nights, were expressed as a mean. The results are presented 
in Tables 83 - 92,.section 25.0, chapter three. 
Graphs P and ~ (section 25.0, chapter three) are-~ ~loit. of nights 
against the group mean difference score from the baseline for each 
sleep stage; the difference score 1= used so. that any cbanges- trom , 
.' -.. -.. ,,"-
the baseline could be clearlypbserved. From these graphs, it can be 
seen that the most pronounced changes from the baseline are an increase 
in stage 2 sleep and a decline in~! sleep on the fourth drug night. 
Inspection of results table 89 reveals that the REM latency declined 
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markedly on the fourth recovery night. In order to gain some indication 
as to whether these observed trends were significant, it was decided 
to compare the Paracetamol group with the placebo group from the A.S.A. 
study. The two groups were matched for age and sex, but the studies 
were conducted at different times. 
There was also the problem 01' the two groups being 01' mlequal size, 
with four subjects in the Paracetamol group and eight in the placebo 
group. Boneau (1960) and Havlicek and Peters on (1974) have shown that 
both the t and F tests are more susceptible to deviations from the 
mlderlying assumptions 01' the tests, such as non-normality and mlequal 
group variances, when the group sizes are unequal. The groups which 
they assessed had group sizes with a ratio 01' approximately 1 to 5, 
whereas, in the present case the ratio is only 1 to 2, but there is 
, 
also another problem: the Paracetamol group size is small. The short-
comings 01' performing statistical analysis upon such data was fully 
appreciated, but it was considered that it would aid in the overall 
interpretation 01' the results. 
An !NOVA for repeated measures ,dth unequal·group sizes was 
performed according to the computational procedure described in Winer 
(1971, page 601). The !NOVA was performed only on those sleep stages 
which, from the graphs P and Q, appeared to show pronounced changes, 
namely, stage 2 and REM sleep over the drug nights. Inspection 01' the 
results tables 8, - 92, section 25.0, chapter three, revealed that 
REM latency, over the recovery,nights, was the only other sleep 
parameter which showed any marked changes. The AlWVA SUIlllllal':Y tables for 
those parameters which approached statistical significance are presented 
in Tables 9, and 94, section 25.0, and the rest are in Appendix. XVI. 
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22.0 RESULTS 
The !NOVA revealed that the difference between the Paracetamol 
and placebo groups for stage 2 sleep, over the drug nights, was only 
significant at the ten per cent level (F = 3.3, df 1,10, P~ .1). 
REM latency showed a drug by night interaction effect, over the recovery 
nights, also at the ten per cent level of significance (F = 2.4, df 4,40, 
P, ~ .1). The changes observed in REM sleep did not even approach 
. " \ ,. , 
statistical significance. The null 'h.~p:thesis has been rejected at 
the five per cent level of significance for all the other analyses 
conducted in this research prcgramme •. Since the results of this 
Paracetamol study were significant at only the ten per cent level, it 
is obviously not clear whether the trends which could be observed upon 
Paracetamol administration were pharmacologically significant. The 
!NOVA revealed that the results of the Paracetamol study were on the 
.' ' 
borders of statistical significance in comparison with the placebo 
group. More subjects will be required before the effects of Paracetamol 
. upon sleep can be clarified, but the effects, if any, are not as great 
as those observed with A.S.A. administration. 
From the graphs P and Q, it appeared that none of the other sleep 
stages were markedly effected by Paracetamol administration. Tables 
90, 91 and 92 revealed that sleep onset time, total sleep time and REM 
periodicity s~owed no marked changes with Paracetamol administration. " 
23.0 DISCUSSION OF RESULTS 
OVerall, the results in~icated that the effects of Paracetamol 
upon sleep are likened more to those of A.S.A. than placebo. The Para-
cetamol group findings are, in some respects, a part replication of the 
A.S.A. findings. Common to both drugs is the increase in stage 2 sleep 
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and the tendency for a slight deoline in REM sleep upon drug administration. 
Upon :comparison of the two graphs P and H, it can be seen that with 
Paracetamol administration stage REM returned to baseline. on R1 and 
ana. increased'beyond it .. on R2' 'bUt with A.S.A. stage REM continued to 
fluctuate below the baseline over the recovery nights. With regard to 
the changes in stage 2 sleep, the increase was more pronounced for the 
.. 
A.S.A. group. All eight subjects showed an increase in stage 2 on the 
second night of A.S.A. administration, but in the case of Paracetamol 
only one subject showed a marked increase in stage 2 on the second drug 
night and two subjects on the fourth drug night. Furthermore, the 
Paracetamol. group did not show the declining trend in stage 4 sleep, 
which was found to be significant for the A.S.A. pilot study group, apart 
from on the second drug night. The A.S.A. main study group did show 
a declining trend in stage 4 sleep over the drug nights, reaching a 
~ on the second drug night, but this was not statistically 
significant. As mentioned in section 11.0, chapter three, the observation 
that a few of the subjects in the placebo group also showed a decline 
in stage 4 sleep, on the second drug night, raised the possibility that 
the declining trend observed with A.S.A. administration may be due to 
other factors. The A.S.A. pilot study findings may be an artefact due 
to the absence of a control group. 
There is also another confounding variable, which may have caused 
different trends'to'be observed with different groups of subjects, that 
of large individual variability in response to the drugs., This was noted 
for the A.S.A. group and for the Paracetamol group;; for example, subject 
, .. . 
2 on the second Paracetamol night shcwed a marked decline in stage 4 
of 15 minutes, whereas, for the other three subjects there was little 
observed change in stage 4 on this particular night. With regard to 
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the decline in REM latency (night x drug interaction effect at P L.. .1), 
inspection of results table 89. indicated that it was the fourth recovery 
night which showed the marked decline in REM latency. For the 
A.SeA. group there was a significant decline in REl1 latency over all 
the recovery nights, when compared with the placebo. 
The general, overall impression. gained from the results was that , 
Paracetamol was having a similar, but lesser effect upon sleep in 
comparison with A.S.A. This was reflected in the changes in stage 2, 
which were in the same direction for both drugs, but in the case of 
Paracetamol, the changes were less marked and did not peak until the 
fourth drug night. The trends· in REM latency were similar for both drugs, 
but in the case of Paracetamol, the decline was most marked on the 
, 
fourth recovery night. Paracetamol also appeared to be causing less 
disruption to stage 4 sleep. The reasons for these sleep changes may 
be similar to those speculated for A.SeA., that is, the increase in 
stage 2 sleep may be acting as a kind of buffer to compensate for the 
disruption in other sleep stages, such· as . REM sleep, in this case. 
Once again, a qualitative change in REM sleep was found on the recovery 
nights. As suggested for the A.S.A. study,· this may be due to the 
action of some drug metabolites on the REM triggering mechanisms. 
Paracetamol shares some common properties with A.S.A. Apart from 
its antipyretic and analgesic effects, it has been shown to inhibit 
the syntheSiS of prostaglandins from in vitro enzyme preparations, 
(Flower and Vane, 1972). Ther~fore, one may speculate that if both 
drugs were exertmg some of their effects through the inhibition of 
prostaglandin synthesis, and since there is reason to believe that the 
prostaglandins may play some role in the sleep mechani~, then these 
~------~--------------------........... 
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drugs maY' have similar effects upon sleep. However, there is the 
distinct possibility that the drugs are.acting.v12. different pathvra;rs 
and the prostaglandins maY' not be the correct link between them. 
There are slight pharmacological differences between the two drugs; $ 
for example, Gazzard et al. (191;) found that Paracetamol, at normal, 
therapeutic doses, did not release tryptophan from its binding site to 
h~ serum albumin. Paracetamol has less overall toxicity and side-
e££ects than A.S.A.; Paracetamol does not prodUce gastric iiritation, 
erosion and bleeding at therapeutic doses, which maY' occur after A.S.A. 
administration (Goodman & Gilman, 1970). It is unlikely that· the 
slight differences in the effects of these twu drugs upon sleep was due 
to the fact that Paracetamol does not bind to serum albumin, at therapeutic 
doses. _ < It would appear that at the dosage of A.S.A. ,~ed in the present 
study, the increase in free tryptophan, if any, was small and short-
lived. The results of the previous studY' supported this idea, because 
the therapeutic dose of A.S.A. used was insufficient to bring about an 
increase in the urinary output of 5-HIAA;-5-HIAA is a breakdown product 
, 
of ~dr~xyLryp~e, which is produced from tryp~ophan. This is 
the pathway bY' which tryptophan is believed to exert its effects upon 
sleep. 
Regardless of all the various actions and pathways previouslY' 
considered, it must not be overlooked that the effect of these drugs 
upon sleep maY' be due to adverse side-effects. However, since Paracetamol 
has less adverse side-effects than A.S.A. at therapeutic doses (Goodman 
& Gilman, 1970) and appears to have similar effects to those of A.S.A. 
upon sleep, it would be reasonable to assume that the effects of these 
drugs upon sleep cannot be explained solely on_the basis of side-effects. 
211 
There is also the possibility that the slight differences in the effects 
of these two drugs upon sleep may be due to their respective pharmokinetics. 
For example, Paracetamol is reported to reach peak plasma. levels after. 
30 minutes - one hour after administration of a single therapeutic 
dose.' Detectable levels of Paracetamol are reported to be present in. 
the plasma for about five hours after a single therapeutic dose. A.S.A. 
has been shown to reach peak plasma levels after about two hours and then 
gradually decline (Goodman & Gilman, 1970). 
Since both Paracetamol and A.S.A. are drugs with a wide variety 
of actions, it is possible that many more speculations could be made 
in connection with how these drugs bring about the observed changes in 
sleep. Support for some of these ideas previously put forward, such as 
. 
the inhibition of prostaglandin synthesis, would involve entering 
~: : 
further into the realms of biochemiStry. Although an attempt was made 
along these lines with the urine analysis of 5-HIAA (chapter three, 
part II), it merely skimmed the surface of a complex field. Nevertheless, 
the results from the studies in this chapter revealed that A.S.A. does 
affect sleep. Its effect was classified as being slightly arousing, 
because of the significant increase in stage 2 sleep, a light stage of 
s·leap. There are some indica.tions from the results of: the· Paricetamol 
pilot study that it exerts a similar effect to that of A.S.A. upon 
sleep, but to a lesser degree. More subjects are required before the 
action of Paracetamol upon sleep can be clarified. 
24.0 CONCLUSIONS AND FURTHER RESEARCH 
Sleep, after the administration of a therapeutic dose of. Paracetamol 
(1 x 500 mgs., four times per day), showed a trend toward an increase 
in stage 2 sleep and a decline in REM latency upon drug withdrawal.· 
~---------------
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These findings were similar to those observed upon A.S.A. administration. 
The next step would be to conduct a larger, controlled study with 
pa-~cetamol,'similar to the A.S.A.ma!n ctudy, to determine if the 
results of this pilot study could be replicated. 
In concluding one ought to go back and consider the reasons for 
investi~ting the effects of A.S.A. and Paracetamol upon sleep. These 
investigations stemmed from the comments made by many of the self-reported 
insomniacs of chapter one that they frequently took Aspirin to relieve 
their insomnia;, tberef'ore, theini tial illterest lay in the' effects of 
A.S.A. upon insomnia. As a result of the literature search,it became 
apparent that no previous study had examined the effects of A.S.A. upon 
normal, human sleep. It was therefore considered that, within the time 
available, priority ought to be given to the investigation of the 
, 
effects of A.S.A. upon normal sleep, rather than abnormal sleep. The 
results of the A.S.A. study indicated that it was having a slight arousing 
effect upon sleep, because of the significant increase in stage 2 sleep, 
a light stage of sleep. However, A.S.A. did not increase the sleep 
, 
latency or decrease the total sleep time of the group of subjects to 
a significant degree. The subjects used in the A.S.A. studies were all 
self-reported good sleepers and therefore, one would not expect A.S.A. 
to be able to reveal any possible sleep inducing properties which it 
may possess. The findings of,the daytime study by Pfeiffer et al. (1967) 
indicated that A.S.A. may have a slight sedative effect, but these 
results were not conclusive because of some of the points noted in 
section 1.0, chapter three. Once a table of standards has been drawn 
up for the EEG model of sleep onset insomnia (chapter two), the sedative 
potential of A.S.A. could be assessed by this method. 
................ -------------------------
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However, as discussed in section 11.0, otthis chapter,. since -the· 
completion of this research programme, 'the abstract of an investigation 
of the ef.fectsof a single dose of A.S.A. (650 mgs.) upon the sleep 
of a group of insomniacs has been published (Hauri & Silberfarb, 1978). 
Even in the light of this recent work, the further research proposal 
to investigate the sedativepotent1al of A.S.A. by means of the EEG 
model of sleep onset insomnia is still feasible, because the group mean 
sleep onset time of Hauri and Silberfarb's (1978) insomniacs was only 
~0.9 minutes and no standard deviations were given. There, is therefore 
the possibility that Only one or two insomniacs had a long sleep onset 
time. One could argue that, as for the present study, A.S.A. had once 
again been unable to reveal its sedative potential. 
" 
, 
;. 
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25.1E:cplana.tory Notes for the Results Tables 
All means in the· results tables are expressed to the nearest whole number. 
All figures in the results tables are expressed in minutes unless 
otherwise stated. 
A.S.A. Acetylsalicylic Acid (Aspirin), 2 x 300 mg., three times per 
day. .. 
A.S.T. Analysed Sleep Time refers to the amount of each sleep record 
analysed from the time of sleep onset. A.S.T. is the lowest 
common measure of total sleep time for all subjects on all 
nights. 
B - The average score for the three baseline nights. 
B - The score on the xth baseline night. x 
P Paracetamol, 1 x 500 mg., four times per day. 
Recovery nights. 
'; 
T.. Diet supplemented with foods relatively high in tryptophan content • 
. Number of stage Changes - A stage change was counted each time a subject 
passed from one stage of sleep into another providing the time spent 
in any particular stage was at least ,two minutes. 
In the GENSTAT printout group 1 is the A.S.A. group and group 2 is 
the placebo group. 
\ 
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Results Tables for A.S.A. Pilot Study: Subjects 1 - 4 are males 
.and sub.1ects 5 - 8 aJ:.·e females. 
sta,2;e.W+1 Table 22 
Treatment :s A1 A2 R1 .~ 
Subject 
1 16 20 28 25 21 
2 22 24 20 24 17 
3 37" 25 21 29 29 
4 11 21 15 17 11 
5 25 10 15 27 39 
6 9 37 2 24 36 
7 14 17 19 3 24 
8 1 ~2 12 16 ~6 
Mean 18 25 17 21 27 
S.D • 9.9 10.4 7.4 8.4 10 
. Sta~ 2. Table 26 
Treatment :s A1 A2. ' .. ~1 . R2 
Subject ! 
1 190 199 190 180 . 177 
2 166 167 159 179 r, 202 {, 
3 148 170 171 184 " 173 
4 177 167 207 184 177 
5 197 192 197 203 215 
6 165 173 160 200 165 
7 185 193 214 191 187 
8 16~ 168 - 161 169 161 
Mean 174 179 183 186 182 
S.D. 16.3 13.6 21.7 11.3 17.5" 
sta~ ~ Table 21 
Treatment :s A1 ~ R1 ~ 
Subject 
1 39 34 24 67 63 
2 40 49 39 36 36 
3 47 48 42 31 56 
4 30 36 27 27 30 
5 40 34 19 24 16 
6 62 55 80 16 59 
7 31 28 19 23 33 
8 2~ 28 §g :21 22 Mean 43 '39 35 40 
S.D. 11 10.3 20 17.8 16.9 
A.S.T. for the above three tables is equal to 420 minutes. 
For statistical analysis the above scores were expressed as 
a change from the baseline. 
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SleeE Onset Time Table 61 
Treatment B A A2 R1 ~ Subject 1 
1 14 12 11 16 7 
2 22 18 30 51 20 
3 25 16 16 14 12 
4 13 12 10 8 10 
5 18 15 13 19 32 
6 10 18 20 26 18 
7 27 45 20 34 30 
8 22 22 22 21 22 
Mean 21 22 18 24 20 
S.D. 8.4 12.7 6.7 13.6 10.3 
Total SleeE Time Table 62 
Treatment B A1 A2. R1 ~ Subject 
1 426 422 420 424 430 
2 455 453 447 421 449 
3 423 447 429 455 454 
4 453 432 458 420 460 
5. 427 428 441 435 426 
6 527 520 503 472 507 
7 424 426 421 435 420 
8 202 222 228 222 212 
Mean 455 457 457 450 457 
S.D~ 40.2 43.0 42.2 38.9 35.4 
For statistical analysis the scores were expressed as a change 
from the baseline. 
, , 
, 
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stage ~ Table 6~ 
Treatment B A1 A2 R1 R2 
Subjeot 
106 67 1 85 84 97 
2 80 66 84 66 57 
3 104 93 103 79 92 ' 
4 99 95 109" 108 99 
5 73 83 93 67 66 
6 99 82 92 78 91 
7 112 101 110 ' 101 86 
8 27 18 23 11 62 
Mean 94 85 99 80 82 
S.D. 13.1 11.0 9.5 15.9 16.4 
A.S.T. for the above table is equal to 420 minutes 
Table 62A 
Source S.S. d.f. M.S. F P df1,df2 
" ~ : 
Night 2029 4 507.0 7.9 5% 1 f 7-
Subjeot 4521 7 645.9 10.1 5'fo 1 4 f . 
Residual 1805 28 64.5 
Total 8355 39 
Conservative Test 
Newman-Keuls Multiple Comparison 
R1 R2 A1 B A 
R1' ns ,ns 1% 1~ 
R2 ns 1% 1% 
A1 5'/0 1% 
B ns 
For statistioal analysis the scores were expressed as a change from 
the baseline. 
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Trend Testfor:Sta.ge 4 Sl;~p(A.S.A. Pilot StudY) 
Table 62B 
S.S. d.f. I1.S. F P df1,df2 
1703.8 3 567.9 9.1 0.1% 3,21 
342.2 1 342.2 5.5 5% 1,21 
300.1 1 300.1 4.8 5% 1,21 
1060.9 1 1060.9 16.9 0.1% 1,21 
0.6 0 
2441.0 7 348.7 5.6 0.1% 7,21 
1316.7 ·21 62.7 
5461.5 31 
.. --.. - .... , ... 
Baseline 
Graph G: To Illustrate the Cubic Trend for Stage 4 Sleep 
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Results Tables for the A.S.A. Main Stud;£: (Subjeots numbered 1 
-8 
are the A.S.A. group and subjects 9 - 16 are the Placebo Group. 
st~ W+1 Table 6!1 
Night B A1 Az A ~ R' R3 R4 R6 Subject 4 2 
1 17 " 5 5 14 1 20 20 1 13 
2 17' 6 15 13"" 9 15 27 12 12 
3 6 15 ' 29 39 9 11 12 9 9 
4 18' 12 15 16 10 8 17 22 8 
5 25 14 22 8 50 10 8 10 19 
6 13 18 11 12 12 11 9 9 8 
7 9 30 5 T 9 15 5 16 14 
8: 11 21 :2 12 12 22 8. 10 11 
Mean 15 15 13 15 14 14 13 11 12 
S.D. 5.8 8.1 8.8 10.1 14.9 :2.2 1·:2 6.1 2·1 
9 4 12 19 7 8 12 18 13 10 
1<1 33 24 44 16 12 36 19 22. 18 
11 213 42 10 27 22 33 43 33 28 
12 21 29 21. 38 29 32 11 22 30 
13 16 20 23 23 27 12 1~ , 14 14 
14 3" 2 3 0 7 1 7 9' 4 
15 14 13 13 1 7 12. 22 13 9 
16 'I 8' o 26 2 4 12 10 I 10 Mean 00 16 .. 19 200 14 15 19 18 17 15 
S.D. 11;1' 12.8 12~.3 14 10 12.? . 11.2 8.9 9·2 
stage 2 
o Table 6:2 
Night B A1 A2 A4 R ' Rz R3 R4 R6 Subject 1 
1 198 209 212 216 192 160 173 164 197 
2 147 166 188 171 140 136 141 151 177 
3 176 170 185 151 169 194 141 169 176 
4 156 161 182 185 173 163 163 210 146 
5 203 228 219 210 197 224 242 226 199 
6 176 192 196 195 166 197 204 175 169 
7 204 206 218 209 196 195 174 214 197 
8 120 206 221 222 2!11 222 220 208 22~ Mean 181 192 204 195 184 187 182 190 18 
S.D. 21.!1 24.2 18.!1 2!1·1 29.8 31.1 36.6 21·9 2!1.!1 
9 186 187 163 185 191 1910 180 187 191 
10 184 181 152 192 194 185 177 184 190 
11 164 161 197 156 159 158 162 .160 158 
'12 175 176 168 166 161 . 159 194 171 160 
13 171 149 168 164 200 166 172 188. 160 
14 192 177 o 1800 , 169 189 187 167 191- 167 
15 185 164 199 204 180 199 178 182 157 
16 120 199 139 128 128 1:26 11:2 1:2!1 1~8 Mean 173 1. 7 171 171 175 175 168 177 1 8 
S.D. 19.8 16.6 20·1 23.5 2!1·2 11.2 23.:2 12.9 1!1.5 
A.S.T. for the above tables is equal to 400 minutes. 
For statistical analysis the above scores were expressed as a'change from 
the ba.seline. 
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For statistical analysis the scores below were expressed as a change, 
from the baseline. 
stage 3, Table 66 
Night B A1 A2 A4 R1 R2 R3 R4 R6 Subject. 
1 22 17 33 23 20 29 16 26 21 
2 27 23 24 ~ 27 44 36 12 21 30 
3 27 18 27 18 21 19 37. 26 23 
4 27 27 49 ' 31 36 40 38 31 33 
5 42 40 24 55 35 ' 48 42 22 38 
6, 31 22 23 29 42 45 24 . 39 21 
T 34 27 41 21 31 19 28 38 28 
8 24 20 38 12 8 26 8 8 26 
Mean 29 ' 24 32 27 30· 33 26 26 28 
S.D. 6.4 7.4 ' 9.6 12.9 12.3 11.2 12.8 10 6 
9 25 18 16 22 25 12 17 18 19 
10 24 35 29 25 19 33 25 26 26 
11 19 17 30 29 28 28 24 27 28 
12 27 19 27 24 15 21 20 19 18 
13 25 19 22 19 26 33 24 30 26 
./ 14 34 48 40 51 29 33 32 32 32 
15 17 17 17 12 26 18 18 , 26 20 
16 30 31 31 36 31 23 28 ~~ 26 Mean 25 26 27 27 25 25 24 24 
S.D. 5.5 11.4 7.9 11.9 5.3 7.9 5.1 5 5 
, ' 
stage 4 ' Table 67 
Night B A,1 A2 A4 R1 R2- R' R4 R6 Subject 3 
1 79 78 80 69 75 102 I 110 116 89 
2 93 72 42 65 84 97 105 94 83 
3 65 61- 53 74 70 70 71 47 66 
4 106 97 84 102 110 102 98 88 131 
5 42 20 35 33 36 32 35 37 44 6 60 66 63 52 51 37 30 83 38 
7 61 62 56 47 73 75 90 64 52 8 50 ga 28 ~f g§ 41 59 64 ~~ Mean 70 55 70 75 74 S.D~ 21.7 22 20.1 21.8 ' 22.8 29.7 31.1 26 31.5 
9 84 80 108 93 104 99 99 101 101 
10 61 50 74 64 69 42 75 62 55 11 79 73 60 75 87 80 65 77 84 12 90 83 76 60 91 73 75 80 82 
13 76 91 79 81 37 78 74 64 88 , 
14 94 80 93 103 86, 108 ' 104 92 132 
15 83 101 80 84 81 82 73 83 93 16 116 109 85 105 114 98 108 104 110 
Mean 85 83 82 83 ' 84 83 84 83 93 
S.D. 15.9 18 14.2 16.7 23.3 20.4 16.7 15.6 22.5 
A.SoT. for the above tables is equal to 400 minutes. 
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For statistical analysis the scores below were expressed as a change 
, from the baseline • .. 
stage ~+~ Table 68 
Night B A1 A2 A4 R1 R2 R3 R4 R6 
Subject 
1 101 95 113 92 . 95 . 131 126 142 110 
2 120 95 66 92 128 133 117 115 113 
3 92 79 80 92 91 89 108 73 89 
4 . 133 124 133 133 146 142 139 119 164 
5 84 60 59 88 71 80 77 59 82 
6- 91 88 86 81 93 82 54 122 59 
7 95 89 97 68 104 94 118 102 .80 
8 1~ H .. 66 22 61 61 61 12 10 
Mean 99 88 88 88 99 102 100 101 96 
S.D. 19·2 18·1 25·1 22·1 21.8 28.6 30.2 29.4 33.1 
9 109 98 124 115 129 111 116 119 12Q 
10 85 85 103 89 87 75 100 88 81 
11 98 90 90. 104 115 108 89 104 112 
12 117 102 103 84 106 94 95 99 100 
13 101 110 101 100 63 111 98 94 114 
14 128 128 133 154 115 141 136 124 164 
15 100 118 97 96 107 100 91 109 . 113 
16 146 1~0 116 . 141 112 121 1:26 1:2:2 1:26 
Mean 110 109 108 110 108 108 108 109 118 
S.D. 19.4 18.9 14.6 25 25 19.4 19.3 15·2 24.5 
Stage ID! Table 62 
Night B A1 A2 A4 R1 R2 R3 R4 R6 Subject 
1 84 91 70 78 112 89 81 93 80 
2 116 133 131 124 . 123 116, 115 122 98: 
3 126 136 106 . 118 . 131 106 139 149 126 
4 93 103 70 66 71 87 84 49 82 
5 88 98 100 94 82 86 73 105 100 
6 120 102 107 112. 129 110 133 94 164 
7 92 75 80 116 91 96 103 68 109 
8 112 22 28 110 82 81 102 110 22 Mean 105 105" 95 102 103 97 104 99 106 
S.D. 11 20.:2' ;20.2 20.8' 23·2 11·2 21.1 31 27.6. . .. 
9 101 10l} 94 93 72. 86 86: 81 79 
10 98 110 101 103 109 104 104 106 111 
11 110 107 103 111 104 101 106 103 102 
12 87 93 108 113 105 115 100 108 110~ 
13 112 121 108 113 110 111 113 104 112 
14 77 93 84 77 89 71 90 76 65 
15 1Q1 105 91 99 106 89 109 96 121 
16 111 113 112 128 12~ 111 1:2~ 106 26 Mean 100 106 ' 101 105 102 . 99 10 98 100 
S.D. 13.:2 9·2 11.1 12·4 1:2.2" 12.2 16.2 12.3 18·2 
A.S.T. for the above tables is equal to 400 minutes. 
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, For statistical analysis the scores below were expressed as a change 
" 
from the baseline. 
REl1 La tencI Table 10 
Night B A1 A2 A4 Rl ~ R3 R4 H6 Subject 
1 ' 147 123 153 130 143 80 167 165, 141 
2 89 67 51 42 63 67 67 59 51 
3 70 67 73 78 77 64 68 68 62 
4 116 121 118 133 132 74 110 140 149 
5 129 59 61 129 227 148 159 124 66 
6, 131 124 134 158 51 38 142 130 28 
7 157 99 143 152 80 76 143 163 128 
8 126 108 111 10~ 141 100 112 1 ~1 121 
Mean 12.1 96 106 11 114 81 121 ,123 95 
S.D. 28.8 27.6 39 39.1 58.3 32.2 38.6 39.4 41·5 
9 123 123 70 130 171 129 50 117 167 
10; 51 59 136 48 34 40 140 71 93 
11 47 46 89 39 56 49 38 48 72 
12 100 150 76 77. 90 147 '182 139 102 
13 50 42 55 66 39 57 47 41 57 
14 120 78 93 132 125 158 160 182 128 
15 82 62 133 161 62 87 127 78 62 
,16' :22 -:2:2 :2~ :22 50 48 60 41 22 
Mean 79 77 88 88 78 89 101 90 92 
S.D., 31·2 32 31.2 46.2 41.8 48.5 51.8 21•6 32·2 
REl1 Periodicitl Table 11 
Night B Al A2 A4 Hl ~ H3 R4 H6 Subject 
1 91 101 129 155 89 100, 66 171 109 
2 102 117 84 113 91 86 88 113 96 
3 103 87 122 141 127 80 107 109 90 
4 101 84 58 89 125 77 ' 128 114 105 
5 105 78 86 103 114 108 93 121 75 
6 89 88 85 5,8 98 78 94 83 88 
-7 97 86 99 109 99 71 105 81 109 
8,· 20 16 86 24 88 ~~ ~t 88 81 Mean 97 90 94 108 104 110 94 
6.~ 
, 
12'~ 22.8 30.3 16 12'2 11·2 29.1 12·2 S.D. 
9 69 69 103 81 86 119 90 98 90 
10 86 98 64 107 92 81 79 84 81 
11 78 
-
70 73 82 78 90 70 79 80 
12 83 94 97 87 92 113 54 103 100 
13 94 104 115 100 95 102 103 94 102 
14 93 102 90 ' 81 80 80 96 102 94 
15 97 89 92 108 109 ' 102 117 109 101 
16 20 8~ 61 81 82 20 22 88 80 
Mean 8& 89 88 91 90 97 88 95 91 
S.D. 2·2 13.6 18.1 12.1 9·1 14·2 12·1 10·2 2·1 
A.S.T. for the above tables is equal to 400 minutes. 
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For statistical analysis the scores below were expressed as a change 
, from the baseline. 
SleeE Onset Time Table 12 
Night B A A2 A4 R1 R2 R3 R4 R6 Subject 1 
1 17 16 13 ·n 27 12 11 ; 9 13 
2 11 18 20 15 27 8 13 32 .16 
3 19 25 9 15 9 12 22· 28 12 
4 30 10 10 12 30 9 14 10 11 
5 18 30 19 10 18 16 14 13 14 6 12 10 16 18 20 2.7 38 19 37 
7 11 6 23 13 2 10 6 14 9 
8 ~1 24 29 41 21 40 12 12 22 
. Mean 21 19 17 17 21 17 16 19 17 
S.D. 13.6 10.2 6.8 2·2 10.5 11.2 2.8 8.3 2.1 
9 60 67 65 47 40 42 45 42 47 
10 26 62 26 30 29 46 13 29 20 
11 32 52 31 37 37 42 43 47 34 
12 36 74 29 42 30 43 37 34 44 
13 20 63 20 11 25 15 15 12 14 
14 30 32 28 19 23 16 39 8 15 
15 12 15 18 10 15 12 24 28 13 
16 22 66 12 11 28 22 28 21 22 
Mean 32 54 29 27 28 30 31 28 26 
S.D. 14.2 20.2 15.6 14·2 1·2 14·1 12.4 - 13.6 . 13·1 
Total SleeE Time Table 12 
Night B A1 A2 A4c R1 ~ R3 R4 R6 · Subject. 
1 403 456 415 415 410 405 421 413 417 
2 400 400 401 405 400 402 400 402 403 
3 431 419 419 417 419 420 419 418 417 
4 401 455 417 413 400 415 420 421 418 
5 404 404 405 404 410 404 427 404 405 6 420 422 411 407 402 402 447 401 403 
7 443 421 400 434 423 477 406 423 406 8 411 42~ :1:00 :1:00 :1:02 :1:00 :1:00 :1:0:1: 406 Mean 414 42 409 412 408 415 418 411 409 
S.D. 15·2 20·1 8 10·1 8.9 25.9 15.7 9.1 1 
9 401 442 440 437 416 400 427 415 401 
10 434 .448 442 446 412 419 473 434 444 
11 463 470 458 464 439 468 481 463 469 
12 450 444 435 443 427 413 450 430 438 
13 436 454 434 453 415 449 443 442 452 
14 426 432 427 446 449 426 441 446 451 
15 444 443 438 450 424 443 420 425 452 
16 421 :1:22 :1:22 :1::1:6 410 422 :1:21 :l:2~ :1:42 Mean 434 448 439 448 424 431 446 43 444 
S.D. 12 11.1 8·2 8 12·2 21·1 21.6_ 1:1:·2 12.6 
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Number of stage Changes Table 74 
Night II A1 A2 A4 R1 R2 R, R4, R6 Subject 
1 48 ,8 45 41 42 47 . ,8 ,7 40 2 49 46 44 45 56 59 49 48 58 , ,8 47 52 50 ,4 ,4 5, ,4 
" 4 50 4, 61 56 60 65 61 6, 44 
5 71 76 60 72 76 54 54 56 74 6 55 54 57 48 51 74 45 51 45 
7 60 71 52 50 47 42 54 72 49 8] ~1 21 ~1 :26 :22 62 :20 :22 ~:2 Mean· 52 54 52 50 50 56 48 49 48 
SIDs 2.8 1:2·2 616 1012 1~IO 1:2·2 1010 1~.:2 12.6 
9 ,3 41 37 35 43 34 37 36 38 
10 42 52 41 56 41 57 50 46 49 
11 52 44 41 54 54 53 53 46 52 
12 61 57 62 42 ~I 60 47 65 55-13 64 52 57 59 69 61 64 59 
14 50 6, 48 57 52 51 58 . 53 53 
15 41 43 37 30 51 36 ,9 51 41 
16 62 61 12 2:2 60 ~2 ~2 ~2 ~ Mean 51 52 50 48 52 51 49" 51 49 S.D. 11.:2 8.4 1:2·1 11.1 1·2 11·1 8~2 9.6 1.1 
A.S.T. for the above table is equal to 400 minutes. 
For statistical analysis the scores above were expressed as a change, 
from the baseline. 
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Signif'icant !NOVA Su.mma.ry Tables for the A.S.A. Main Study 
Stage 2 - Dru~ Ni~ts Table 72· 
. So=ca S.S. d.f. M.S. F P df1,df2 
Between Subjects 
Treatment; 4720~4 1 4720.4 14.5 1% 1,14· 
Subjects within 
treatments 4544.8 14 324.6 
'lithin Sub.jects 
Nights 493.0 2. 246.5 1.5 ns 1,14 
Nights x Treatments 178.6 2 89 • .3 0.5 ns 1,14 
Residual 4672.4 28 166.8 
Total 14609.2 47 
Conservative Test 
Total SleeE Time - Drug Ni~ts Tabl~ 16 
So=ce s.s. d.f. M.S. F P df1,df2 
Between Sub~ects 
Treatment 602.1 1 602.1 .0.9 . ns 1,14 
Subjects within 
treatments 9762.5 14 697.3 
Within Sub~ects 
Nights 1830.9 2. 915.4 9.4 1% 1,14 
Nights x Treatments 350.3. 2 175.2 1.8 ns 1,14 
Residual 2735.5' 28 97.7 
Total 15281.3 47 
Conservative Test. 
Newman-Keuls 11ul tiEle Comparison Test 
A2. A4 A1 
A2 570 170 
A4 ns 
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SleeE Onset Time - Drug Nishts Table '1Z 
Source S.S. d.f. M.S. F P df1,cli'2 
Between Subjects 
Treatment 892~7 1 892.7 3.5 ns 1,14 
Subjects within 
treatments 3556.5 14 254.0 
Within Subjects 
Nights 2005.8 2. 1002.9 1Q.8 1% 1,14 
Nights x Treatments 1620.1: 2 810.1 8.7 1% 1,14 
Residual 2609.4: 28 93.2 
Total 10684.5 41' 
Conservative Test 
NeWman-Keuls MultiEle Comparison Test 
ns 1% ; ; 
Lop;a.rithmic Transformation of SleeE Onset Times - DrU~ Nights 
Table 18 
Source S.S. d.f. M.S. F P cli'1,cli'2 
Between Sub,jects 
Treatment 0.5. 1 0.5· 0.9 ns 1,14 . 
Subjects within 
treatments 8.7 . 14 0.6 
Within Subjects 
Nights 1.8 2. 0.9 . 6.4. 2.5% 1,14 
Nights x Treatments 1.5 2 0.7 5.3 5.0% 1,14 
•• Residual 4.0 28 0.1 
Total 16.5· 47 
Conservative Test 
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- REM Latencl - Recove~ NiBtts Table 12 
Source S.S. d.t". M.S. F P df"1,df"2 
Between Subjects 
Treatment 11472.1' 1 11472.1 5.5 5% 1,14 
Subjects within 
treatment 29332.8 14 2095.2-
Within Subjects 
Nights 7162.6: 4 1790.7 ' 1.7 ns .1,19.: 
Nights x Treatments 5425.9, 4 1356.4- 1.3 ns 1,,19 
Residual 57813.() 5& 1032.4 ' 
Total 111206.1 79 
Conservative Test 
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Homo~nei~ of Error Variances 
stage W+1 Table 80 
1. Subjects within grOUPS 
a) Drug nights Fmax = 4.2 elf 2,7 ns 
b) Recovery nights Fmax = 1.9 elf 2,7 ns 
2. Nights x Subjeots within groups 
a) Drug nights Fmax = 1.3 df 2,14 ne' 
b) Recovery nights Fmax = 1.8 elf 2,28 ns 
Stage 2 
1. Subjects within groups 
a) Drug nights Fmax = 1.6 elf 2,7 ns 
b) Recovery nights Fmax = 4.7 elf 2,7 ns 
2. Nights x Subjects within groups 
a) Drug nights Fmax = 3.0 elf 2,14 ns 
b) Recovery nights Fmax = 1.9 df 2,28 ns, 
Sta~ 3 
1. SubJects within grOUpS 
a) Drug nights F = 1.5 elf 2,7 ns max 
b) Recovery nights F = 1.0. elf 2,7, ·ns max 
2. Nights x Subjects within grOUpS 
a) Drug nights F = max 5.9 elf 2,14 Significant at 1% level 
b) Recovery nights F = max 5.9 elf 2,28 Significant at 1% level 
stage 4 
1. Subjects within grOUpS 
a) Drug nights Fmax = 1 ~O elf 2,7 ns 
b) Recovery nights Fmax = 1.2 elf 2,7 ns 
2. Nights x Subjects within grOUpS 
a) Drug nights Fmax = 1.6 elf 2,14 ns 
b) Recovery nights Fmax = 1.5 elf 2,28 ns 
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;'Stage 3+4 
, 
1. Subjects within grOUpS 
a) Drug nights Fmax = 1.0 d.t' 2,1 ns 
• 
b) Recovery nights Fmax = 1.0 d.t' 2,1 ns 
2. Nights'x Subjects within grOUpS 
a) Drug nights Fmax = 1.1 d.t' 2,14 ns 
b) Recovery nights Fmax = 1.8 d.t' 2,28 ns 
Stage REM 
1 .. Subjects within grOUpS 
a) Drug nights F = 3.0 d.t' 2,1 ns max. 
b) Recovery nights Fmax = 1.0 d.t' 2,1 ns 
2. Nights x Subjects within grOUpS 
a) Drug nights Fmax = 3.4 d.t' 2,14 Significant at 5% level 
b) Recovery nights Fmax = 3.4 d.t' 2,28 Significant. at 196 level 
REM Latency 
., 
. 
1. Subjects within grOUpS 
a) Drug nights Fmax = 1.4 d.t' 2,1 ns 
b) Recovery nights F = 2.0 d.t' 2 T ns max . , .
2. Nights x Subjects within grOUPS 
a) Drug nights Fmax = 3.8 d.t' 2,14 Significant at 5% level 
b) Recovery nights Fmax = 1.1 d.t' 2,28 ns 
REM Periodicity 
1. Subjects within grOUPS 
a) Drug nights Fmax = 4.3 d.t' 2,1 ns 
b) Recovery nights F = 1.7 d.t' 2,1 ns 
malt 
2. Nights x Subjects within grOUpS 
a) Drug nights F' = 1.6 
malt 
d.t' 2,14 ns· 
b) Recovery nights Fmax = 2.8 d.t' 2,28 Significant. at 1% level 
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; Sleep Onset Time 
1. Subjects within grOUpS 
a) Drug nights Fmax = 1.1 df 2,7 ns 
b) Recovery nights F = 1.8 df 2,7 ne 
max ' 
2. Nights x Subjects within grOUpS 
a) Drug nights Fmax = 3.4 df 2,14- Significant at 5% level 
b) Recovery nights Fmax = 1.2 df 2,28 ne 
Total Sleep Time 
1., Subjects within grouns 
a) Drug nights Fmax = 2.2 df 2,7 ns 
b) Recovery nights Fmax = 1.1 df 2,7 ne 
2. Nights x Subjects within grOUpS 
a) Drug nights Fmaz = 2.6 df 2,14' ne 
b) Recovery nights Fmax = 1.8 df 2,28 ne 
:: ; 
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Results Tables for Urinary Analysis of 5=HIAA Study, 
Urinary Excretion of 2-Hydro~indoleacetic Acid (2HIAA} in m~. Eer dal 
Table 81 
Day B1 B2 A1 ~ A3 A4 ~ R' R6 '1' Subject " 
1 6.3 5 4.2 1.1 1 7i 1.4 ' 5.3 3.5 11.9 
2 5.4 4.8 4.8 3.1 5.9 7 * 5.8* 5.5 5.9 3 4 4.4 5 5 4·2 1.1 1'2 4 5.3 
Mean 5.2 ,4.7 4.7 5.3 5.8 5.2 4.9 5 4.9 
S.D. 1.2 .3 .4 1.7 1.3 3.1 3.1 .8 1.3 
Urinary Excretion of 2-H;'ldro~indoleacetic Acid {:2HIAA} Eer 11000mls urine 
Table 82 
Day B1 B2 A1 A2 Al A R1 R3 R6 l' Subject 4 
1 3.4 2.8 - 3.5 2.5 3 2.3 3.3 2.4 1.3 T 
2 3.9 4.2 4.3 4.5 3.4 2.1 2.6 3 .. 5.3 
2 2'2 2'~ 6 :2·1 :2.6 2·2 2.2 1~:1 :1.6 l1ean 3.5 3.5 4.6 4.2 4 . 2.4 3 4.3 4.1 , 
S.D. .3 .1 1.3 1.6 1.4 .4 .4 2.8 ' 2.4' 
* Suspect as to whether total'volume of urine voided was collected 
on these ~10 days. 
l , 
, 
234 
Results Tables for the Paracetamol Pilot Study 
stage W+1 Table 8:2 
Night II P1 P2 P4 R1 ~ R3 R4 R6 Subject 
-1 13 ~O 31 19. 25 29 15 33 24 
2 22 11 21 14- 9 17 31 11 14 
3 10 8 7. 27 7. 13 4 4 19 
~ 10 8 2 8 2 1 10 ~ 2 
Mean 14· 14 15 17 11 17 15 13 17 
S.D. 5.7 10.6 13.2 8 9.9 9.3 11.6 14 6.5 
sta~ 2 Table 8~ 
Night B P1 P2 P4 R1 ~ R3 R4 R6 Subject 
1 202 194 190 204 194 192- 175 164 184 
2 200 188 196 219 202:. . 197 188 229 221 
3' 209 225 238 211 203 198 198 204 210 
~. 18:2 202 188 208 216 128 216 182 182 
Mean 199 202 203 211 204 196 194 197 199 
S.D. 10.1 16.2 23.6 6.4 9.1 2.9 17.3' 27.2 19.3 
-. f. 
i-I 
Sta~. ~ Table 8:2 
Night B P1 P2 P4 R1 .~ R3 R4 R6 Subject 
1 25 30 22 50 25 18 27 14 23 
2:. 29 33 22 30 18· 25 26 20 18 
3 34 23 31 17 32 33.' 28 36 30 
~ 28 ~~ 46 20 ~2 20 12 ~2 ~g Mean 32 30 30 32 29 27 25 28 
S.D .. 5.7 4.7 11.3 13.6 10.2 6.6 4.1 13.5 6.8 
stage ~ Table 86 
Night., II P1 P2 P4- R1 R2 R} R4 R6.. Subject 
1 54 50 55 45 57 54 68 77 56 
2 82 74 67 72 86 76 72 69 77 
3 68 70 70 79 77 63 83 86 65 
~ 11 66 tg 68 62 tg 12 16 82 Mean 70 65 . 66 72 74 77 71 
S.D. 12.3 10.5 9.9 14.7 12.3 11.6 6.4 7 12.8 
A.S.T. for the above tables is equal to 400 minutes. 
For statistical analysis the scores above were expressed as a change 
from the baseline. 
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Sta/1:e ~+~ Table 81 
Night B P1 P2 P4 R1 ~ R3 R4, R6 Subject: 
1 19 80 11 95 82 12 95 91 19 
2 110. 10.1 89 10.2 10.4 10.1 98 89 95 
3 10.2 93 10.1 96 10.9 96 111 122 95 
~ 112 22 122 28 111 10.2 22 112 118 
Mean 10.2 95 98 98 10.2 95 99 10.5 91 
S.D. 15.9 11.4 20..5 3.1 13.3 15.9 8.4 11.1 16 
Sta/1:e REM Table 88 
Night B P1 P2 P4 ~ ~ R3 R4 R6 Subject 
1 10.1 96 10.2 82 99 10.1 115 112 113 
2 14 94 94 65 85 85 83 11 10. 
3 65 14 54 66 81 93 81 10. 16 
4 21 21 8:2 86 11 86 82 ~* 21 Mean 84 89 84 15 84 93 92 88 S.D. 18.6 10. 21 10..8 11.6 10..1 15.6 ; 19.1 19.1 
'. 
" 
REM tatencz Table 82 
Night B P1 P2 P4 ~ .~ R3 R4 R6 Subject 
1 86 119 10.0. 125 111 51 46 50. 55 
2 96 10.1 10.2 242 151 116 10.4 53 120. 
3 99 123 123 . 52 135 111 121 46 130. 
~ 1~2 2~ 1~2 IQ 60. 126 122 60. 2~ Mean 10.4 10.1 111 122 111 116 10.2 52 90. 
S.D. 20..4 31.9 20..2 85.7 41.5 49.5 38.7 5.9 40..9 
REM Periodicitz Table 20. 
Night B 1'1 1'2. P4 ~ ~ R3 R4 % Subject 
1 88 84 75 91 59 80. 90. 16 85 
2. 10.1 78 85 96 10.3 89 94 94 98 
3 91 95 94 95 10.9. 99 78 89 90. 
4 96 10.2 92 98 7& 90. 10.2 82 82 
Mean 94 90. 86 95 81 90. 93 85 89 
S.D •. 5.7 10..6 8.7 3 22.8 7.9 12.5 7.9 1 
A.S.T. for the above tables is equal to 40.0. minutes. 
F9r s~atist.ical analysis the scores above were expressed as a change from 
tlie baseline •. 
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SleeE Onset Time Table 21 
Night B P1 P2 P4 R1 .~. R3 R4 ' R6 Subjeot 
1 8 10 6 3 9 9 15 6 5 . 
2 30 9 6 22 15 18 25 24 9 
3 15 26 17 30 10 18 13 9 13 
!1: :2 2 10 18 12 16 1 11 2 .. Mean 15 14 10 18 12 15 15 14 9 
S.D. 11.2 8.3 5.2 11.3 2.8 4.3 7.5 8.1 3.3 
Total SleeE Time Table 22 
Night B P1 P2 P4 .R, ~ R3 R4 R6: Subjeot 
1 426 430 428 431 422 422 428 440 440 
2 419 430 440 421 414 426 415 432 451 
3 460 446 465 444 458 450 468 467 446 
!1: HO !1:6O !1:11 4:2:2 !1:6!1: !1::21 !1:14 432 442 Mean 444 442 451 438 440 437 446 443 447 
S.D. 25 14.5 20.4 14.9 25.2 15.4 29.2 16.4 4·.8 
" 
.':: 
For statistioal analysis the soores above were expressed as a ohange 
from the baseline. 
--------------------------......... 
2,1 
!NOVA Summary Tables for the Paracetamol Pilot study 
Stage 2 (drug nights) Table 93 
Source SS d.f. MS F P df1, df2 
·Between Sub~cts 
Treatment 841.6 1 841.6 ,., 10}6 1,10 
Subjects within 
treatments 2566.5 10 256.1 
Within Subjects 
Nights 194.1 2 91., 0.4 ns 2,20 
Nights % Treatments 80.8 2 40.4 0.2 DB 2,20 
Residual 4511.8 20 225.6 
REM Latency (recovery nights) Table 94 
,1 
Source SS d.f. MS F P df1,df2 
Between Subjects 
Treatment 4805.5 1 4805.5 2.0 DB 1,10 
Subjects within 
treatments 24452., 10 2445.2 
Within Subjects 
Nights 1124.8 4 1181.2 1.8 ns 4,40 
Nights % Treatments 9,04.6 4 2326.2 2.4 10'/0 4,40 
Residual 38900.1 40 912.5 
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Chapter Four 
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The non-drug, commercial "sleeping aids", namely, the cushions 
providing cycloid vibration, chocolate flavoured Horlicks and the placebo 
condition, cocoa, .did not appear to have any marked effects upon the 
quality or quantity of sleep of a group of self-reported sleep onset 
insomniacs, according to EEG criteria (chapter one). However, some 
very interesting subsidiary findings and observations were made, which 
led to the subsequent studies in this research programme. One such 
finding was the difficulties encountered in obtaining a group of sleep 
., . 
onset insomniacs: . out of the thirteen, self-reported sleep onSet· insomniacs 
who were originally selected on the basis of their responses to the 
sleep questionnaire (Appendix 11), only three actually satisfied the 
. *. 
EEG criteria for sleep onset insomnia (Table 10, section 14.0, chapter 
one). This difficulty arose primarily from the majority of subjects 
overestimating their sleep onset times; thiSphenome~6n has' been· 
reported by several other researchers, for example, Monroe (1967) and 
Freedman and Papsdorf (1976). However, this does not imply that all 
complaints of· insomnia are merely "'products of the imagination", for 
three of the subjects did estimate their sleep onset times quite 
accurately. 
It would appear that after a period of sleeping difficulty, some 
people come to label themselves as "insomniacs", regardless of their 
present sleep onset times. It was also interesting to note that the 
mean sleep onset time of the insomniac group was not significantly 
different from that of a good sleep group (the. placebo group from chapter 
* Throughout this text a subject is olassified as suffering from 
moderate sleep onset insomnia, if he has a sleep onset time of 
30 - 60 minutes, when measured by the EEG. The EEG definition 
of sleep onset time emplciyed here is the time from "lights out" 
until the first appearance of a stage 2 period which is of at 
least five minutes unbroken duration. 
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three). One of the self-reported good sleepers actually had a sleep 
onset time of 60 minutes, yet this subject still classified himself as 
a good sleeper. The difference between the two groups appeared to lie 
mainly within their attitudes and expectations with regard to sleep, 
rather than in an actual time difference. Johns (1977) reported that 
good sleepers were good estimators of their sleep onset times. This 
finding was supported by the results of the study conducted in chapter 
two, which also showed that good sleepers were good estimators of 
their sleep onset times. This indicates that the phenomenon of 
overestimation of sleep onset time is peculiar to the groups of 
self-reported sleep onset insomniacs. 
In an attempt to determine why the insomniacs overestimated their 
sleep onset times, their first hour of sleep was divided into 15 minute 
epochs and compared with that of a good sleep group. There was a 
marked similarity between the two groups, but the insomniac group did 
show significantly more stage changes dUring the first 15 minutes, which 
may have left the impression that they had been awake for 15 minutes 
after their time of sleep onset, as measured b1 the EEG criteria. The 
time from "lights out" until the time that the insomniac returned to 
sleep after their first awakening was also calculated, in order to 
determine if this was the insomniacs' measure of sleep onset time. This 
measure did not agree with their estimates; so this was not a satisfactory 
explanation for the fact that the insomniacs overestimated their sleep 
onset times. 
This study clearly showed that there are two main approaches to 
the study of insomnia, the subjective and the objective. Both have very 
important r~les to play in our understanding of insomnia. One of the 
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most fascinating aspects of the subjective approach is why so many 
insomnaics claims were not supported by the EEG measure. The subjective 
approach is very important in the treatment of insomnia,. for if the 
subject claims that he is sleeping better after a particular treatment, then 
he is effectively cured. However, it is the EEG approach which will 
reveal the actual. effects of the various treatments and whether they 
are altering thc quality or quantity of sleep. It was the objective 
approach which was pursued further, since this was the initial approach 
adopted for the evaluation of the non-cl.rug "aids". 
Although three of the self-reported sleep onset insomniacs were 
fairly good estimators of their sleep onset time, there was no obvious 
feature which distinguished them from the rest of the group. Therefore, 
there appears to be no obvious way of determining the.objective sleep 
onset time from the subjective estimate, apart from bringing the 
self-reported sleep onset insomniacs into the laboratory for several 
nights. Considering the number of subjects from the study in chapter 
one who failed to satisfy the EEG criteria for sleep onset insomnia, 
this procedure is likely to be very time consuming. 
In an attempt to overcome this problem, to some extent, an EEG 
model of sleep onset insomnia was created in the laboratory by allowing 
good sleepers, who were unaccustomed to daytime napping, to nap during 
the morning and afternoon, and measuring their sleep onset times by 
means of the EEG. The group mean sleep onset time of the good sleepers 
during the morning nap session, was 45 minutes, which was significantly 
greater than at night (26 minutes). Although this ~odel will not 
eliminate the problem of selecting a group of insomniacs to satisfy EEG 
criteria, it will serve as a very useful, initial evaluation technique 
, 
< ,. 
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tor various "sleeping aids", be they drug or non-drug: if an "aid" 
were found to, reduce sleep ,.onset times in the mode]" one wquldthen be 
justified in going to the lengths of obtaining a group of insomniacs 
who satisfied the EEG criteria. This model will yield more information 
concerning the sleep inducing potential of various "aids" than if' they 
were administered at night to a group of good sleepers, for such a group 
would typica.l!:y' haVe short 'sleep onset times at the outset and the "aid" 
would have little opportunity to demonstrate its possible effectiveness 
as a sleep inducing agent. Similarly, if' the "aid" was administered 
to good sleepers kept awake by artificial means, such as central nervous 
stimulants, little information would be gained about the sedative 
properties of the drug. One 'might be observing an interaction effect 
of the "aid" with the stimulant and not the typical, characteristic 
actions of the "aid". However, the model does posses~'. one inhe,rent 
disadvantage, that is, it looks at sleep latency during the day and not 
at. night; therefore, there is a time of day dii'1:erence between the 
EEG model of sleep onset insomnia and actual insomnia. 
An interesting finding from the EEG model of sleep onset insomnia 
study was that the naps did appear to be influencing the night time sleep 
onset times: . ,the fourth baseline riight had a Significantly greater group 
mean sleep onset time (42 minutes) than the first (26 minutes). This 
suggested another possible method of creating sleep onset insomnia, but 
further research is needed here. This would involve a similar study 
to the one previously conducted (chapter two), but it would continue 
for a longer period of time, to investigate whether the trends in: -
, . , '. 
increasing sleep onset:.time at night continued.: If insomnia could be 
created at night this would eliminate the time:oi' 'day difference. However, 
consideration must be given to the fact oi' whether the insomnia 
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created in the laboratory would be easily reversible. This study would 
also serve to give some indication as to how many naps it takes before 
'an individual becomes accustomed to napping, at which point the sleep 
onaet times would begin to decline. An unexpected finding was that 
slightly less than half (44%) of the subject sessions during the 
morning actually resulted in sleep; this percentage was considered . 
rather high, as these subjects were habitually non-nappers. One possible 
method of reducing this percentage and thereby.increasing the group mean 
mornini sleep onset time may be to employ the "Morning Type/Evening Type" 
. questionnaire (Home & Ostberg, 1976) in the subject selection procedure. 
It would be expected that subjects who were at their "peak" in the 
morning would be less likely to fall asleep than those who were at their 
"peak" in the evening. This is only a tentative suggestion. 
, 
I,: 
The model was adapted slightly for a drug evaluation study, in 
order that repeated measures on the sedative potential of the drugs could 
be carried out. The results of the model study indicated that, as 
hypothesised, Temazepam had sedative properties. This effect had been 
hypothesised, because Temazepam is a member of the benzodiazepine group 
of compounds, is listed as a tranquiliser,. and has been shown.to bring 
about sedation (Fuccella et al., 1972). However,the drug F.P. did, 
not appear to match Temazepam with respect to its sedative effects: 
it showed more resemblance to the placebo. The repeated measures 
deSign data analysis revealed that the second period, regardless of the 
treatment condition, was more conducive to sleep than the others. 
From this first application study of the EEG model of sleep onset 
insomnia a list of points and possible experimental design changes were 
drawn up for consideration before embarking upon another study with 
the model: 
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'1. Ideally, all the subjects should sleep in the laboxatory for at 
least two nights prior to the napping session and during the 
course of the study. If this is not possible, one nap session 
should be allowed for adaptation purposes and a check kept upon 
the night-time sleep by means of questionnaires. 
2. The number of 30 minute recording periods could be reduced from 
four to three, in an attempt to reduce boredom effects. Likewise, 
the length of the interspersed reading periods could be reduced 
from 30 to 20 minutes. It was found that when the drug was 
exerting a sedative effect (Temazepam), it was very difficult for 
the subjects to keep awake during the 30 minute reading periods. 
Alternatively, if the drug was ,not exerting a sedative effect, 
the subjects became bored during the latter reading periods. 
3. The model needs to be tested with more drugs of known sedative 
potential, such as other members,. of the benzodiazepine group 
alldperhaps some barbiturates in order to produce a set of standards 
against which drugs of unkown sedative potential could be compared. 
4. An alternative experimental design would be to have four groups 
of subjects, each group corresponding to a particular recording 
period. All subjects would be dosed at the same time and each 
group would come to the laboratory at the respective period 
recording times for a one hour nap session. This design would 
have two main aims, firs~ly, to reduce the amount of boredom, 
because thil subjects would only be in the laboratory' for one 
hour instead of ~ hours and secondly to enable longer sleep onset 
times to be investigated. However, this design does introduce 
258 
the problem of inter-subject variability. 
5. ~ the present model studies the subjects were not inst=tecL 
to fall asleep during the EEG recording periods. It would be 
interesting to investigate ,Whether altering the instructions 
given to the subjects would affect. sleep Latency • 
.. 
6. On the basis of the results with Temazepam, it would be worthwhile 
selecting a group of sleep onset insomniacs and evaluating this 
drug upon them. 
This EEG model of sleep onset insomnia shows potential as a useful 
evaluation technique in the drug field. There is also the' possibility 
that the reverse aspect of the model may be useful, that is to allow 
subjects who are accustomed to napping to nap during the afternoon. 
This may result in short sleep onset times which might be useful in 
the evaluation of stimulants. 
, 
The final, main study examined the effects of acetylsalicylic 
acid (A.S.A.) upon sleep. This aspect of insomnia stemmed from the 
comments made by many of the self-reported sleep onset insomniacs that 
the frequently took Aspirin to relieve their insomnia. No previous 
studies have examined the effects of A.S.A. upon ncrma1 sleep; in fact, 
very few analgesics have been.used in sleep research. The effects of 
some of these drugs upon sleep may help eventually in our understanding 
of. the sleep mechanisms in Man. The A.S.A. study was somewhat 
unusual in that it examined the effects of a no~zl, therapeuti~ 
dose of the drug administered throughout the day, whereas, the majority 
, 
;. 
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of drug studies simply evaluate the effects of a drug administered as 
the subject ret~s to bed. 
The results of the A.S.A. study suggested that A.S.A. was exerting 
a slight arousing effect upon sleep, revealed by the significant increase 
in stage 2 sleep, which was accompanied by a decline in stage 4 and a 
slight decline in stage REM, neither of which reached statistical 
significance. The night-to-night variability of stage 3 sleep was 
significantly increased upon A.S.A. administration and the build up . 
of stage 4 sleep was slightly depressed after the first 2t hours of 
sleep. Upon withdrawal of A.S.A.,· there was a significant decline in 
REM latency and an increase in the night-to-night variability of stage 
REM. Various speculations were made in the discussion (section 11.0, 
chapter three) as to how A.S.A. might be exerting these effects. 
There is also the possibility that A.S.A. could be producing changes 
. in the sleep EEG which are undetectableby means of the" visual scoring 
technique of Rechtschaffen and Kales (1968), which was employed throughout 
. , 
this research programme. A further aspect of research would be to 
analyse the EEG by computerised methods. However, at the time of the 
study this approach was not feasible. The visual scoring technique has 
the disadvantage that stage 2 sleep can contain from 0 - 20'/0 of delta 
. act:i.vity, (0.5 - 3.5 Hz., with an amplitude greater than 75 jJ-V) and still 
be classed as stage 2. It is not 1lIltil the amount of delta activity 
exceeds 20'/0 of the activity of a one minute epcoh that it is classified 
as stage 3. It would therefore be interesting to investigate whether 
the increase in stage 2 brought about by A.S.A. administration contained 
a high percentage of delta activity. Feinberg, Fein, ~/alker, Price, Floyd 
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and March (1911), using a computerised EEG analysis technique, found that 
an increased amount of stage 2 produced by the drug Flurazepam contained 
a sufficien~ amount of delta activity to offset the loss of delta 
activity due to the significant deoline in stage 4 sleep. It is possible 
that the increase in stage 2 sleep is. the primary effect of A.S.A. and 
the decline in stage 4 could be secondary, due to the increased amount 
of delta activity in stage 2. This idea is in part borne out by the 
pattern of accumulation of stage 4 after A.S.A. administration. Graph M 
(section 25.0, chapter three)showed that the accumulation of stage 4 
was depressed after the first 2t hours of sleep 6n the second A.S.A. 
night. A pos~ibility is that ail increased amount of delta actiVity .due 
to the rise in stage 2 sleep may have resulted in the "nightly quota of 
delta activitT' being produced in the first 2t hours of sl~ep; hence 
the depression in the build up of stage 4. This suggestion is only 
speculative at present. 
A computer analysis technique may also be very useful in the 
evaluation of insomnia. Such a technique may reveal differences in the 
, 
EEG between the self-reported sleep onset insomniacs of chapter one and 
the good sleepers. Any differences which may be found would provide a 
possible explanation of ..my the subjective reports .. of sleep onset insomnia 
were not always borne out by the EEG measure of sleep latency. As 
suggested by Karacan et al. (1913), "the meaning of insomnia to such 
patients must be sought in subtle EEG disturbances rather than in gross 
disturbances of sleep latency, total sleep time or sleep maintenance". 
Another problem encountered in the studies of this research 
programme was the large amoun~of inter-subject variability for the 
various sleep stages and parameters. This can be observed from the AJilOVA 
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summa,r:r tables. This problem was more evident in the A.S.A. study, as 
a comparison was being made between two groups of subjects. In an 
a~tempt to overcome the difference between the 1aseline scores for the 
the two groups, the scores for each sleep stage and each parameter, for 
each subject, on each night, were expressed as the· difference score by 
subtracting them from the mean baseline value. An alternative approach 
to overcoming this problem may have been to have used a different 
experimental design. Each subject could have acted as his own placebo 
control, but this introduces another variable, that of a. temporal 
factor, whereby a subject cannot receive both A.S.A. and placebo at once. 
The time interval between the two treatments may lead to variations which 
could affect comparisons. This problem of inter-subject variability 
appears to be an inherent problem which will have to be accommodated 
according to the study. The response to A.S.A. also showed a large 
amount of inter-subject Variability. One of the reasons for this might 
have been that the dose of A.S.A. employed was too low to bring about 
a consistent response in allsubjeots. The next step, therefore, would 
be to increase the dose of A.S.A. used or to use a drug with similar 
, 
. but stronger actions, such as indomethacin. However, on ethical grounds 
neither of these approaches was feasible •. 
It was decided therefore, to investigate whether the effects of 
A.S.A. upon sleep were peculiar to this drug or whether related drugs, 
such as Paracetamol, also showed these effects. The results of the pilot 
study conducted with Paracetamol suggested that it was having an effect 
upon sleep similar to that shown by A.S.A., but the effects were less 
marked. However, more subjects are required before the Paracetamol 
findings can be confirmed. Nevertheless, these findings did suggest that 
the effect of A.S.A. upon sleep could not be explained simply on· the 
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grounds of adverse side-effects, as Paracetamol, at therapeutic doses, 
has ve'I'Y fell adverse side-effects (Goodman & Gilman, 1970)~ 
A biochemical pilot study was also conducted with the aim of 
gaining some knowledge of how A.S.A. exerted its effects upon sleep. 
The choice of assay techniques was limited due to the facilities available 
and the fact that it was not feasible to use a technique which involved 
invasive procedures. The colormetric urine analysis.of 5-HIAA was the 
most suitable at the time (Udenfriend et al., 1958). The link between 
A.S.A. and 5-HIAA is that A.S.A. has been shown to release tryptophan 
from its binding site (Smith & Lakatos, 1971), which may pass along the 
metabolic pathway which converts tryptophan to 5-hydroxytryptamine, which, 
in turn is broken dOlm to 5-HIAA. Although the results of this analysis 
may reveal changes in 5-HIAA concentration due not only to A.S.A., but 
also other factors,_such as diet and free fatty acid concentration in 
the plasma, it was considered that if A.S.A. was having any major effect 
upon this tryptophan pathway, then it would be detected by an increase 
in the concentration of urina'I'Y 5-HIAA. This analysis can, therefore, 
, 
only give some indication as to the action of A.S.A. upon 5-HIAA output 
in the urine, as one cannot necessarily conclude that any changes observed 
are due solely to the action of A.S.A. The results of the urine analysis 
pilot study indicated that A.S.A. was having no marked effect upon the 
excretion of 5-HIll. one ·problem encountered with this particular 
assay was that the standard readings fluctuated from day to day. However, 
this assay was sufficiently sensitive to detect a tryptophan load of 
approximately 90 mgs., administered via. the diet. A flurometric assay· 
may be more sensitive to slight changes in the concentration of 5-HIAA 
and ought to be considered if this aspect of the research programme were 
to be pursued further. 
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Overall, the effects of A.S.A. upon the sleep of good sleepers 
suggested that A.S.A. was exerting a slight arousing action rather thim ... 
a sleep promoting one, as suggested by the self-reported, sleep onset 
insomniacs of chapter one. However, A.S.A. has not necessarily been 
given sufficient opportunity to reveal its full sedative potential. 
The recent work by Rauri and Silberfarb (1978) revealed that a single 
dose of A.S.A. (650 mgs.) brcught about a significant increase in the 
total sleep time and a signficant reduction in the amount of wake time 
after sleep onset and the total amount of wake time in a group of 
insomniacs. The baseline group mean. sleep onset time for this group 
of insomniacs was only 30.9 minutes; so A.S.A. may not have been able 
to reveal its sedating properties in this group, as only a few subjects 
may have had relatively long sleep latencies. Overall, the results of 
the Rauri and Silberfarb (1978) study indicated that A~S.A. may be a 
useful hypnotic for those insomniacs suffering from early morning or 
frequent nocturnal awakenings. In view of the findings of the 
Rauri and Silberfarb (1978) study, it would still be beneficial to 
pursue one of the further research proposals put forward in chapter 
three, that is, to assess the sedative. potential of A.S.A. using the 
EEG model of sleep onset insomnia when a table of standards has been 
drawn up. The aim of this study would be to gain some indication of 
whether A.S.A. would be an effective "sleeping aid" for those insomniacs 
whose primary complaint is a long sleep latency. Rauri and Silberfarb 
(1978) reported that A.S.A. had no significant effects upon the stages 
of sleep. The present study revealed that A.S.A. produced a significant 
increa.se in stage 2 sleep, but, that other stages were not Significantly 
altered, whereas, the majority of hypnotics are known to suppress· 
REM sleep. At present one cannot say whether these changes in the sleep 
stages brought about by drugs are detrimental to the subjects;' therefore, 
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one cannot come to the conclusion that A.S.A. has the advantage over 
other hypnotics of not suppressing REM sleep. If A.S.A. is to be 
examined further as a potential hypnotic, consideration must be given to 
the fact that it is known to produce gastric irriation at varying doses 
in different individuals. 
The range of possible drug and non-dr\l.g "aids" for insomnia appears 
,. 
to be a~ost as wide and diverse as the underlying causes of insomnia. 
This may reflect the insomniacs' limitless attempts to obtain a 
"good night's sleep". Since sleep is highly coveted by many, the insomniac 
feels almost compelled to adop"j;some "aid". to sleep. Sleep is held in 
high esteem and the insomniacs feel that they must achieve it regardless 
of the cost. 
'. 
"Do but consider what an excellent thing sleep is: it is so 
inestimable a jewel that, if a tyrant would give his crown 
for it, it cannot be bought:" (Thomas Dekker) 
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APPENDICES 
New Hypnotio Presoriptionsin the United states 
* 1974 - 1976 (in millions) 
Table 1 
1974 1975 1976 
Fluraze:pa.m (Dalmane) 4.45 5.86 
All Benzodiazepines 6.51 8.52 
All Hypnotios 8.29 6.42 
Barbiturate - Benzodiazepine 
ratio 1.27:1 0.75:1 0.62:1 
* Souroe: National Presoription Audit 
From Cohen and Blutt (1978) 
, 
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APPENDIX I. 
i 
" IN· STRICT CONFIDENCE 
SLEEP QUESTIONNAIRE 
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APPENDIX II 
Please complete this questionnaire as soon as possible. You may 
write your answers in the space provided immediately below the question. 
If there is insufficient space. you may continue your answers in the 
blank space at the end of the questionnaire. You may also use this 
space to ask any questions which you may have about the study or to· 
give us any additional information which you think may be useful. 
1. Name: 
2. Age: 
,. Address: 
4. At what time do you usually go to bed? 
5. (a) How long does it take you to fall asleep? 
(b) Has it always taken you this long? 
(c) If not, since when has this been happening? 
/ 
6. (a) Do you wake up during the night? 
(b) If so hOl~ often do you wake up? 
(c) How long does it take you to fall asleep again? 
7. At what time do you wake up in the morning? 
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8. (a) Do you take naps during the day? 
(b) If so, how long for? 
(c) How often? 
9. (a) Do you take anything to help you sleep? 
(b) If so, what? 
(c) Since when? 
(d) Is your doctor prescribing this treatment? 
'. 
10. Ca) Do you smoke? 
" 
Cb) If so, how many on average per day? 
11. Do you suffer from bronchitis? 
12. How many hours sleep per night do you need? 
13. Do you normally get this amount? 
14. Are you on a course. of antibiotics or tran~u1lisers? 
The' above questions make up the basic questionnaire and the following 
questlohsi) -iv) were inse±te.d at the end, according to the.study. 
i) Are you able to take Aspirin/Paracetamol without experiencing 
adverse side-effects? . 
i 
,. ii) 
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Would you be.concerned about having to take a therapeutic dose 
of Aspiriil/Paracetamol '. for four days? 
iii) Do you suffer from menstrual pain to such an exte~t;" that it· is 
likely to affect your sleeping habits? 
iV) It is important for us to avoid using you as a subject during 
menstrual onset, what was the date of your last menstrual 
period? 
I. 
, , 
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IN STRICT CONFIDENCE 
l<lORNING QUESTIONNAIRE 
Please complete this questionnaire upon awakening. Any further comments 
which you would like to make can be inserted at the end. 
1. Name .. Da;j;e: 
2. At what time did you go to bed last night? 
3. How long did it take you to fall asleep? 
4. (a.) Did you awaken during the night? 
(b) If so how often? 
(c) How long did it take you to fall asleep again,? 
5. At what time did you awake this morning? 
6., When you woke up this morning how did you feel? 
- tired 
- average 
- rested 
1. Did you have a hard/easy/ average time awakening this morning? 
8. Do you feel as thOugD you had enough sleep last night? 
9. When you went to bed last night how did you feel? 
- tired 
- a.verage 
- a.lert 
10'. What were yo= dreams like last night? 
_ plea.sant 
- unpleasant 
_ cannot remember 
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11. When you went to bed last night how tense did you feel? 
- tense 
- a.verage 
- relaxed 
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APPENDIX IV 
IN S T R I C T CONFIDENCE 
DAYTIME QUESTI01'NAIRE 
1. Name •••••••••••••••••••••••••••••••••••••••••• Date ••••••••• 
2. Do you feel as though you fell asleep during the rest period? 
••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
3. If so, how long did it take you to fall asleep? •••••••••••••••• 
4. How long were you 'asleep ? ••••••••••••• ~ ••••••••••••••••••••••• 
5., Would you please comment on how you felt at the outset of the 
rest period? e.g. tired, alert, tense, anxious?-
6. How do you feel now? 
1. If you were unable to fall asleep, did it worry you or play on 
your mind in anyway? 
•••••••••••••••••••••••••••••••••••••••••••••••• 
8. Would you please estimate for how long you have been in the bedroom? 
••••••••••••••••••••••••••••••••••••••••••••••••••••• 
9. Would you please list anything which you have had to eat or drink 
since awakening this morning, including your breakfast? 
Thank-You 
NAME: 
ASP I R I N QUE S T ION N A IRE 
IN CONFIDENCE 
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1. Would you please give an estimate of how often you would normally 
take ASPIRIN tablets, for example, twice per week, once per month? 
2. If you had a headache or pain, which drug would you normally take, 
for example, Disprin, A.spro, Aspirin, Anadin,Paracetamol, etc. ? 
3. Can you remember the last time you took an, ASPIRIN tablet or any 
other tablet prior to the study? Would you please indicate when 
and the name of the tablet? 
4. Did the fact that you had to take ASPIRIN for four, days worry you 
at all? 
5. Did you experience any side-effects whilst taking ASPIRIN during" 
the course of the study? 
6. During the course of the study were you on any special diet, for 
example, vegetarian, sugar free, low carbohydrate? 
7. Would you please indicate how you estimate your average, daily 
carbohydrate intake, compared with the student population? 
1 3 5 
more 
2 
slightly more same 
4; 
slightly less less 
Thank You 
LEFT EYE - Al 
RIGHT EYE - Al 
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C4 - Al 
---':L---f4...-0.~~ 
Electrode Placement for Slee Recordin after Rechtschaffen and 
!(ales 1 8 
"EOG - E1 1cm. above and out from outer canthus of left eye. 
E2 1cm. belcw and out from outer canthus of right eye. 
EEG - C3 of international 10/20 system for electrode placements. 
C4 of international 10/20 system for electrode placements. 
Refernece Electrodes - A1 left mastoid 
A2 right mastoid 
An earth electrode (C
z
) was located betw~en C3 and C4 
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THE EEG 11EA.SUREMENT OF SLEEP 
EEG activity can be divided into four main kinds of EEG rhythms: 
1. Alpha - The frequency of this rhythm varies between 8 and 12 Hz., 
with an amplitude of 25 to 100 microvolts.Alpha activity appears 
to be mainly localised in the occipital and parietal areas of the 
brain. It is the most prominent EEG activity to be found in the 
waking brain, although in some individuals it is.virtuaJ.ly absent. 
Alpha activity typicallY appears when the eyes are closed and the 
subject is relaxed, with little on his mind. 
2. Beta - There is some disagreement concerning the frequency range 
of this activity, although the consensus gives the range between 
14 and 30 Hz. The amplitude is low and seldom exceeds 20 micro-
'. , 
volts. Beta is normally found in the frontal and central areas of 
the brain, and it is considered to be a background activity which, 
in wakefulness, is prominent in the absence of alpha. Therefore, 
its presence is taken to indicate varying degrees of tension or 
excitement. 
3. Theta - The frequency range of this actiVity is from 4 to 7 Hz., 
with an amplitude of about 30 microvolts. It is not normally found 
in much quantity in the adult waking EEG and is most evident during 
dozing or light sleep. 
4. Delta - The frequency of delta ranges from 0.5 to 3.5 Hz., with an 
amplitude. of up to 150 microvolts. It is not usually evident in the 
adult waking EEG, but is very prominent during deep sleep. 
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The Sleep stages 
stage W (waki:,.g) 
This corresponds to the waking state'Which is Characterised by,EEG 
alpha activity, with some beta activity. There is a high tonic EMG, 
) 
rapid eye movements (HEMs) and blinking are very evident. 
stage 1 
Here there is a relatively low amplitude, mixed frequency EEG 
activity with a prominence in the theta range; vertex sharp waves 
may appear towards the end of the stage. The ECG (electro-oculogram) 
shows slow eye rolling, and there is a fairly high tonic EMG which is 
generally below that of wakefulness. Stage 1 generally occurs in the 
transition from wakefulness to other stages of sleep and tends to be 
" 
of relatively short duration. This stage occupies approximately 
5-10% of the total sleep time (TST) of the young adult. 
stage 2 
'* -The EEG shows clear signs of sleep spindles and K complexes • 
There is a quantitative absence of delta activity to preclude it from 
stage 3. The ECG is quiescent and the Ef:IG is lower than that for 
stage 1. This stage occupies 40-50}'0 of the TST of the young adult. 
* The term sleep spindle refers to EEG activity between 12 and 14 Hz. 
The presence of a sleep spindle should not be defined unless it is 
of at least 0.5 seconds duration, that is, one should be able to 
count 6 or 1 distinct waves within the half-second period. 
- K complexes are defined as EEG waveforms haVing a well delineated 
negative sharp wave which is immediately followed by a positive 
component. The total duration of the complex should exceed 
0.5 seconds. 
, 
i, 
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S·tage 3 . 
Delta activity is present in the EEG record for at least 2()D~, but 
not more than 50)6, of the time. There may also be K complexes anu 
spindles present in the EEG. El1G and ECG are of a similar level to 
Stage 2. Stage 3 is considered by many researchers to be a transitory 
stage between Stages 2 and.4, and it occupies between 5 and 1()D~ of the 
TST of the young adult. 
stage 4 
Delta activity is present for a mdIUUmwn of 5()D~ of the time and 
frequently the EEG record is completely dominated by this activity. 
Sleep spindles may be present. The ECG is quiescen~ and the El1G tends 
to be low, but still higher than that of the REM stage •. stage 4 
occupies 15-20)6 of the TST·of the young adult. 
stage REM 
The EEG shows low voltage fast activity of mixed frequency, similar 
to that found in wakefulness. Episodic HEMs are present: and the El1G 
reaches the lowest level found in any stage. stage REM occupies 20-2~~ 
of the TST. 
(navies & Home, 1975). 
\ . 
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, 
; Nori-Significant !NOVA Summary Tables for the Study Investigating the 
Effeots of Cyoloid Vibration upon Good Sleepers 
SleeE Onsat Time 
Souroe S.S. d.!'. M.S." F di'1'di'2 
Treatment 34.5 3 11.5 0.3 n.s. 3;15 
Subjeots 1914.8 5 383.0 8.5 0.1% 5,15 
Residual 674.7 15 45.0 
. Total 262400 23 
stage W+1 
Souroe S.S. d.f. M.S. F P di'1,di'2 
Treatment 181.5 3 60.5 0.9 n.so 3,15 
Subjeots 1806.75 5 361.4 5.7 1.0% 5,15 
Residual 949.75 15 63.3 
... 
Total 2938.0 23 
Stage·2 
Souroe S.S. . d.f. M.S. F, P di'1,di'2 
Treatment 392.3· 3 130.7 0.5 n.s. 3,15 
Subjeots 6658.8 5 1331.8 5.0. 1%' 5,15 
Residual 3976~2 15 265~1 
Total 11027.3 23 
stage 2 
Souroe s.s. d.f. M.S. F P di'1,df2 
Treatment 22.4 3 7.5 0.3 n.s. 3,15 
Subjeots 386.4 5 77.3 2.7 n.s. 5,15 
Residual 431.8 15 28.8 
Total 840.6 23 
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stage ~ 
Source S.S. d.f. M.S. F P df1,df2 
Treatment 325.7 3 108.6 1.3 n.s. 3,15 
Subjects 4659.0 5 931.8 10.9 0.1% 5,15 
Residual 1277 .3 15 85.2 
Total 6262.0 23 
Stage ~±:l: 
Source S.S. d.f. M.S. F P df1,df2 
Treatment 398 3 132.7 2.3 n.s. 3,15 
Subjects 4484 5 896.8 15.8 0.1% 5,15 
Residual 849 15 56.6 
Total 5731 23 
Staf\:eREM 
Source S.S. d.f. I1.S. F P df1'df2 . 
Treatment 892.3 3 297.4 1.5 n.s. 3,15 
Subjects 2001.8 5 400.4 2.0 n.s. 5,15 
Residual 2955.2 15 197.0 , 
Total 5849.3 23 
Total SleeJl Time 
Source S.S. d.f. I1.S •. F P df1,df2 
Treatment 250 3 83.3 1.6 n..s. 3,15 
Subjects 307 5 61.4 1.2 n.s. 5,15 
Residual 787 15 52.5 
Total 1344 23 
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Non-5imificant !NOVA Summary Tables for the Study investigating the 
Effects of Non-Drug "Sleeping Aids" upon the Sleep of a Group of 
Self-RepQtted, Sleep Onset Insomniacs. 
Sleep Onset Time . 
. Source S.S. d.f. M.S. F P df1,df2 
Treatment 302.9 3 101.0 0.6 n.s. 3,21 
Subjects 6776.8 7. 968.1 5.9 0.1% 7:',21 
ResidUal 3470.8 21 165.3 
Total 10550.5) 31 
stage W+1 - IV!lole Night 
Source S.S. d.f. M.S. F P df1,df2 
Treatment 283.3 . 3 94.4 0.7 n.s. 3,21 
Subjects 2285.5 '1 326S 2.5 5% 7,21 
Residual 2725.2 21 129.8 
Total 5294+0 31 
stage ,'+1 - First Half of Night 
Source S.S. d.f. 11.S. F P df1,df2 
Treatment. 94.4 3 31.5 1.0 n.s. 3,21 
Subjects 433.2 7 61.9 2.0 n.s. 7,21 
Residual 642.4 21 30.6 
!l'otal 1170.0 31 
• 
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Stae;!! W+1 - Second Half of Night 
Source 5.5. d.f. M.S. F P df1,df2 
Treatment 411.0 3 137.0 2.3 n.s 3,21 
Subjects 122-1.0 7 174.4 3.0 2.SOfo 7,21 
Residual 1228.7: 21 58.5 
Total 2860.7 31 
Sta.,o:e 2 
Source 5.5. d.f. M.S. F P df1,df2 
Treatment 550.5) 3, .183.5 0.7 n.s. 3,21 
Subjects 6511.8 7 930.3 3.4 2.5% 7,21 
Residual 5741.8. 21 273.4 
Total 12804.1 31 
• 
" 
stage 2 i 
Source 5.5. d.f. }I.S. F P df1,df2 
Treatment 234.8 3 78.3 2.5 n.s. 3,21 
.' Subjects 988.0 7 141.4 4.5 1% 7,21 
Residual 659.2 21 31.4 
Total 1882.0 
Sta.,o:e :l: 
Source 5.5. d.f. M.S. F P df1,df2 
Treatment 51.1 3 17.0 0.2 n.s. 3,21 
Subjects 4572.3 7 653.2 8.0 0.1% 7,21 
Residual 1708.6 21 81.4 
Total 6332.0 31 
stage REl1 
Source S.S. d.!. M.S. F P df1,df2 
Treatment 646 :3 215.3 1.1 n.s. 3,21 
Subjects 2473 7 353.3 1.8 n.s. 7,21 
Residual 4012 21 191.-0 
Total 7131· 31 
REl1 Latency 'I 
Source S.S. d.!. !-I.S. F P df1'df2 
Treatment 1034 3 344.7 0.2 n.s. 3,21 
Subjects 10949 7 1564.0 1.0 n.s. 7,21 
Residual 34237 21 1630.3 
Total 46220 31 
Total Slee;e Time 
Source S.S. d.!. M.S. F P df1,df2 
Treatment 442c 3 147.0 0.5 n.s. 3,21 
Subjects 11025 7 1575.0 5.2 1%· ., 7,21 
Residual 6397 21 304.6 
Total 17864 31 
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Number of sta~ Chan~s 
Source 5.5. d.f. 11.5. F P df1,df2 
Treatment 207.8 ; 69.; 0.9 nos. ;,21 
Subjects 2454.5 7 350.6 4.4 1% 7,21 
Residual 1689.4 21 80.4 
Total 4351.7i 31 
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Non-Significant ANOVA S~ Tables for the EEG Model of Sleen Onset 
-- Insomnia Study. 
stage ':1+1 
So=ce S.S. d.f. H.S. F P df1'df2 
Night 84.7 _ 3 28.2 0.4 n.s. 3,21 
Subject 548.4 7- 78.3 1.05 n.s. 7,21 
Residual 1568.8 21 74.7 
Total 2201.9 31 
stage 2 -
So=ce 5.5. d.f. }!.S. F P df1,df2 
Night 133&0 3 446..0 2.6 n.s. 3,21 
Subject 12149.5 7 1735.6 10.3 0.,1% 7,21 
Residual 3542.5 21 168.7 
" 
, ' 
Total 17030.0 31 
stage ~ 
So=ce 5.5. d.f. M.S. F, P df1,df2 
Night 92.3 3 : 30.8 1.4 n.s. 3,21 
Subject 1007.0 7 143.6 6.6 0.1% 7,21 
Residual 453.7 21 21.6 
Total 1553.0 31 
Stage 4 
So=ce 5.5. d.f. M.S. F P df1,df2 
Night 94.5 3 31.5 0.3 n.s. 3,21 
Subject 10116.5 7 1445.2 15.7 n.s. 7,21 
Residual 
. 1933.0 21 92.1 
Total 12144.0 31 
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" S ta.ge REr>! 
Source S.S. d.!. M.S. F P df1,df2 
Night 574"a . 3 191.6: 3.05; n.s. 3,21 
Subjeot 5411.0 7 773.0 12.30 0.1% 7,21 
Residual 1320.2 21 62~9 
Total 7306~0 31 
Total SleeE Time 
Source' S.S. d.!. M.S. F P df1,df2 
. Night 2395.4 3 798.5 2.5 n.s. 3,21 
Subjeot 18597.3 7 2656.8 8.2 0.1% 7,21 
Residual 6799.3 21 323.8 
Total 27792.0 31 
.. ); 
staR \'1+1 
Source 
Night 
Subject 
Residual 
Total 
S'IIa.,o:e 2 
Source 
Night 
Subject 
Residual 
Total 
. 
Sta.,o:e 2 
Source 
Night 
Subject 
Residual 
Total 
Stage 2+4 
Source 
Night 
Subject 
Residual 
Total 
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APPENDIX XI 
Non-8ignificant !NOVA S~ Tables for the AsPirin 
Pilot Study 
S.S. d.!. 11.S. F P df1,df2 
577.6 4 144.4 1.7 ns 4,28 
651 ~ 1 7 93.0' 1.1 ns 7,28 
2400.8 28 85.7 
3629.5 39 
. S.S. d.! • I1.S. F P df1'd!2 
736.5 4 184.1 1.2 ns 4,28 
5270'.7 7 753.0 5.0' 1% 7,28 
420'6.7 28 150'.2 
i. 
10213.9 39 
S.S. d.!. 11.S. F P df1,df2 
338 4 84.5 0.5 ns 4,28 
3489 7 498.0' 2.7 2.5% 7,28 
5099 28 . 182.0' 
8926 39 
S.S. d.!. M.S. F P df1,df2 
2476.4 4 619.1 2.4 ns· 4,28 
6614.8 7 9~5.O' 3.6. 1~ 7,28 7354.8 28 2 2.7 
16446.0 39 
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.APPENDIX XI ctd. 
St!!:S:e REl1 
Source S.S. d.f. M.S. F P df1,df2 
Night 657 4 164.) 1.2 ns 4,28 
Subject 5772 7 824.6 6.0 0.1% 7,28 
Residual )864 28 1)8.0 
Total 1029) )9 
REl1 Latency 
Source S.S. d.f. M.S. F P df1,df2 
Night )042 4 760.5 0.4 ns 4,28 
Subject 14749 7 2107.0 1.1 ns 7,28 
Residual 5)297 28 190).5 
Total 71088 39 ;: , , 
Total SleeE Time 
Source S.S. d.f. M.S. F P df1,df2 
Night )47 4 86.8 0.4 ns 4,28 
Subject 5055) 7 7221.9 )6.6 0.1% 7,28 
Residual 5524 28 197.) 
Total 56424 39 
SleeE Onset. Time 
Source S.S. d.f. 11.S. F P df1'df2 
Night 182 4- 45.5 0.8 ns 4,28 
Subject 2411 7 344.4 6.2 0.1% 7,28 
Residual 1568 28 56.0 
Total 4161 39 
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APPENDIX XII 
.Non-Significant ANOVA Summary Tables for the Aspirin Main study 
over the drug nights. 
stage ',1+1 
, ., Source 
Between Subjects 
Treatment 
Subjects within 
treatments 
Ifithin Subjects 
Nights 
Nights x Treatments 
Residual 
Total 
stage 2 
Source 
Between Sub,lects 
Treatment 
Subjects ,'/i thin 
treatments 
Ifithin SubJects 
Nights 
Nights x Treatments 
Residual 
Total 
S.S. ',d.f. 
46.1 1 
2934.1 14 
41.3 2 
114.0 2 
2300.0 28 
5441.5 41 
S.S. d.f. 
143.5 1 
1436.5 14 
124.1 2 
83.3 2 
2083.9 28 
3811.3 41 
M.S. 
46.1 
209.6 
23.1 
51.0 
M.S. 
143.5 
102.6 
62.1 
41.1 
14.4 
F 
0.2 
0.3 
0.1 
"'F 
1.4 
0.8 
0.6 
p 
ns 
ns 
ns 
P 
ns 
ns 
ns 
1,14 
2,28 
2,28 
df1,df2 
1,14 
2,28 
2,28 
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stage 4 
Scurce S.S. d.!. 11.S. F P df1,df2 
Between Subjects 
Treatment 660.1 1 660.1 2.0 ns 1,14 
Subjects Id th~ 
4693.8 treatments 14 335.3 
Within Subjects 
Nights 179.3 2 89.7 0.8 ns 2,28 
Nights x Treatments 78.8 2 39.4 0.3 ns 2,28 
Residual 3263.9 28 116.6 
Total 8875.9 47 
stage 2+4 
Source S.S. d.!. M.S. F P df1,df2 
Between Sub~ects 
Treatment 1250.5 1 1250.5 3.7 ns 1,14 
Subjects within 
treatments 4775.0 14 341.1 
"'i thin Sub,iects 
Nights 11.4 2 5.7 .04 ns 2,28 
Nights x Treatments 12.0 2 6.0 .04 ns 2,28 
Residual 4125.9 28 147.4 
Total 10174.8 47 
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APPENDIX XII ctd. 
stage REM 
Source S.S. d.!. M.S. F P df1,df2 
Be-b..reen Subjects 
Treatment 414.2 1 414.2 1.3 ns 1,14 
Subjects within .. 
treatments 4649.3 14 332.1 
1fithin Sub~ects 
Nights 513.5 2 256.8 2.3 ns 2,28 
Niggts x Treatments 90.5 2 45.3 0.4 ns 2,28 
Residual 3035.3 28 108.4 
Total 8702.8 47 
REM latenc;,! 
Source S.S. d.!. M.S. F P df1,df2 
Between Sub~ects 
Treatment 4860.2 1 4860.2 4.0 ns 1,14 
Subjects within 
treatments 16965.5 14 1211.8 
vii thin Subjects 
Nights 2037.1 2 1018.6 1.2 ns 2,28 
Nights x Treatments 259.6 2 129.8 0.2 ns 2,28 
Residual 22981.9 28 820.8 
Total 47104.3 
291 
REr1 Periodici ty 
Source \ S.S. d.f. 'M.S. F P df1,df2 
Between Subjects 
Treatment 117.2 1 117.1 2.2, ns 1,14 
Subjects within 
treatments 9541•6 14 52.4 
liithin Sub,jects 
Nights 947.8 2 473.9 2.1 ns 2,28 
Nights x Treatments 525.1 2 262.6 1.2 ns 2,28 
Residual 6411.8 28 229.0 
Total 17543.5 47 
,.Number of stage Changes 
Source S.S. d.f. M.S. F P df, ,df2 
Between Subjects 
Treatment 3.0 1 '3.0 \ .03 ns 1,14 
Subjects within 
treatments 1503.7 14 107.4 
Within Subjects 
Nights 116.4 2 58.2 .97 ns 2,28 
Nights x Treatments 2.4 2 1.2 .02 ns 2,28 
Residual 1684.6 28 60.2 
Total 3310.0 47 
stage W+1 
Source S.S. d.f. 
Between Subjects 
Treatment ·.·148.6 1 
Subjects within 
treatments 1677.8 " 14 
~lithin Subjects 
Nights 103.1 4 
Nights x Treatments 76.2 4 
Residual 
.3308.3 56 
Total 5314.0 79 
Stage 2 
Source S.S •. d.f. 
Between Sub.jects 
Treatment 292.6 1 
Subjects ~li thin 
treatments 12179.5 14 
lvi thin Sub~ects 
Nights 861.6 4 
Nights x Treatments 227.6 4 
Residual 14866.4 56 
Total 28427.7 79 
. M.S. 
148.6 
119.8 
25.8 
19.1 
M.S. 
292.6 
870.0 
215.4 ' 
56.9 
265.5 
F 
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APPENDIX XIII 
P df1,df2 
1.2 . ns 1,1<1-
0.4 ns 4,56 
0.3 ns 4,56 
F P df1,df2 
0.3 ns 1,14 
0.8 ns 4,56 
0.2 ns 4,56 
29~ 
APPENDIX XIII ctd. 
stage 3 
Source 5.5. d.f. n.s. F p df1,df2 
Betl"een Subjects 
Treatment 11.3 1 11.~ 0.07 ns 1,14 
Subjects within 
treatments 2166.8 14 154.8 
lVithin Sub.jects 
Nights 171.1 4 42.8 1.0 ns 4,56 
Nights x Treatments 118.1 4 29.5 0.7 ns 4,56 
Res~dual 2.512.8 56 44.9 
Total 4980.0 79 
Stas:e :1: 
Source 5.5. d.f. H.S. ;F p df1,df2 
Beween Sub,jects 
Treatment 63.0 1 63.0 0.1 ns 1,14 
Subjects ,,,ithin 
treatments 6320.3 14 451.5 
i'lithin Subjects 
Nights 264.4 4 66.1 ' 0.4 ns 4,56 
Nig}:Jts x Treatments 66~.4 4 165.9 1.0 ns 4,56 
Residual 9283.4 56 165.8 
Tctal 16594.5 79 
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Sta~ 3+4 
Source S.S. d.f. H.S. F P df1,df2 
Between Sub~ects 
Treatment 12.8 1 12.8 0.03 ns 1,14 • I 
Subject within I 
treatment 7088.6 14 506.3 
'''ithin Subjects 
Nights 83.6 4 20.9 . 0.1 ns 4,56 
Nights x Treatments 662.6 4 165.6 0.8 ns 4,56 
Residual 11543.4 56 ·206.1 
Total 19391.0 79 
Stage REl'! 
Source S.S. d.f. M.S. 'F P df1'df2 
Between Sub,jects 
Treatment 171.1 1 171.1 0.3 ns 1,14 
Subject within 
treatment 9221.1 14 658.7 
'Vi thin Subjects , 
Nights 670.3 4 167.6 1.0 ns 4,56 
Nights x Treatments 197.3 4 49.3 0.3 ns 4,56 
Residual 9807.6 56 176.1 
Total 20067.4 79 
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REM Periodicitl 
Source. 5.5. d.!. M.S. F P df1'df2 
Between Subjects 
Treatment: 515.1 1 515.1 1.2 ns 1,14 
Subject within 
treatment 5840.5 14 417.2 
\Vi thin Subjects 
Nights 1360.4 4 340.1 1.5 ns 4,56 
Nights x Treatments 1842.6 4 460.6 2.0 ns 4,56 
Residual 12760.7 56 227.9 
Total 22319.2 79 
Total Sleep Time 
Source 5.5. d.!. 11.5. /;F P df1,d!2 
Between Sub,jects 
Treatment 277.5 1 277.5 0.4 ns 1,14 
Subject within 
treatment 9693.4 14 689.7 
Ylithin Subjects 
Nights 2106.7 4 526.i 2.9 ns 1,19 
Nights x Treatments 1091.8 4 273.0 1.5 ns 1,19 
Residual 10115.5 56 180.6 
Total 23284.9 79 
Conservative Test 
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APPENDIX XIII ctd. 
Sleep Onset Time 
Source S.S. d.f. M.S. F P df1,df2 
Between Subjects 
Treatment 0.6 1 0.6', 0 - ns 1,14 
Subject within 
treatment 9168.7 14 654.9 
Wi thin Subjects 
Nights 75.6 4 18.9 0.3 ns 4,56 
Nights x Treatments 114.8 4 28.7 0.4 ns 4,56 
Residual 3678.0 56 
Total 13037.7 79 
Number of stage Cha.n~s 
Source S.S. d.f. M.S. F P df1,df2 
Between SUbJects 
Treatment 64.8 1 64.8 0.3" ns 1,14 
Subject within 
, treatments 2661.0 14 190.1 
Wi thin Subjects 
Nights 247.3 4 61.8, 0.9 ns 4,56 
Nights x Treatments 107.8 4 27.0 0.4 ns ' 4,56 
Residual 3921.3 56 70.0 
Total 7002.2 79 
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APPENDIX XVI 
Non-Significant ANOVA Summar:y Table for the Paracetamol Pilot study 
stage REM 
S=ce SS d.f. MS F P df1,df2 
Between Subjeots 
Treatment 220.6 1 220.6 1.1 ns 1,10 
Subjects within 
treatments 1997.3 10 199.7 
Within Subjects 
Nights 315.8 2 157.9 2.4 ns 2,20 
Nights x Treatments 280.1 2 140.1 2.2 ns 2,20 
Residual 1278.6 20 63.9 
Total! 4092.4 35 
Placebo Tablet Composition 
Maize Starch 51.85";6 
Lactose 47.2596 
* Aerosil 200 0.22596 
Magnesium Stearate B.P. 0.675% 
100.00>;6 
Shape: Normal Concave 
Weight: 315 mg. 
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APPENDIX XVII: 
* Aerosil 200 is a form of colloidal silicon dioxide permitted 
for human consumption. 
. 
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